Information management using Web 2.0 technology by Duffy, Juliet (Juliet Maria)
Information Management Using Web 2.0 Technology
By
Juliet Duffy
Bachelors of Science in Chemical Engineering, University of Colorado at Boulder, 2002
Submitted to the MIT Sloan School of Management and the Department of Chemical Engineering
in Partial Fulfillment of the Requirements for the Degrees of
MASSACHUSETTS IN
OF TECHNOLO
Master of Business Administration OFTECHNOLO
AND JUN 10 201
Master of Science in Chemical Engineering
LIBRARIE
In conjunction with the Leaders for Manufacturing Program at the
Massachusetts Institute of Technology ARCHIVES
June 2009
© 2009 Massachusetts Institute of Technology
All rights reserved
Signature of Author
'May 8, 2009
Chemical Engineering, Sloan School of Management
Certified by
Kfistala Jongt Prather, Thesis Supervisor
Assistant Professor Kristala Jones Prather, Department of Chemical Engineering
Certified by
v Roy Welsch, Thesis Supervisor
Professor of Statistics and Management Studies, Sloan School of Management
Accepted by
William Deen, Professor of Chemical Engineering
Chairman, Committee for Graduate Students Chemical Engineering
Accepted by __
J Debbie Berechman
Executive Director of MBA Program, MIT Sloan School of Management
This page has been intentionally left blank
Information Management Using Web 2.0 Technology
By
Juliet Duffy
Submitted to the Sloan School of Management and the Department of Chemical Engineering
Division on May 8th, 2008 in Partial Fulfillment of the Requirements for the Degrees of Master of
Business Administration and Master of Science in Chemical Engineering
ABSTRACT
Web 2.0, the ultimate platform for tacit based knowledge work has finally arrived. User driven,
collaborative platform based tools including wikis, web mash-ups, discussion boards, linkage based
search engines, and tagging have the potential to vastly change how information is managed and
how knowledge work is captured. This thesis investigates how the new paradigms and tools of
Web 2.0 can be applied to the Pharmaceutical Industry and assist with information management at
The Novartis Institute for BioMedical Research (NIBR). Applying Web 2.0 tools to NIBR's
chemical compounds, targets, assays, people, and projects in a well thought out framework has the
potential to yield tremendous productivity improvements in the drug discovery process.
Effectively harnessing the collective intelligence of thousands of scientists within Novartis's
worldwide research network will enable a paradigm shift. A large, extremely knowledgeable user
community can more effectively annotate metadata, hyperlink to important content, establish tags,
and collectively author content. Such activities will not only improve the search ability of
information but also allow important scientific connections to emerge linking biology to chemistry
and furthering Novartis's understanding of disease.
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Chapter 1: Thesis Overview
1.1 Overview
Pharmaceutical drug discovery is a very risky and expensive endeavor. The R&D process for
bringing a new drug to market can take ten to fifteen years to complete and cost up to USD 1.0
billion/drug. On average, only one in 10,000 originally synthesized compounds will become a
commercially available drug.' Furthermore, the industry is struggling under looming patent
expirations, price controls imposed by governments and insurance companies, and rapidly rising
drug discovery costs. Given these current challenges, it is imperative that the industry examines
ways to increase the efficiency of the drug discovery process and reduce costs associated with
discovering new chemical entities.
1.2 Problem Statement
In a 2004 white paper addressing industry productivity challenges the U.S. Food and Drug
Administration commented "if biomedical science is to deliver on its promise, scientific creativity
and effort must also focus on improving the medical product development process itself."2
Information management is one aspect of the product development process that is often neglected.
Indeed, effective sharing of data has been specifically identified by the FDA as one of the actions
companies can take to improve product development.3 Information management is a tremendous
challenge for pharmaceutical research organizations. Researchers are not only exploring and
generating massive amounts of data about the vast realms of the human genome (20,000-25,000
genes), they are also trying to map that information to the chemical space, typically screening
chemical libraries containing anywhere froml-5million compounds on a regular basis. The sheer
volume and diversity of information that is generated is often overwhelming.
Information management challenges are not only constrained to the pharmaceutical industry. The
internet and advent of digital storage has exponentially driven worldwide data proliferation. It is
estimated that 4.0 exabytes (4.0*1019) of unique information will be generated this year, more than
Novartis Company Website, About Novartis- Research and Development, n.d. Web. Accessed 14 April 2009
http://www.novartis.co m/about-novartis/co rporate-citizenship/business-conduct/research-developements.shtml
2 "Innovation or Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products." Food and
Drug Administration (FDA) (2004). Whitepaper.
3 Stephens, Susie. Enabling Semantic Web Inferencing with Oracle Technology: Applications in Life Sciences
SpringerLink Book Series Lecture Notes in Computer Science, Springer Berlin/ Heidelberg 3791 8-16 (2005)
in the previous 5,000 years. Additionally, the amount of new technical information is doubling
every two years." 4
How is this excessive data generation being managed on a worldwide scale? Interestingly, a new
paradigm in information generation and management has arisen. Often referred to as "next
generation web" and dubbed "Web 2.0" this powerful paradigm shift has profound implications for
how internet users, companies, and individuals alike generate and manage data.
1.3 Thesis Overview
This thesis investigates how the new paradigms and tools of Web 2.0 can be applied to the
Pharmaceutical Industry and assist with information management at The Novartis Institute for
BioMedical Research (NIBR). Specifically, the project explores the concept of using web-based
Compound Homepages, similar to an internal Wikipedia, to share information about chemical
compounds.
The thesis begins in Chapter 2 by providing background information on Novartis and explores the
productivity crisis faced by the pharmaceutical industry. The next section, Chapter 3, provides an
overview of tacit (i.e. knowledge based) work and explains how firms that successfully manage
tacit interactions can gain a significant productivity advantage over competitors. An overview of
various Web 2.0 tools (wikis, blogs, tagging, etc.) is provided in Chapter 4 and specific case study
examples of Web 2.0 usage within the life sciences industry are explored in Chapter 5.
Chapters 6 and 7 present the study methodology and results from user interviews conducted at
Novartis. The user research explores employee attitudes toward Web 2.0 and provides an
assessment of the current Novartis data environment. Chapter 8 provides a three-lens analysis and
explores strategic, cultural, and political barriers the firm should be aware of while implementing
change.
Chapter 9 highlights how Web 2.0 has the potential to vastly improve internal search, break down
organizational silos by connecting employees, and classify and capture compound information
through user-generated tags. Chapter 10 provides a specific web framework for capturing
information related to a specific research project, while Chapter 11 briefly examines how Novartis
4 Fisch, Karl Living in Exponential Times. The Kim Komando Show, n.d. Web Video. Accessed 17 March 2009
http://videos.komando.com/2008/1 2/22/living-in-exponential-times/ Original video source data:
http://www.lps.k 12.co.us/schools/arapahoe/fisch/didvouknow/sourcesfordidyouknow.pdf
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captures information regarding compound terminations and addresses how the organization can
learn from project failures.
Lastly, Chapter 12 explores three different web-based functionalities for a Compound Homepage
web system: 1.) Web Portals - to unify diverse sources of information in one easy to find place 2.)
Tagging- to allow the user community to classify compounds and explore scientific relationships
between chemistry and biology, and 3.) Wiki environment - to establish a user community for
sharing and capturing scientific information.
Chapter 2: Industry and Company Background
2.1 The Value of Pharmaceuticals
Pharmaceutical products are a major weapon in treating disease and add tremendous value to the
health care system. According to Dan Vasella, the CEO of Novartis, the purpose of the
pharmaceutical industry is to reduce the incidence of disease, reduce death associated with disease,
improve quality of life, and reduce suffering. 5
Indeed, the introduction of new and novel drugs for treating all types of diseases has had a dramatic
impact on human mortality. From 1965 - 1999, pharmaceuticals have significantly lowered the
death rates for individuals with rheumatic fever, hypertensive heart disease, and Ischemic heart
disease (Figure 1).
Drop in dealth rate for diseases treated with
pharmaceuticals 1965-1999
Figure 1: Medicinal Impact on Mortality (1965-199)6
Often pharmaceuticals are viewed as the most expensive component of healthcare and are unfairly
blamed as the primary reason behind rising healthcare costs. A 2007 Price Waterhouse Coopers
study showed that roughly 2/3 of consumers estimated that prescription drugs account for between
5 Daniel Vasella, CEO & Chairman of Novartis, presentation to CEO Perspectives Class, MIT Sloan, Cambridge, MA
4 Feb 09. Lecture
6 Ibid. (5) & EFPIA 1999 
- 2002
-41%
-61%
-67%
-75%
40% - 79% of U.S. healthcare costs. This consumer perception was far from the truth. In reality,
prescription drugs actually account for <10% of US healthcare expenditures.7
Dollar for dollar prescription medicines actually help to mitigate other healthcare expenditures.
They decrease the need for hospitalizations, surgeries, nursing home admission and other costly
healthcare alternatives. A 2005 study found that a 20% increase in patient adherence to taking
prescribed pharmaceuticals yielded substantial savings. Every $1 spent on diabetes, cholesterol,
and blood pressure medicines resulted in overall healthcare savings of $7.10, $5.10, and $4.00
respectively.8
2.2 The Pharmaceutical Industry
The pharmaceutical industry is a multi-billion dollar industry with total global sales of $712B USD
in 20079. The industry has experienced significant global growth over the past decade (Table 1).
According to IMS Health, an agency that tracks 95% of all prescription drug sales in over 80
countries, the global pharmaceutical market will experience growth of 5-6% next year for total
expected global sales of U.S. $735-745 billion.10 Megatrends driving industry growth include an
aging population, an increased prevalence of chronic disease associated with unhealthy lifestyles,
scientific advancement, and developing world growth markets that are now able to afford
pharmaceutical care. I
Table 1: Global Pharmaceutical Sales, 1999-200712
1999 2000 2001 2002 2003 2004 2005 2006 2007
Global sales (US$ billions) 334 365 392 428 499 560 605 649 712
Growth over previous year 14.5% 11.5% 11.8% 9.5% 10.3% 8.0% 7.3% 7.1% 6.4%
7 "Putting Patients First - Meeting the Drug Discovery Challenge " Novartis Institute for Biomedical Research, New
Employee Orientation. Cambridge, MA. June 2008 & PriceWaterhouseCoopers 9 Jan 07
8 M.C. Sokol et al. "Impact of Medication Adherence on Hospitalization Risk and Healthcare Cost." Medical Care
43.6: 521-530 (2005). Print.
9 Parexel's Bio/Pharmacuetical R&D Statistical Sourcebook, PAREXEL International Corporation (2008/2009). Print.
1o Ibid. (9)
" Daniel Vasella, CEO & Chairman of Novartis, presentation to CEO Perspectives Class, MIT Sloan, Cambridge, MA
4 Feb 09. Lecture.
12 Ibid. (9)
The industry is relatively concentrated among a handful of large players. In 2007, the top ten
pharmaceutical firms accounted for 51.3% of global prescription sales, with the largest firm, Pfizer,
capturing 7.5% of the market (Table 2).
Table 2: Top 10 Companies by Worldwide Prescription Drug Sales in 200713
Rank Company Rx Sales (2007) % Worldwide
US$ billions Market Share
1 Pfizer 42.6 7.50%
2 Sanofi-Aventis 38.8 6.80%
3 GlaxoSmithKline 37.8 6.60%
5 Roche 30.7 5.40%
6 AstraZeneca 28.4 5.00%
7 Merck & Co 25.8 4.50%
8 Johnson & Johnson 24.0 4.20%
9 Eli Lilly 16.9 3.00%
10 Abbott Laboratories 16.1 2.80%
2.3 Novartis Overview
Novartis is the 4th largest pharmaceutical company in the world, ranked by 2007 prescription drug
sales (Table 2). The company was created by the 1996 merger of pharmaceutical companies Ciba-
Geigy & Sandoz. The $27 billion deal was, at the time, the biggest industrial merger in history. The
resulting combined company was named Novartis based on the Latin "novae artes", meaning "new
skills". 14 In 2008 Novartis products treated over 850 million patients worldwide15 .
Novartis operations span beyond prescription pharmaceuticals with businesses in various health
care areas. Daniela Vasella, the Chairman and CEO of Novartis describes the company's strategy
as fulfilling four different customer needs: newer better drugs, affordable quality drugs, self-
treatment without prescription, and disease prevention (figure below)
13 Parexel's Bio/Pharmacuetical R&D Statistical Sourcebook, PAREXEL International Corporation (2008/2009). Print.
14 "Putting Patients First - Meeting the Drug Discovery Challenge " Novartis Institute for Biomedical Research, New
Employee Orientation. Cambridge, MA. June 2008
15 Novartis Company Website, n.d Web. Accessed 3 Feb 2008 http://www.novartis.com/
Customer Needs
New and Better drugs
(efficacy, side-effects)
Affordable quality drugs
Self-treatment without
prescription
Disease prevention
Business Segments
Pharmaceuticals: Innovative medicines with
improved efficacy and fewer side effects.
Sandoz: Affordable, high-quality generic treatment
options following the expiry of patents.
Consumer Health: Empowering patients with
various consumer products that enable healthy
lifestyle choices. Products include over the counter
(OTC), Ciba Vision, and animal health.
Vaccines and Diagnostics: Products to fight
vaccine-preventable viral and bacterial diseases, as
well as diagnostic tools.
Figure 2: Novartis Business Divisions focused on Understanding Customer Needs' 6
2.4 Novartis Institutes for BioMedical Research (NIBR) Overview
The research for this thesis project took place solely within the Novartis Institutes for BioMedical
Research (NIBR). NIBR is the research organization of Novartis and focuses on early stage drug
discovery through pre-clinical development.
Research is De-coupled from Commercial Activities
Prior to 2003, the Novartis research and discovery group was headquartered in Basel, Switzerland
and reported directly into the Pharmaceutical Business Division. In 2003 Novartis made a
deliberate strategic decision to separate the R&D entity from the commercial side of the
pharmaceutical organization thus forming Novartis Institutes for BioMedical Research (NIBR).
The unique separation of the research division from its commercial counterpart gave the new
research organization several advantages. Research headquarters were moved from Basel to
Cambridge, MA in order to take advantage of geographic proximity to other global healthcare
research centers. The geographic shift allowed the R&D center to tap into additional drug
16 Daniel Vasella, CEO & Chairman of Novartis, presentation to CEO Perspectives Class, MIT Sloan, Cambridge, MA
4 Feb 09. Lecture.
discovery talent, establish collaborations with other intuitions, and gain biologics know-how for
advancing its biotechnology portfolio. 17
Secondly and most importantly, the separation gave the research division greater autonomy in
portfolio prioritization decision making process. A study of the pharmaceutical industry by the
Boston Consulting Group showed that commercial predictions of peak sales at the time of drug
launch were often vastly inaccurate with little to no correlation to actual market sales (Figure 3).
Additionally, actual commercial value was vastly under predicted for many novel chemical
compounds. Revenue from Copaxone, a novel multiple sclerosis therapy, was under predicted by
10x, revenue from Topamax, a migraine medication, was under predicted by 5x (Figure 3).
Novartis realized that commercial predictions were often inaccurate and felt that criteria beyond
estimated commercial value should drive decision making within the R&D process.
Best ~i esiate ofI sae of drug [ell I5~ short iof
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0.5 1
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Figure 3: Forecasting Not Applicable for Portfolio Decisions 1 8
17 Elton, Jeff, NIBR COO speech to MIT Leader's for Manufacturing Class. Novartis Institute for Biomedical
Research. Cambridge, MA. Aug. 2008
18 Biniszkiewicz, Detlev - Portfolio Prioritization Research. Boston Consulting Group, 17 Feb 09
r Uderstiate
10.VEvrstmae
Therefore, NIBR established a new model for advancing research projects, one in which drug
candidates are prioritized and advanced through the pipeline based on unmet medical need and an
understanding of the underlying disease biology (mechanistic understanding). An ideal Novartis
development candidate would rank both highly in unmet medical need and disease understanding
(Figure 4).
-
E
Understanding of Mechanism
Figure 4: Novartis Model for Prioritizing R&D Portfolio
2.5 Industry Productivity Crisis
According to the U.S. Congressional budget office, the pharmaceutical industry is one of the most
research intensive industries in the United States. "Pharmaceutical companies invest as much as
five times more in research and development, relative to their sales, than the average U.S.
manufacturing firm". Indeed, the 2007 average industry for R&D expenditures as a percentage of
sales was 16.4%and R&D investment reached a record $58.8B USD." 19 Research and development
costs are not only substantial; they have significantly ballooned over the past two decades. In 1987
PhRMA members spent $5.5B USD in R&D; today that spending has increased by 8x (Figure 5).
450
S35 , ---- --
4* 0 - ------ -
'510 .
1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007
Figure 5: Total R&D Investment reported by PhRMA Member Companies1987-200720
As research costs have risen dramatically, the number of new U.S. Food and Drug Administration
new drug approvals (NDAs) has been relatively flat (Figure 6). The average number of NDA
approvals per year over the last two decades (1987-2007) was 83.4. New drug approvals in 2001,
2002, 2003, 2005 and 2007 were below that average. Additionally, little productivity increase has
occurred with new molecular entity approvals (NMEs), a subclass of NDA's representing drugs
with a novel chemical structure. In 2005- 2007 NME approvals were below levels approved in the
late 1980's (Figure 6).
19 Pharmaceutical Industry Profile. Pharmaceutical Research and Manufacturers ofAmerica (PhRMA) Washington,
DC (2008). Print.
20Parexel's Bio/Pharmacuetical R&D Statistical Sourcebook, PAREXEL International Corporation (2008/2009). Print.
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Figure 6: Number of NDAs and NMEs Approved by Year, 1987 - 200721
Average NDAs
approved per year
(1987 to 2007) = 83.4
Reasons for the decline in productivity have been examined extensively within the pharmaceutical
community. A higher bar for regulatory scrutiny, increased expectation and cost of running
clinical trials, and difficulty of translating highly academic research into effective therapies have all
been cited. Regardless of the rationale, the industry is suffering from a productivity crisis. The
crisis not only poses ramifications for the industry, but also healthcare systems around the world.
Decreasing productivity means that the research cost associated with each successful drug approval
continues to rise. The Tufts University Center for Drug Development estimates the cost of
bringing a single new pharmaceutical drug to market at roughly $1.3billion (in year 2005 dollars).
Furthermore, only 2 out of every 10 marketing drugs are able to produce revenues that match or
exceed research and development costs. 22
One of the factors contributing toward enormous R&D expenditures is the very low probability that
a chemical compound ever reaches the marketplace. For every 5,000 - 10,000 compounds tested,
5 of those will reach clinical trials and only one will become an FDA approved drug (Figure 7).
Furthermore, the R& D process is lengthy taking anywhere from 10 to 15 years to develop a single
new drug. 23
2 1Parexel's Bio/Pharmacuetical R&D Statistical Sourcebook, PAREXEL International Corporation (2008/2009). Print.
22 Vernon, John, Joseph Golec, and Joseph DiMasi, "Drug Develoment Costs when Financial Risk is Measured Using
the Fama-French Three Factor Model", (2008). Unpublished working paper. Submitted to the Journal of Health
Economics.
23 Pharmaceutical Industry Profile. Pharmaceutical Research and Manufacturers ofAmerica (PhRMA) Washington,
DC (2008). Print.
I
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Figure 7: Probability of Success for FDA Approved Pharmaceutical24
2.6 Improving Information Management to help solve the Productivity Crisis
What can be done to reverse the industry productivity trend and help to jump start R&D
productivity engines? A 2004 Food and Drug Administration (FDA) whitepaper focused on this
issue. The paper points to importance of the product development process and making process
improvements for bringing new drugs through the development pipeline. "If biomedical science is
to deliver on its promise, scientific creativity and effort must also focus on improving the medical
product development process itself."25
One aspect of the medical product development process is the effective storing and sharing of
organizational information. Indeed, information management is one aspect of the product
development process that is often neglected. Information management is a tremendous challenge
for pharmaceutical research organizations. Researchers are not only exploring and generating
massive amounts of data about the vast realms of the human genome (20,000-25,000 genes), they
are also trying to map that information to the chemical space, typically screening chemical libraries
containing anywhere from 1-5 million compounds on a regular basis. The sheer volume and
diversity of information that is generated is often overwhelming. Improvement to IT systems and
data management would not only allow Novartis to be more competitive, it would allow
knowledge to be more accessible throughout the organization having profound implications for
solving the productivity crisis.
24 Ibid. (23)
25 "Innovation or Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products." Food and
Drug Administration (FDA) (2004). Whitepaper.
Chapter 3: Tacit Organizational Work
3.1 Definition of Tacit Work
McKinsey classifies the work that corporations engage in under three types of activities:
transformational, transactional, and tacit. Transformational activities include the extraction or
conversion or raw materials into a product. Transactional activities are classified as being routine
and repetitive (think working on a production line). The third type of work, classified as tacit
activities, is more complex. These activities rely on continuous collaboration with organizational
colleagues, complex problem solving, making judgments, drawing on forms of information, etc.
Essentially, tacit activities are those of so-called "knowledge workers."
Traditionally, firms have been engaged primarily in transformational and transactional activities.
As these activities lend themselves to standardization and automation, historical gains in firm
efficiencies have been focused on optimizing and improving these types of activities. The trend in
work has now reversed with a large portion of work in developed countries now focusing on
knowledge based tacit activities (Figure 8).
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Figure 8: More Jobs Require Tacit Interact ions 26
26 Beardsley, Scott, Bradford Johnson and James Manyika "Competitive advantage from better interactions" McKinsey
Quarterly 2 (2006). Print
3.2 Tacit Work is Harder to Understand and Optimize
It is extremely important for companies to both understand the tacit knowledge work that takes
place as well know how to boost the productivity of these knowledge workers. As improving tacit
productivity is not as straightforward as standardizing a production line or leaning out a
manufacturing facility, this is easier said than done. McKinsey's study of 8,000 US companies
found that the performance of companies in heavily tacit sectors varied far more than that of other
companies 27. This suggests that companies and industries engaged in highly tacit activities have
"significant competitive headroom" 28 for improving productivity in knowledge workers.
Companies that master this activity will be able to gain a significant advantage over rival firms in
the industry. According to McKinsey, "executives will have to learn how to compete, innovate and
mange in an era when tacit interactions dominate and drive firm performance". 29
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27 Beardsley, Scott, Bradford Johnson and James Manyika "Competitive advantage from better interactions" McKinseyQuarterly 2 (2006). Print
28 Ibid. (27)
29 Ibid. (27)
30 Ibid. (27)
3.3 Leveraging Information Technology
As knowledge work is very dependent upon the sharing of information, collaboration, making
judgments based on available information, tools that help to improve those activities can boost
productivity of tacit organizations. Information technology (IT) is commonly cited as such a tool.
In McKinsey's study, tacit-dominated organizations in the top 25% of labor productivity invested
five times more in IT for their employees than firms in the bottom quartile.31 Increasingly,
companies are exploring a new generation of "Web 2.0" tools that encourage employee
collaboration and a decentralized approach to information capture.
31 Beardsley, Scott, Bradford Johnson and James Manyika "Competitive advantage from better interactions" McKinsey
Quarterly 2 (2006). Print
Chapter 4: Web 2.0
4.1 What is "Web 2.0"?
"Do we finally have the right technology for knowledge work? Wikis, blog, group-messaging
software and the like can make a corporate intranet into a constantly changing structure built by
distributed, autonomous peers - a collaborative platform that reflects the way work really gets
done. " - Andrew McAfee, Web 2.0 Expert, Harvard Business School Professor
Appropriately, we turn to Wikipedia for a definition of Web 2.0:"Web 2.0 is the second generation
of web development and design that aims to facilitate interconnectivity and interactivity of web-
delivered content." 32 Web 2.0 technologies are essentially digital platforms that allow for content
generation, sharing, and refining information over the internet.33 Unlike the first generation of web
development, often referred to as "Web 1.0", Web 2.0 focuses on increased flexibility and
decentralization. A broad community of users is responsible for creating website content, rather
than a single top-town source. Key differences between web generations are highlighted below
(Table 3).
Table 3: Comparison of 1"s and 2 nd Generation Web Technologies
Web 1.0 Web 2.0
Style Centralized De-centralized
Created by a single Content is created by community users.
Content generation source. "Top-down" "Bottom-up" flow of information
flow of information
Static web-pages that Community constantly changes and
Web page editing are non-user editable updates pages
32 "Web 2.0" Wikipedia, n.d. Web. Accessed 27 Feb 09 http://en.wikipedia.org/wiki/Web 2.0
33 McAfee, Andrew "Enterprise 2.0: The Dawn of Emergent Collaboration" MIT Sloan Management Review, 47. 3(2006). Print
4.2 Examples of Web 2.0 Tools
In order to fully understand Web 2.0, it is useful to define some of the different types of Web 2.0
platform tools and explore specific examples of these tools that are currently being used over the
World Wide Web.
Blog or Weblog- A website that is usually maintained by an individual author where posts and
responses to those posts accumulate over time. Entries are usually posted in reverse-chronological
order. Blogger.com describes blogs as:
"A blog is a personal diary. A daily pulpit. A collaborative space. A breaking-news outlet.
A collection of links. Your own private thoughts. Memos to the world. Your blog is whatever
you want it to be. There are millions of them, in all shapes and sizes, and there are no real
rules ".34
Blog Examples:
* A Personal Blog: Harvard Business School Professor Andrew McAfee blog on The
Business Impact of IT. http://andrewmcafee.org/blog/
* Technology Blog :Medgadget, Focused on emerging medical technologies:
http://www.medgadget.com/
* Other Blogs - 2007 Weblog winners: http://2007.weblogawards.org/
Tagging - Simple descriptions called "tags" are used to identify and classify content. Items can be
tagged with multiple tag descriptors. Categorization emerges over time as the result of user
tagging.
Tagging Examples:
* Delicious- A social web bookmarking site where you categorize your bookmarks by
tagging them with descriptors. You can share these categorizations and explore tag
collections created by other users. http://delicious.com/
* Flickr, a photo sharing website, allows users to create tags in order to categorize content.
Searching for "red dog" on Flicker yielded the photo below:
34 "What's a Blog" Blogger, n.d. Web. Accessed 27Feb 09 http://www.blouger.com/tour start.g
28
Photo was also tagged with the
following "tag" descriptors:
- Red
-Halloween
- Hotdog
- Costume
- Matt
Figure 10: Photo obtained by searching Flickr for "red dog"
Wikis -"A wiki is a page, or collection of web pages, designed to enable anyone who accesses it to
contribute or modify content." 35 Contrary to blogs, where contributions are usually by one author,
wiki's are authored by multiple individuals within the community. The content is highly
interactive with a constant re-write and editing process.
Wiki Examples:
Wikipedia -(http://www.wikipedia.org/) an online, collaborative encyclopedia written by
volunteer authors around the world. Wikipedia is one of the largest reference websites
attracting over 684 million visitors in 2008. There are more than 75,000 active contributors
working on more than 10,000,000 articles in more than 260 languages.36
RSS Feeds - Really simple syndication (RSS) allows users to keep track of changes on particular
websites by "pushing" relevant information rather than "pulling" information (i.e. relying on a user
to constantly revisit a website to see if new information has been posted). Software called
"aggregators" periodically visit the subscribed to sites, and download new headlines. These
headlines are then displayed together on the aggregator with links back to the website.
RSS Example:
Subscribe to any website that has an RSS icon (" ")
35 "Wiki" Wikipedia, n.d. Web. Accessed 27 Feb 09 http://en.wikipedia.orewiki/Wiki
36 "Wikipedia: About" Wikipedia, n.d. Web. Accessed 27 Feb 09 http://en.wikipedia.org/wiki/Wikipedia:About
Social networking software (SNS) - Social networking allows individuals to connect together in
online communities. Connections can be based on shared activities and interests, professional
associations, friendships, etc.
SNS Examples:
* Facebook- started as a limited community for university students to allow students to reach out
and connect with others in their university. It has now grown into a global community with
over 200 million active users 37, roughly the population of Brazil.38 www.facebook.com
* LinkedIn- social network focused on establishing and maintaining professional relationships.
Members can recommend the work of other individuals, keep track of current and former work
colleagues, post resumes, etc. Linkedn has over 36 million members in 200 countries. A new
member joins Linkedin approximately every second. 39http://www.linkedin.com/.
Mash-up- A webpage that aggregates information from a variety of different sources. For
example, a mash-up page might pull information about a singer/songwriter artist from Wikipedia, a
video of that artist from YouTube and a map on how to get to the latest concert from GoogleMaps.
Mash-up Example:
* Foxy Tunes -A music site from Yahoo Music. The Foxy Tunes mash up of the artist Bjork
includes song lyrics pulled from Yahoo!, photos from Flickr, videos of Bjork on You Tube.
You can even view ratings of the artists albums and buy them through an Amazon
window.http://www.foxytunes.com/artist/biork
37 "Press Room Statistics" Facebook, n.d. Web. Accessed 2 May 09 http://www.facebook.com/press/info.php?statistics
38 "List of Countries by Population" Wikipedia, n.d. Web. Accessed 21 April 09
http://en.wikipedia.org/wiki/List of countries by population
39 "About Us" LinkedIn, n.d. Web. Accessed 27 Feb 09 http://press.linkedin.com/about
4.3 Web 2.0 in Business
Once solely the domain of the public internet, Web 2.0 is gaining widespread acceptance and usage
within the business community. Companies are increasingly turning to Web 2.0 tools to help
manage knowledge work. In June of 2008, McKinsey & Company surveyed two thousand
companies around the world and asked about their Web 2.0 usage. 34% reported using blogs, 33%
RSS feeds, 32% wikis, and 28% social networking tools (Figure 11).
Usage had not only increased from the previous year (2007), but companies reporting using a wider
range of diverse tools. 2007 survey respondents said their companies had adopted just over two
Web 2.0 tools on average. 2008 respondents indicated that they adopted 2.5 tools from the same
list and more than three from an expanded one.40
Is your company currently using any of the following
Web 2.0 technologies or tools?
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Social 8 2007, n=2847
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Figure 11: Web 2.0 Tool Usage4'
In addition to just reporting the use of Web 2.0 technologies, some companies are reporting that the
technology has started to transform the way that they organize and manage themselves. 16% of the
McKinsey survey respondents stated that Web 2.0 has "created major new roles or function in our
organization" while 14% reported that "it has changed the way our organization is structured."42
40 "McKinsey Global Survey Results: Building the Web 2.0 Enterprise" The McKinsey Quarterly (2008). Print.
41 Ibid. (40)
42 Ibid. (40)
Chapter 5: Case Studies of Web 2.0 use in Life Sciences
Although examples of Web 2.0 use are plentiful in many industries and business settings, it is most
relevant to examine specific uses within life sciences. Three specific case studies outlined below
provide evidence that:
* Web 2.0 technologies are being adopted within the life sciences industry, in many cases by
direct competitors to Novartis.
* User driven organizational and collaborative principles are providing value for gene
annotation.
* Public data consolidation for chemical compounds via mash-ups, data portals, and
hyperlinks has successfully allowed multiple data sources to be presented within one single
system providing a one-stop shop for chemical information.
5.1 Case Study #1: Pfizerpedia (Wiki)
Pfizer's Research Technology Center (RTC) located in Cambridge, MA, has developed an internal
encyclopedia dubbed "Pfizerpedia" as a tool to help research scientists collaborate, share and find
information. Pfizerpedia was initially conceptualized by a Christopher Bouton, a computational
biology group leader at Pfizer. Frustrated with a narrow siloed view of R&D projects, Chris
wanted to get a larger system level overview of research world. He downloaded Media Wiki, the
software used by Wikipedia, and posted some internal Pfizer content to seed the site.43 Leadership
subsequently helped promote the project throughout the organization and nurtured the Pfizer Web
2.0 phenomenon.
Available metrics point to Pfizerpedia's immense success. The site was launched at the beginning
of 2006 and "within one year was receiving 12,000 hits per month by users across Pfizer
worldwide." 44 The internal wiki currently has 10,000 different articles and has been adopted
throughout the organization to the extent that "even Pfizer's cautious regulatory affairs group is
using the wiki."4 5
John Castledine, the Director of Learning and Development for Pfizer's Global Research and
Development (PGRD) Division comments "For organizations that need to create and nurture an
innovative culture, the development of an internal 'wiki' site can be an important element. It is
43 Mullin, Rick "Seeing The Forest At Pfizer" Chemical Engineering News 85.36 (2007):29. Print
44 Ibid. (43)
45 "Enterprise 2.0 Attendees Talk Strategy" Information Week, 14 June 2008, Web. Accessed 18 Feb. 2009
http://www.informationweek.com/news/internet/social_network/showArticle.jhtml?artic l e lD = 208403742
certainly the case at Pfizer, where increasing evidence points towards the usefulness of Pfizerpedia
in enabling our employees to share and access knowledge more quickly than before. The ability to
publish freely attributed information on line can help overcome any tendencies that may exist
towards 'silo protectionism' or a bureaucratic approval process." 46
Pfizerpedia works in conjunction with a number of other Pfizer IT tools, rather than replacing
them. Scientific data repositories and documents still reside on document management systems
with security authorization, the wiki just provides an easy way to link to these. Furthermore,
Pfizerpedia has been an important tool in helping to direct intranet traffic to other Pfizer discussion
groups and blogs where more detailed scientific collaboration and discussion takes place on
specific topics.
The Pfizer case study is interesting in that it points to several things:
* Researchers are interested in and willing to share information-This is especially
apparent given that Pfizerpedia is run off of Media Wiki software. Often the use of wiki-
markup language is cited as barrier for wiki adoption. Pfizer scientists were so interested or
enticed to share information that they were willing to overcome the Wiki-markup language
barrier and invest the time to learn it.
* The tool is useful- With over 12,000 hits per month Pfizer employees are visiting the
Pfizerpedia site because it is directly providing value to them.
* Quality issues are minimal- Pfizer has official "curators" that maintain the website and
remove inappropriate entries. According to Pfizer employee and wiki creator Chris Bouton,
"a very minimal amount of that work is done. It just isn't needed".47 The community has
been able to successfully establish norms and rules of behavior and encourage appropriate
behavior.
46 "Pfizerpedia: knowledge repository at Pfizer" Chartered Institute of Personnel and Development, n.d. Web.
Accessed 21 Feb 09 http://www.cipd.co.uk/helpingpeoplelearn/ pfzrpd.htm
47 Mullin, Rick "Seeing The Forest At Pfizer" Chemical Engineering News 85.36 (2007):29. Print
5.2 Case Study # 2: Gene stub page generation on Wikipedia (Wiki)
In 2008 five scientists, supported by the Genomics Institute of the Novartis Research Foundation
(GNF), undertook an effort to engage the scientific community to create a worldwide wiki
community, specifically for annotating gene function. Rather than create a new wiki site, the
scientists decided to leverage off of the existing Wikipedia platform and add new Wikipedia pages
for genes not already represented.
Although established gene portals and model organism databases (e.g. Entrez Gene, Ensemble,
Mouse Genome Database) contained useful tools for referencing gene function, the scientists felt it
was important to create a format that allowed for flexible, freely edited articles.48 Furthermore,
project organizers felt it would be beneficial to leverage the power of the collective community,
relying on small contributions from countless different users around the world.
Rather than wait for Wikipedia pages on various genes to emerge over time, project organizers
hypothesized that they could accelerate the process by constructing "stub" pages (Figure 12) as
building block templates and a starting place for further annotation. Stub pages contained a sidebar
with external gene identifies, links to other primary source databases, and gene expression patterns.
Relevant literature references were also harvested from Entrez Gene). After a basic stub page
format was established, stub pages were constructed automatically on the Wikipedia site using an
automated Java based computer program.
48 Huss III, Jon, et al. "A Gene Wiki for Community Annotation of Gene Function" PLoS Biology, Public Library of
Science 6.7:e75 (2008). Print.
sw r . Protein sttue
. .at n d aJ rbbon diagram a '
-. $ , . .a'aa: .444.94 ±4 n M fl :..
Astaana 44w noat fi7n e w e n x g dit c ation . re n"t . ~..
after stub page addition (Figure 13). The dramatic distribution shift toward higher page rankings49 Huss 111, Jon, et al. "A Gene Wiki for Community Annotation of Gene Function" PLoS Biology, Public Library of
Science 6.7:el 75 (2008). Print.
' Ibid. (49)ria dtae~Pu~.BlIcations~ :~ ~~~ I~~~l~:~:::::
Figure 12: EaeofWkieiaGn geylam si~u49
As~~~~~~ ofIi~~~ Febuar 208 7,0 e gn tb wr ratdad60 xsig iiei pgswr
amended~~": toicue diinl eecntn.I he1 eksfloig epae diin
50 Ibid. (49)
Wikipedia gene pages feeding a cycle of additional viewing exposure and enforcing a positive
feedback loop of content generation (Figure 14).
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The Gene stub page generation case study highlights several important points:
* Mash-up's successfully aggregate scientific information. The gene pages on Wikipedia
are similar to "mash-ups" aggregating information from a variety of sources (e.g. Entrez
Gene, Protein Data Bank, etc.)The wiki platform works synergistically with these existing
reference sources rather than replacing them.
* Pre-existing structure is important. Individuals are more likely to add information if a
wiki page already exists. The activation energy of creating a new page is much higher than
adding a simple edit.
* Positive feedback loops are non-trivial. The ability to leverage positive feedback loops
will play a big role in obtaining additional exposure to the user community and help ensure
the gene project's success.
5.3 Case #3: ChemSpider (Mash-up)
ChemSpider is a chemistry search engine that contains compiled data on more than 20 million
compounds. The website serves as an aggregator, pulling chemical structure information from a
variety of sources and compiling it in one easy to search data portal. ChemSpider is part Web2.0
mash-up and part information portal. External information is both integrated directly into the
website (mash-up) as well as simply linked back to the original data source (portal). The
ChemSpider database is open to the public at no charge.
The inherent value of ChemSpider lies within its ability to aggregate many diverse sources of
information. Hundreds, if not thousands, of chemical databases exist containing information on
chemical compounds. Examples include: literature data, chemical vendor catalogs, toxicity data,
analytical data, regulatory postings, patent information, etc. Both the wide variety of available
information and sheer volume of different data sources make it nearly impossible for an individual
user to determine the availability of data for a single chemical compound. ChemSpider changes
that fact and answers the commonly asked question: "is there specific information about my
chemical?" 52
As this thesis investigates an internal Novartis web system specifically for chemical compounds, it
is extremely useful to explore the functionality of ChemSpider in detail. Very similar, and in some
cases identical, functionality is later suggested for the Novartis Compound Homepage web tool.
Searching for Chemicals
The user can search ChemSpider by typing in a one of several chemical identifier names (Figure
15). Chemical compounds can have a variety of different names so it is important that the search
interface recognizes and associates these different identifiers to the correct chemical structure.
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Figure 15: Search Interface for ChemSpider5 3
In addition to searching by names, scientists can also search by chemical structure. This is very
powerful because it provides a way for chemist to think and search in structural terms rather than
relying on textual based searches. In its discussion of ChemSpider, the Chemistry International
52 About Chem Spider, ChemSpider, n.d. Web. Accessed 05 Mar 09 http://www.chemspider.com/About.aspx
53 ChemSpider Search, ChemSpider, n.d. Web. Accessed 05 Mar 09 http://www.chemspider.com/Search.aspx
magazine points out the importance of this feature. "Chemists' natural affinity for communication
via chemical structures demands the need to perform searches in a natural (i.e. structure-based)
language"54 ChemSpider users can use a chemical structure editor (Figure 16) to either draw a
molecule from scratch or import and make changes to a molecule by specifying it via another
identifier (IUPAC name, InChi, Smiles, etc). Searching the web by chemical structure was
previously very difficult. ChemSpider changes that by opening the door to web-based structure
searches.
Covert Load 4Edit
Figure 16: ChemSpider Chemical Editor Interface: Used to Search by Compound Structure
5 5
Properties of the chemical such as molecular weight, mass, etc. are displayed after a user executes
a search (Figure 17). Chemical identifiers such as SMILES string, InChi and InChlKeylink
directly into Google so that the user can execute structural based searches with the Google search
engine.
Additionally, a section on names and synonyms imports a list of all known names for a particular
chemical compound. In the case of an approved drug, such as the example below of Xanax, the list
of names can be quite extensive including many drug and trade names in different countries
(Figure 18).
54 Williams, Antony "ChemSpider and Its Expanding Web" Chemistry International 30.1 (2008). Print
55 ChemSpider Structure Search. ChemSpider, n.d. Web. Accessed 05 Mar 09
http://www.chemspider.com/StructureSearch.aspx
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INHERENT PROPERTIES, IDENTIFIERS AND REFERENCES
ChemSpider ID: 2034
Empirical Formula: C1I;HCiN
Molecular Weight: 308,7649
C Nominal Mass: 308 Da
Average Mass: 308.7649 Da
Monoisotopic Mass: 308.082874 Da
Systematic Name:
SMILES:
InChI:
InChIKey:
Std. InChI:
Std. InChlKey:
8-chioro-1- methyl-6-phenl-4H-[ 1,2,4]triazolo[4,3-a][ 1,4]benzodiazepine
Clc3cc2\C(=N/Ccl nnc(n lc2cc3)C)c4ccccc4
InCh1=1/C17H13CIN4/cl-lt-20-21-16-10-19-17(12-5-3-2-4-6-12)14.9.1
3(18)7-8-15(14)22(11)16/h2-9M,10H2,1H3
YREFGVBLTWC3P-J. 
_FFA6QYA
InChl=lS/C17Hl3CIN4/cl-11-20-21-16-10-19-17(12-5-3-2-4-6-12)14-9-
13(1817-8-15(14)22(11116/h2-9H,10H2,1H3
VREFGVBLTWBCP.-UHFFFAOYSA-N
Figure 17: ChemSpider Chemical Properties, Identifiers and References5 6
- NAMES AND SYNONYMS
Validated by Experts, Validated by Users, Non-Validated, Aem-ve4-by-U ets, Redirected b
249-349-2 [EINES/ELINCS
28981-97-7 RNI
4H-(1,2,4)Trlazolo(4,3-a) (1,4)benzodiazepine, 8-chloro-l-methyl-6-phenyi-
4H- [1,2,4]triazolo[4,3-a] [ 1,4]benzodiazepine, 8-chloro--n-methyl-6-phenyl-
8-Chlor- 1-methyl-6-phenyi-4H- 1.,2,4]triazolo[4,3-a][ 1,4]benzodiazepin
8-chioro- 1-methyi-6-phenyl-4H-[ 1,2,4]trazolo[4,3-a][ 1,4]benzodiazepine
8-chloro-l-methyl-6-phinyl-4H-[1,2,4]triazolo[ 4,3-a][1,4]benzodiaz(pine
Alprazolam (3PS/USP)
Alprazolam [USAN:BAN:INN:3AN]
Anxyl
More...
Anxyl
Panistat
Staccato-alprazolam
Xanax (TN)
4H-s-Triazolo(4,3-a)(1,4)benzodiazepine, 8-chloro- 1-methy-6-phenyl-
B-Chloro- 1- methyl-6- phenyl- 4H-s-trazolo(4,3-a)( 1,4)benzodiazepine
8-Chloro- I- methyl-6-phenyl-4H-s-trazolo[4,3-air1,4benzodiazepine
Alcelam
Algad
Alpaz
Alplax
Alpram
Alprax
alprazolam fWJikU
Alprazolamum [INN-Latin]
Aipronax
Alprox
Alzam
Alzolam
Alzon
Anpress
Apo-Alpraz
Azor
BBSC-2025
Bestrol
Cassadan
Constan
CP0000149316
Figure 18: ChemSpider List of Names and Synonyms for FDA Approved Drug, Xanax5 7
56 ChemSpider Search. ChemSpider, n.d. Web. Accessed 05 Mar 09 http://www.chemspider.com/Search.aspx
" Ibid. (56)
Mash-up applications in ChemSpider include the integration of Wikipedia articles related to the
particular drug (Figure 19) as well as well as a description detailing the pharmacology, mechanism
of action, indication, etc. (Figure 20).
Alprazolam, also known under the ride.Xname Xanax, Xanor and Niravam, is a short-acting drug of the benzodiazepine class used
to treat moderate to severe anxiety disorders, panic attacks, and as an adjunctive treatment for anxidy associated with moderate
deoression. It is also available in an extended release form, Xanax XR. Both forms are now available generically. Alprazolam possesses
anxiolvttc, sedative, hnot amnesic, anticonvulsant and muscle relaxant properties. Alprazolam Is a potentially addtiYve drug and
long term use of alprazolam may cause a physical dependence to develop and benzodiazeoine withdrawal syndrome to appear during
discontinuation. In the USA, alprazolam is the most commonly misused benzodiazepine and is a schedule IV controlled drug. fald
more... or Edit at Wikipedia...
Figure 19: Mash-up of Wikipedia Article on ChemSpider Website
DESCRmPTION
Description: A triazolobenzodiazepine compound with antianxiety and sedative-hypnotic actions, that is efficacious in the
treatment of panic disorders, with or without agoraphobia, and in generalized anxiety disorders. (From AMA
Drug Evaluations Annual, 1994, p238)
Drug Type: Small Molecule; Illicit; Approved; Investigational
Pharmacology: Alprazolam, a benzodiazepine, is used to treat panic disorder and anxiety disorder. Unlike chlordiazepoxide,
clorazepate, and prazepam, alprazolam has a shorter half-life and metabolites with minimal activity. Like other
triazolo benzodiazepines such as triazolam, alprazolam may have significant drug interactions involving the
hepatic cytochrome P-450 3A4 isoenzyme. Clinically, all benzodiazepines cause a dose-related central nervous
system depressant activity varying from mild impairment of task performance to hypnosis. Unlike other
benzodiazepines, alprazolam may also have some antidepressant activity, although clinical evidence of this is
lacking.
Mechanism of Benzodiazepines bind nonspecifically to benzodiazepine receptors BNZ1, which mediates sleep, and BNZ2, which
Action: affects affects muscle relaxation, anticonvulsant activity, motor coordination, and memory. As benzodiazepine
receptors are thought to be coupled to gamma-aminobutyric acid-A (GABAA) receptors, this enhances the
effects of GABA by increasing GABA affinity for the GABA receptor. Binding of the inhibitory neurotransmtter
GABA to the site opens the chloride channel, resulting in a hyperpolarized cell membrane that prevents further
excitation of the cell.
Indication: For the management of anxiety disorder or the short-term relief of symptoms of anxiety and for the treatment
of panic disorder, with or without agoraphobia.
Half Life: 6.3-26.9 hours
Figure 20: ChemSpider Description of Pharmaceutical Xanax
In addition to providing users a window view directly into data sources such as Wikipedia (Figure
19), ChemSpider uses pointers, via hyperlinks, that allow the user to navigate directly back to the
original data sources. In some cases this information is publically available free of charge (e.g.
PubChem, NIST). In other cases the data is housed within a commercial database where a user
needs a subscription to access information (e.g. Journal of Heterocyclic Chemistry). External data
sources are identified by a mouse-over pop-up window that gives the user additional information
about a particular database (Figure 21).
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Figure 21: ChemSpider Associated Data Sources for Xanax
to treatmoder 
----
depessio. r i Name; Journal of Hecerocycic Chemistry
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Another useful section within the ChemSpider website is the predicted properties table (Figure 22).
In Silico properties of chemical compounds are calculated based on algorithms provided as part of
collaboration with Advanced Chemistry Development (ACD) labs.58 Chemists routinely use LogP,
polar surface area, Lipinski's rule of 5, etc. in order to assess the drug like properties of a particular
compound.
IX PREDICTED PROPERTIES
LogP:
ACD/LogD (pH 5.5):
ACD/BCF (pH 5.5):
ACD/KOC (pH 5.5):
#H bond acceptors:
#Freely Rotating Bonds:
Index of Refraction:
Molar Volume:
Surface Tension:
Flash Point:
Boiling Point:
ACD/LogP: 2.50
XLogP: 4,90
2.5
46,67
544.74
4
1
1.71
225.5 cm 3
52,1 dyne/cm
261.6 0C
509 OC at 760 mmHg
# of Rule of 5 Violations:
ACD/LogD (pH 7.4):
ACD/BCF (pH 7.4):
ACD/KOC (pH 7.4):
#H bond donors:
Polar Surface Area:
Molar Refractivity:
Polarizability:
Density:
Enthalpy of Vaporization:
Vapour Pressure:
0
2.5
46.71
545.23
0
43.07 A '
88.22 cm 3
34.97 10"2 4cm3
1.36 g/cm3
77.94 id/mol
1.77E-10 mmHg at 25 0 C
Figure 22: ChemSpider Predicted Properties Table for Xanax
5" ChemSpider User Guide. ChemSpider, n.d. Web. Accessed 06 Mar 09
http://www.chemspider.com/docs/chemspider_manual.pd f
Lastly, in addition to serving as a mash-up aggregator and linking portal, ChemSpider fosters a
sense of community among its users. The site includes a user forum where members can view and
edit posts related to chemistry discussions and a blog published by the sites founder. Furthermore,
site users are encouraged to be both data depositors as well as curators. In order to help maintain
the quality of the site, registration is required to deposit information and file changes/additions are
flagged internally to be reviewed by the ChemSpider staff. 59
ChemSpider has demonstrated its usefulness by attracting a large number of community users.
According to a May 2008 article from Nature, over 5,000 users per day are currently accessing the
site. 60 ChemSpider is an excellent example of how the new realities of the Web 2.0 are improving
access to scientific information, creating unique user communities, and possibly changing the face
of science by speeding up discovery.
ChemSpider case study highlights several important points:
* The amount of information available for a specific chemical is tremendous- This
suggests that mash-ups are a useful tool in aggregating this different information. The
amount of information available will only grow as scientific discovery pushes the frontier.
* Chemists need to be able to search by structure as well as by name-Structural based
searching is very powerful, especially given the multitude of different compound naming
conventions. Chemists think in structural terms and prefer to search by structure.
* Pointers, via hyperlinks, that take users back to root databases are helpful-Pointers
allow scientists to not only explore content in other databases, but validate the
trustworthiness of that data. They also vastly expand the scope of information available
within the "single click of a mouse key." 61
59 "Watch out for explosive Mouse on ChemSpider", ChemSpider Blog, 04 Mar 09. Web Accessed 04 Feb 09
http://www.chemspider.com/blog/
60 Brumfiel Geoff, "Chemists spin a web of data" Nature 453 (2008). Print.
61 Dejan Bojanic, The Novartis Institute for BioMedical Research, Center for Proteomic Chemistry
Chapter 6: NIBR User Research Methodology
6.1 Overview of Research Methodology
Extensive user research was conducted as a first step in evaluating the feasibility of "Compound
Homepage" a NIBR wide, Web 2.0based system for keeping track of chemical compounds. The
user research not only evaluated the current Novartis data environment, but also explored NIBR
specific cultural beliefs and attitudes about information sharing. Additionally, users were asked
about their awareness of, and attitudes toward Web 2.0 technologies including wiki usage, social
networking, etc. Forty five individuals within various groups of the NIBR organization were
interviewed (Table 4).Although interviews were conducted in many different groups, a majority of
stakeholders interviewed were part of the Center for Proteomic Chemistry (CPC) and Global
Discovery Chemistry (GDC) organizations. These two organizations are very chemistry centric and
would thus be the main users of the Compound Homepage. Interviews were conducted in a 1:1
setting and typically lasted anywhere from one to two hours each.
Table 4: Departmental Breakdown of NIBR Individuals Interviewed
Platform Groups # People
Interviewed
Biologics Center 0
Developmental & Molecular Pathways 4
Global Discovery Chemistry 14
Service Organizations
Disease Areas
Cardiovascular & Metabolism 0
Infectious Disease 0
Neuroscience 0
Ophthalmology 1
# People
Interviewed
Education Office 1
Global Security 0
IT and Automation (NITAS) 4
Novartis Knowledge Center 0
Research Facility Operations 0
# People
Interviewed
6.2 NIBR Organizational Structure
Novartis Institutes for BioMedical Research (NIBR) is organized in a matrix function by platform
groups, disease areas, and service organizations. Disease areas focus only on one particular disease
and have a high concentration of highly trained biology specialists. Conversely, platform groups
work across all disease areas. For example, members of the Center for Proteomic Chemistry
support high throughput screening activities for a variety of drug candidates in many different
disease areas. Similarly, chemists in the Global Discovery Chemistry platform group might work
on an oncology project at one time, but then later support a cardiovascular drug. Platform groups
were the focus of the user interviews as they tended to have a higher percentage of chemists.
6.3 Interview Question Themes
A wide variety of question themes were explored with interview participants. Samplings of
interview questions, grouped by themes are presented below. Please refer to Appendix A and
Appendix B, for the complete list of all interview questions.
Theme 1: Understanding job function
In order to understand information usage of a particular individual it was important to gain a
context surrounding the job function, organizational responsibilities, etc.
Q: What organization are you in? How long have you been at Novartis?
Q: What is your job function? What does your group do?
Q: What is your educational background? (biologist, chemist, biochemist, etc.)
Theme 2: Internal Data Generation and Usage
The second category of questions helped to explore both data generation and data usage. What type
of compound specific data were scientists generating? What format was this information stored in
and where was this stored?
Q: What information about particular compound(s) do you generate on a regular basis?
Where is this information that you generate currently stored? (ex: reports, databases, etc)
Q: What internal information about particular compound(s) do you use/consume on a
regular basis? Where is that information stored? How often do you access each of these
databases/info sources? Which ones are most important? (please rank priority)
Q: What are the key pieces of info you need to make a decision(s) in your role/job?
Q: Do you deal with compounds on a 1:1 basis or more as a set, using/viewing multiple
compounds at one time?
Theme 3: External Data Sources
Scientists were asked about their external (i.e. non-Novartis generated) data usage. The goal was
to identify websites and data services individuals were using so that frequently used applications
could be linked into Compound Homepage.
Q: What external data sources do you use? (ex: PubMed). What information do you
typically extract from these sources? How often do you access each of these databases/info
sources (daily, weekly, etc)? Which ones are most important?
Q: Do you think you would reference external databases more frequently if these databases
were available in one easy to find/click portal?
Q: How often do you go outside of Novartis to access information in an external database?
(daily, weekly, once a month)
Theme 4: Benchmarking the NIBR Information Environment
In order to evaluate Novartis's current environment for data management, interviewees were asked
how easy it was to find information they needed, how much time they spent trying to track down
data, etc. Password usage and resolution of access requests were also explored.
Q: How easy it is to find access to the internal information you are looking for?
Q: What information is easy to find? What information is hard to find? What makes it hard
to find/access?
Q: How much of your time do you spend looking for information? (avg. time per week)
Any specific examples?
Q: If you don't have access to a certain internal database how long does it take for you to
get access? Any examples?
Q: If you've had a job elsewhere in Pharma/biotech how did the data environment compare
to what we have at NIBR?
Theme 5: Web 2.0 Awareness
Interviewee familiarity with social networking sites and other external wiki's, such as Wikipedia,
was assessed. Additionally, questions probed beyond simple usage and investigated if individuals
had experience in actually editing or creating wiki's.
Q: Do you have any experience with using Wiki's (such as Wikipedia)? How much?
Q: Have you ever edited or helped to create a Wiki? If no, why not?
Q: Have you ever used Facebook? (yes/no), Linked-in? (yes/no)
Theme 6: Wiki Usage
Wiki usage questions explored the likelihood that the interviewee would actually contribute to an
internal Novartis compound wiki. Interviewees were also asked if they used any of the other
Novartis wikis (HTS pipeline wiki, safety profiling wiki, Target wiki).
Q: What wikis (if any) are you aware of at Novartis? Which of these do you currently use
on a regular basis?
Q: If the interface allowed for user input would you be interested in adding notes/text to
keep the Wiki up to date?
Q: Would you add content? How often (weekly, daily, monthly) Why or why not?
Q: How could we encourage people to add content to the wiki and avoid the "blank page
syndrome"?
Theme 7: Novartis Culture
Web 2.0 experts have previously noted that organizational culture is important for Web 2.0
adoption. 62 In addition to asking users directly about the culture, Novartis interviewees were
probed more informally on how they felt about sharing information, the likelihood of scientists to
want to post scientific information on an internal website, etc.
Q: What is the Novartis culture like surrounding documentation of work? Do people check
that things get documented appropriately? Do they care? Does this come up in year-end
reviews?
Q: How do people feel about sharing information? Would you be comfortable posting
information to a NIBR wide website? Any concerns?
Q: Should wiki users be allowed to add content and links? To what extent? Who should
input info? Should this be open to anyone in Novartis? Project team members only?
Theme 8: Exploration of Potential Compound Homepage Functionality
Lastly, specific functionality of Compound Homepage was explored. Users were asked about the
usefulness of linking; tagging, and wiki functionality
Q: How useful is the linking functionality? (The ability to go to the compound homepage
and have links to sources of information in Novartis on that particular compound).
Q: Do you think the "friends" applications within Facebook could have relevance for
compound Wiki? If so, suggest some useful "friends/network" groups of compounds.
Q: Would the friend/association groups actually be useful or just interesting to have?
Q: Would a compound wiki section, where you could post comments and write about
specific compounds be useful? Overall, would you use this tool (yes/no/maybe)?
Q: Is there any specific information or functionality that you'd like to see included in Wiki?
62 McAfee, Andrew. Personal Interview by Juliet Duffy. Aug 08.
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Chapter 7: NIBR User Research Results
Interview results were analyzed by grouping answers to specific thematic questions as well as
reoccurring comments together. In some cases, participants were directly asked to numerically rate
or comment on specific items. Where applicable, these answers are presented in graphical
distributions.
Methodology Disclaimer:
Interviewees were not selected from a random sample; rather they were identified on the basis of
recommendations from other interviewees. For example, at the completion of each interview,
individuals were asked "Who else would be good to talk with? or "Do you know any individuals in
department xxx that I could interview?"
Not all interview participants chose to answer each question, and some individuals provided
information about topics that were not necessarily asked about in the standardized interview
questions. In these cases, statistics specifying the percentage of individuals that felt or believed a
certain way are not available. Where possible, the author has attempted to designate if a majority
of individuals felt a certain way or if the expressed opinion was just of one particular individual.
All quotations presented are anonymous in order to protect the identity of individual
researchers/interviewees. Twenty two different individuals contributed quotations for this thesis.
All names referenced throughout the thesis, including in other chapters, have been changed and do
not represent the names of any employees within the Novartis organization.
7.1 Theme #1: Understanding job function
As expected, researchers at Novartis routinely engage in highly tacit knowledge based activities:
performing experimentation, analyzing data, evaluating multiple drug candidates at various stages
in the discovery pipeline, etc. Work is very information intensive requiring access to and
interpretation of a wide range of data. Novartis employees are highly trained within their scientific
specialties. The overwhelming majority of candidates that were interviewed hold PhD's in either a
subspecialty of chemistry or biology.
7.2 Theme #2: Internal Data Generation and Usage
Both the amount of data, as well as the diversity of the types of data surrounding chemical
compounds within NIBR is tremendous. Many types of data, as well as functional activities of
each organization can be grouped according to drug discovery phase. It is useful to highlight the
various stages of drug discovery at NIBR.
Drug Discovery at NIBR
sPoc PoC
Preclinical
Development Clinical
Optiiztion Study
Phase:
DO D1 D2 D3 D4
CSP= candidate selection point/process
sPoC= selection of Proof of Concept
PoC= Proof of Concept (in humans)
Figure 23: Drug Discovery Phases at NIBR 6
Drug Discovery Phases
* Do / Early Stage Discovery - This stage of drug discovery focuses on understanding the
biology of the disease. Specific biological "targets" within the disease pathway are
identified. Activating or inhibiting these particular targets change the phenotypic or
biological response. For example, inhibiting a specific target in a cancer pathway may
lead to tumor shrinkage/tumor death.
* D1 / Assay Characterization - Specific tests or "assays" are developed in order to
effectively measure the biological response to a specific drug. These assays will be
subsequently used to test different chemical compounds for their ability to either
activate or inhibit a specific biological target.
* D2/ Hit Finding - Millions of chemical compounds are screened within a specific assay
in order to identify chemicals that interact with the specific biological target. This
activity is referred to as "high throughput screening."
* D3/Lead Optimization - Specific promising lead compounds identified from the high
throughput screening are further refined. The compounds are optimized to create
suitable drug like properties. The safety profile, metabolites, pharmacokinetic
properties are studied and optimized for a particular chemical series.
63 "Putting Patients First - Meeting the Drug Discovery Challenge " Novartis Institute for Biomedical Research, New
Employee Orientation. Cambridge, MA. June 2008
Data usage and generation surrounding chemical compounds can be broken down into various drug
discovery phases. Although certain pieces of information are used or generated at all stages, the
majority of information tends to be pretty aligned with the development process (Figure 5).
Table 5: Examples of Data Related to Chemical Compounds
Discovery Stage Examples of Data Generated* Examples of Data
Usage*
Early Stage Target * Most data relates to targets and not to Chemical * Compound history both
Discovery & Assay Compounds (i.e. proteins, disease pathways, genetic internal & external
Development (Do, D1) expressions, etc) * Compound origination &
* Affinity Proteomics (3-D grid matching compound what library?
identification with cell type & protein pulled out) * Patent data
Hit Finding/High * Compound Identification Information. Analytical data such * Primary, secondary,
throughput Screening as liquid chromatography & high res mass spec safety profiling assay
(D2 ) * Synthesis route results
* Compound registration information * Compound purity &
* Primary -biochemical assays Identity information
* Secondary assays - counter screens to rule of false hits * Patent data
* Safety profiling results - looking for off-target effects
Lead Optimization * Metabolites - what kind of metabolites does this compound * Bioavailability
(D3) produce? * Identity of metabolites
* Pharmacology - In vivo (testing MTD - maximum * Results of toxicity
tolerated doses (you can't tell any adverse effects), ATD - studies in animal models
acute toxic dose. * Commercial information
* Phenotypic studies in disease area. Example: mice models * Formulation testing
of the disease, did the tumor change size, etc.? results
* Solubility for formulation
*Note: Examples are for illustrative purposes only and not inclusive of all activities
Information Storage Formats
* Specialized Formats - Data throughout Novartis is stored in multiple formats. Many of
these formats are very specific to the scientific application and require specialized software
to both view and store information. For example, analytical compound identification tests
such as NMR, Mass Spectroscopy, etc. are captured in a binary data format. Viewing and
manipulating these data requires the appropriate software package such as Advanced
Chemistry Development (ACD) or Top Spin. In some cases the data can be converted to an
image or an Adobe Acrobat file. In other instances the data must remain in a specialized
format (e.g. the specialized Spot Fire files used by the Global Discovery Chemistry
Chemogenetics and Proteomics group).
* Avalon Data Warehouse - Assay results for a particular compound test are housed in a
central database and accessed by users through a data warehouse interface called Avalon.
Individuals throughout the NIBR research organization rely very heavily on Avalon. Over
90% of Novartis employees interviewed motioned using Avalon. Information retrieval
from Avalon can be very difficult, especially if a user doesn't have specific metadata
information such as the type of assay, exact assay name, individual that ran the assay, run
date, etc. or if the user is trying to retrieve data for a very large number, 100+,
compounds/tests.
* Importance of PowerPoint- Many data files and summary reports are stored in a
PowerPoint format. NIBR teams rely so heavily on sharing information through PowerPoint
that one particular individual dubbed PowerPoint as "the official currency of
Novartis. "Almost every individual interviewed mentioned using or storage some type of
data/information within a PowerPoint file.
* Science is visual -Science is a very visual language. Chemists communicate primarily
through drawings of chemical structures, assay results are often best viewed in a graphical
format (IC50 curves), and biology is understood and communicated in pictures
(DNA/protein bands on an electrophoresis gel, pictures of tumor shrinkage, etc). One
reason that PowerPoint is heavily utilized is the ability to import and annotate many
different types of visual images.
Team Centric Data Organization
The data environment at Novartis Research is highly organized around project teams. Information
is shared among team members primarily via a team data storage site. Three team sites are
common: an internal shared storage drive (G:drive, L:Drive, etc), a Lotus Notes Team Space
(similar to a shared drive) or an external collaboration platform (Groove) used when teams
communicate with external collaborators. Specific file storage and organization guidelines do not
exist on a global level. Instead, organization structure is highly dependent on each particular team.
Some teams have very organized structured files in one particular location. Other teams store data
randomly across multiple different platforms including email.
"How a project team captures information is very individual for the team. Things are stored
multiple times, in many different places. For example, on my most recent project we primarily use
our G: drive folder and Groove (shared collaboration software platform). However, some
presentations, like those for decision board, will go to the decision board team space. It's pretty
much up to the project team leader to decide how/where information is stored".
Restricted Access
Team file storage sites are heavily password protected and restricted solely to team members. As a
result, the majority of data is not visible outside of the immediate team. Additionally, team sites
and locations are often buried so it's very difficult for those outside of the team to even locate the
shared drive, never-the-less obtain access to it. Multiple interviewees expressed frustration with
their inability to access team data.
"Data from other projects that's not already in Avalon is impossible to find without help. To get
access to other team's folders or G:drives you'd have to specifically ask the project team leader for
permission"
Viewing Individual Compounds vs. Sets
Many times, scientists are not interested in one particular chemical compound, but rather a set or
series of different compounds. Usually a particular drug scaffold is identified and individual
chemical groups are modified on that core chemical scaffold in order to improve the properties of a
compound. For example, replacing a highly hydrophilic (water loving) group with a functional
hydrophobic (water hating) group will increase a compounds ability to pass through the lipid bi-
layer membrane of a cell and access intracellular targets.
Many teams classify and define lead chemical compounds by grouping them into particular
collections based on structure similarity of core scaffold properties. An example of this is shown
below (Figure 24).This particular project team classified their lead compounds in six different
chemical series. Each series contained anywhere from 1-100+ compounds and were tracked via a
team excel spreadsheet. Specific examples of individual chemical compounds are noted by black
dots associated with chemical compound code names (i.e. RAL122).
Note: all chemical code names, individual series, and milestones presented in the figure below are
not accurate and have been altered significantly in order to preserve data confidentiality.
Compound Series Organization
XFR251
RAI122m
RF 71XPFi28
QEN293
XN 0022
BWL428 QW =111 JFZS
Phen 14tridazoaes. . FP,4
RTW42'r9
D2a D2b D3 CSP sPOC
.. CSP sOC .
Hit Lead LeadHitto lead Nominaton Optimization
Figure 24: Example of Project Organization by Chemical Series*
*Note: all chemical code names, individual series and milestones have been altered in order to disguise data
Individuals participating in the user interviews were specifically asked "Do you deal with
compounds on a 1:1 basis or more as a set?" The majority, 56% percent of individuals surveyed
indicated that they dealt with compounds on both an individual and a grouping basis.21% percent
of survey respondents only examined compounds as a set, while just 12% of respondents reported
only looking at compounds on a one-on-one basis (Figure 25).
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Figure 25: User Interview Results, "How do you deal with Compounds?"(n=34)
Q: Do you deal with compounds on a 1:1 basis or more as a set?
"It's important to examine compound series as a set to see if there are trends across the
whole compound series"
"We look at more thanjust one compound. More often we are interested in 1, 000 structural
analogs of this".
"On an individual basis- I'm an organic chemist, I only synthesize one compound at a
time. "
"Both extremes. Sometimes I want to know exactly about one drug. Sometimes you want to
know about the entire class of compounds ".
Often the need to examine either individual compounds or sets of compounds was driven by the
stage of the project. High throughput screening and the examination of structure activity
relationships (SAR), changing specific compound functional groups and monitoring how biology
activity changed with structural modifications, tended to warrant examination of large sets of
compounds. Conversely, literature examination, refining the compound to eliminate a safety
liability, or testing a specific compound in animal models demanded examination of an individual
compound.
"I examine both sets of compounds and individual compounds. In the beginning of the
project I tend to only look at one compound (who made compound, why was it made, etc?)
as project progresses we know the structure activity relationship (SAR) we'll tend to look at
more sets"
"Both. The outcome of a screen is a huge set. The challenge is to get rid of noise and find
the diamonds. To do this I have to prioritize clusters (as a set). Other times I'll only want
to look at a specific compound. This might be a compound inspired by literature, or I'll
want to know very specific compound properties (permeability, solubility, etc)"
Size of Sets
In order to understand how users will want to view sets of compounds, and the implications for
viewing compound groupings within the Compound Homepage system, it is important to
understand the relative size of the chemical sets. Individuals that specified that they examine data
in sets were asked specifically what size sets they typically examined. Apart from high throughput
screening activities, which deal with hundreds of thousands of compounds at one time, answers
tended to fall primarily within three size categories. The distribution of answers was roughly
evenly split between the three sized groups indicating approximately equal usage of each sized
group.
* Small sets (10-30 compounds)
* Medium Sized Sets (100-200 compounds)
* Larger sets (1,000-3,000 compounds)
7.3 Theme #3: External Data Sources
In addition to examining internal NIBR data sources, external data databases that contained
information about chemical compounds were identified. The list below was obtained from the
NIBR Information Technologies group (NITAS) and gives an idea of the large number of external
data sources available with information on chemical compounds.
Pharmapendium
Patents
CERES
Feed
Prous Integrity
Pipeline Databases
GVK
GeneGo
WDI
ChemSpider
CAS sources
Medline PLUS
Various FDS/EMEA sources
PubChem
DrugBank
PDR
KEGG
ChemDI
Vendor Databases
Wikipedia
Human Metabolic Database
IUPAC Gold Book
Figure 26: NITAS list of Available External Databases
Scientists were asked about their external (i.e. non-Novartis generated) data usage related to
chemical compounds. Every time an individual reported using a certain external database, that
database was added to a list. The compiled list, ranked according to frequency of reported usage, is
presented below (Table 6). Interestingly, Wikipedia was cited three times and Google was cited
twice as data sources that were used on a regular basis.
"Wikipedia is a very, very useful tool. I use this daily. It's also amazing what one can find
in Google without having to do a literature search. "
Additionally, the usage of a database portal was explored. Scientists were asked "Do you think
you would reference external databases more frequently if these databases were available in one
easy to find/click web portal?"
~~I11~_ Ij I
Table 6: Usage of External Data Sources (reported during user interviews)*
# of people
reported using Database Name Description of Database (if available)
database
8 Database of compounds that have demonstrated biological
Prous Integrity activity. Contains proposed mechanisms of action.
7 Contains 2M compounds with their known biologicalGVK
activities taken from patents & literature searches.
7 "PubMed includes millions of citations from MEDLINE and
other life science journals for biomedical articles. PubMed
PubMed includes links to full text articles and other related
1,64
resources 4
7 S d References from currently published journals and patentsSciFinder from more than 59 patent authorities 65 .
4 Pharmapendium Information on drugs & their established side effects
Pharmapendium
4 Bioinformatics pathways database but they recently startingGeneGo linking in compounds.
3 World Drug What it a clinical candidate? Was it a drug? Was it ever
Index (WDI) withdrawn? etc.
3Wikipedia Online, collaborative encyclopedia written by volunteer
authors around the world.
3 Patent Structure Markush structure as well as individual structures linked to
Searching Intellectual property information.
2 "ChemBank is a public, web-based informatics environment
ChemBank created by the Broad Institute's Chemical Biology Program.
Includes freely available data derived from small molecules
and small-molecule screens". 66
2 NCBI databases National Center for Biotechnology Information, databases of
(OMIM) gene sequences.
2 Google World Wide Web Search Engine. www.google.com
*Note: Databases with just one person reporting usage are not show in this table.
64 PubMed, NCBI, n.d. Web. Accessed 2 May 09 http://www.ncbi.nlm.nih.gov/pubmed/
65 SciFinder Website, American Chemical Society, n.d. Web. Accessed 2 May 09
http://www.cas.org/SCIFINDER/SCHOLAR/
66 "What is ChemBank" ChemBank, n.d. Web. Accessed 2 May 09 http://chembank.broad.harvard.edu/
External Data Usage and Awareness
There was a fairly wide discrepancy of individual databases used by scientists. Prous Integrity,
GVK, PubMed and SciFinder databases were mentioned routinely (Table 6) by scientists but over
fifteen other databases were referenced by just one individual. Although certain databases are
specific to only narrow job functions, in general many of the chemical databases could potentially
be useful for a wider audience. It is hypothesized that many employees simply don't know about
the existence of these databases.
Individuals within Strategic Alliances, the business development in-licensing group, talked about
licensing the use of ChemNavigator for Novartis. ChemNavigator is a huge clearing house with
over 12 million different compounds. A user can search for a specific compound and then order it
through a catalog or "explode the hit by catalog". Ordering such chemicals could save chemists a
significant amount of time in the synthesis of new chemical structures. Often, synthesis steps are
complex and require a significant amount of research and time. The ability to order something
close to the end product, further along in the synthesis pathway, would be a significant time and
money saver. Despite the potential benefits of this tool, only one chemist that I spoke with had
even heard of ChemNavigator. In an environment of information overload it is difficult to locate
and keep track of potential resources.
Passing Through Compound Identification Information
Simply directing users to external databases via hyperlinks in a web portal would help to raise
awareness but is not necessarily any more effective then ensuring scientists have bookmarked
external web access points of interest. Indeed, when scientists were asked about their usage of
external data sources over one-third of scientists resorted to opening up their web browsers to view
their bookmarked favorite sites. One of those scientists commented:
" Why would I use this portal ifI already have my favorite databases bookmarked? It's not going
to help my life. "
The real power of an external database portal would be enabling timely and effective search by
passing the appropriate compound name automatically to the database of interest. This would save
users a significant amount of time. Currently, every time the user enters a new database he/she is
be required to re-enter the chemical name in order to search that particular database.
By instituting an information pass through, a user could navigate to a particular internal Compound
Homepage and then execute the external search for a number of different databases directly from
that page. One individual commented:
"A portal is useful only ifI can pass through a compound identification and not have to re-enter
into the search each time. "
Intellectual Property Protection
Searching external databases for information on chemical compounds, with or without a chemical
name pass through potentially puts the organization at risk for compromising data security. The
fear is that another pharmaceutical company or competitive intelligence gathering entity might
monitor searches of external databases originating from Novartis. By gathering the search criteria
a competitor could deduce what specific chemical compounds are of interest, prior to the patent
filings of those compounds. Novartis already has specific guidelines in place to limit the use of
this practice. At least four individuals brought this up as a concern:
"Functionally an external search hub would be beautiful. Practically there are a lot of concerns
about passing proprietary compounds over the firewall into external databases without having any
level of security. "
"Should we pass information to an external databases? Ifyou pass say an inchikey identification
string how strictly do you read Novartis guidelines, etc. ? How much do you trust the websites you
are passing to this? Basically, to be safe you'd have to wait until Novartis had filed a patent on
that particular chemical compound. This would probably not occur until the late D3, lead
optimization stage"
Eliminating the intellectual property risk would be possible and has already been done by several
different individual departments. Novartis obtains licenses to a number of commercial external
databases. These agreements can be structured to allow Novartis to import a specific database.
Once an internal copy of the database is available within the internal firewall searching is safe and
secure.
Searching for structural similarities
Eight interviewees mentioned the need to execute external searches not only by individual
chemical compounds but also by a specific series or related group of compounds. Often a
particular chemical compound will not have any public literature or any information associated
with it, but a closely related structural analog will have published literature. Finding these close
chemical analogs can be extremely powerful in both avoiding an already patented chemical space,
as well as predicting biological functionality and properties by similar associations.
"I like to be able to execute a structural similarity search with all literature in the public domain
for a particular chemical scaffold. For example, if I have a certain scaffold I'd like to know that
information was published on a similar structure, say without a certain nitrogen group. "
7.4 Theme#4: Benchmarking NIBR's Information Environment
In order to evaluate Novartis's current data management environment interviewees were asked how
easy it was to find information they needed, how much time they spent trying to track down data,
etc. Password usage and timely resolution of database access requests were also explored.
It is difficult to find certain types of information
In order to benchmark the current data environment, interviewees were asked "On a scale of 1-10
(l=extremely difficult), how hard is it to find information you are looking for?" The majority of
interviewees reported that it was difficult to find information within NIBR's corporate
environment. The distribution of answers ranged from 1 to 8, with an average score of 3.8 (Figure
27).
How hard is it to find information you are looking for?
(Scale 1- 10, with 1=extrememlyhard) n = 22
Figure 27: Distribution of Interviewee Responses
A large portion of interviewees indicated that their ability to find information was highly dependent
on what type of information that they were searching for. Of the thirty two interview participants
who we asked to rate their ability to find information, roughly 1/3 refused to answer the question
on a numerical scale and simply stated "It depends" or "It's incredibly mixed. "
"The ability to find information can really range from 1-10 depending what you are looking for"
1 2 3 4 5 6 7 8 9 10
Participants were therefore specifically asked to define examples of information that was hard to
find as well as easy to find. A number of different themes emerged from this questioning and are
presented below.
Current Data Environment is Not Intuitive
Interviewees consistently stated that one of the problems with the current data environment was
that it was not intuitive to navigate. The author's experience at Novartis echoed this. Many
different databases and information systems are present but it's difficult to navigate between these
or even develop the detailed knowledge required to use a particular system. This is especially
difficult if the data system was not used on a regular basis.
The author frequently had very detailed discussions with interviewees about Avalon, a particular
chemistry data warehouse system. The author was surprised at the extremely wide-range of user
expertise for this particular system. Some users were Avalon experts and could extract and
manipulate a large amount of data from the system. Other, even routine users had only very basic
knowledge of the system. Over ten interviewees made comments stating "Avalon is incapable of
xxx". In reality, the system was capable of that functionality; the user just didn't have knowledge
of how to perform that particular function. The wide-discrepancy of user expertise is most likely
attributed to the fact that Avalon is not intuitive. Many of the features are not obvious and require
detailed training to understand how to use the full range of functionality.
"Many people don't know how to use Avalon, I'd say 80% of my colleagues don't know how to use
Avalon. "
As the information environment is not intuitive and very fragmented, users are forced to climb up a
very significant learning curve. As a result, productivity is substantially lower for new Novartis
employees or those individuals in new job roles and positions. The problem is so significant that
one particular Novartis department developed an informally run training session for all new
employees. A seasoned departmental expert, someone who had been at the company for 20+years,
routinely sits down with all new employees and reviews "how to go about finding things at
Novartis". This particular individual was requested to teach this class so often, that he had even
developed rough syllabus and supplemental information.
Improving the usability of data warehouse systems or providing information in a very easy to
search web based environment could significantly lower the learning curve and improve
productivity. Two individuals expressed their frustrations:
"How hard is it to find information? Using the official tools, with official training I would give this
a "0 ": Becoming creative and using my network, I'd give it a "6"
"When Ifirst started (at Novartis) it took quite a bit of time to find things. Now I know where to
look. "
Information that is easy to find
Information that was easy for individuals to find fell in approximately four different categories:
* Data within project teams - Employees expressed general satisfaction with being able to
find data within their specific project teams. File storage organizational structure varied
from team to team but in general project teams stored data within a Lotus Notes team folder
or a particular shared hard drive space (example G:drive). Members of the team had access
to this information and seemed to be able to navigate relatively easily throughout the shared
drive/folder space. Teams were slowly adopting SharePoint, with some team files stored
within the new SharePoint team spaces.
* Current data- Several individuals commented that they can easily find/access information
that was created within the past year.
* Information that is stored in current Novartis Wikis/Web Portals - Several
organizations within Novartis have recently created Wiki/Web Portals targeted to capture
specific information generated by their department. The "Profiling Wiki" is a linking portal
that integrates in vitro safety screening information for specific compounds into a one-page
summary snapshot of safety information. This profiling wiki was mentioned repeatedly in
user interviews as data that was easy to find. An example of a profiling report is presented
in Appendix C (note: the compound is a publically available, non-proprietary Novartis
compound).
* Physical/Chemical Properties of Compounds - Specific chemical properties such as
solubility, purity, dose response curves (IC50 results), etc. are stored in a central NIBR
wide-database and accessed through a data warehouse called Avalon. The general census
was that this type of information was easy to find and retrieve if the user had access to
specific metadata (i.e. the exact name of the assay, project code, etc.)
"In Avalon - ifyou have a very specific query and knowledge how to get data it's easy"
Information that is difficult to find
Interviewees were specifically asked to indentify information that was difficult for them to find.
Answers tended to align along six different themes. Firstly, information outside of an employee's
immediate sphere of influence (e.g. project team or department) was often difficult to locate. In
particular, in vivo data was specifically difficult to locate. Next, metadata, the contextual
information surrounding experimental results, was infrequently captured. Additionally, accessing
data for large sets of compounds and project status updates were difficult. Lastly, historical data
including project decision rationale or information about project/compound failures was
problematic. Additional specifics of the six categories are discussed in more detail below:
* Information outside of my project - The data environment at NIBR is highly organized
around individual project teams. It is often very difficult for employees to access information
outside of their immediate team environment. Five individuals specifically voiced their
frustrations at the difficulty of finding information outside of their immediate teams:
"I would rate the ability to find information at NIBR a 2 or 3 because it's hard to find
information outside my project. "
"Data from other projects that's not already in Avalon is impossible to find without help. To
get access to other team's folders or G:drives you'd have to identify and specifically ask the
project team leader for permission. "
Avalon, the information warehouse for chemical compounds serves as the primary mechanism
for providing cross-organization visibility outside of project teams. Avalon provides numerical
testing results and is unable to capture the rich data required for drug discovery.
* Animal and Human Clinical Data - Information relating to compounds further along in the
research development process was repeatedly mentioned as difficult to access. In vitro
(lab/bench top testing results) were easily accessible but in vivo data (animal or human testing
results) were almost impossible to locate for individuals outside of the immediate project team.
When asked "What information is hard to find?" seven people specifically elaborated on the
difficulties associated with gaining access to in vivo data.
"In vivo information or data that was produced just with a program is impossible to find.
You'd have to know the biologist or pharmacologist to get access to this data .Novartis is good
at capturing early data (in vitro) but once compounds are tested in vivo we don't capture this
systematically. "
"Human PK data is impossible to get and we need to have this! I can't get a simple table of
average oral bioavailability and dose for the drugs we put in phase I. I have no idea how these
drugs fared in man. I don't even know what database this information is located in. "
"What data is impossible to access? Animal studies that have been done with the compound. "
"One of the key things I'd want in a wiki/data portal would be in vivo data generated in the
disease area pharmacology groups and MAP. This data is just not accessible at the moment.
It would even be useful to just know that this data exists. "
"Clinical stuff is hard to access. Even ifyou have access it's hard to get anything useful out of
this. You can't effectively search this data; it is structured by report study number. You don't
know what study is for. The database is designed to please the FDA, not to help research
scientists. "
* Metadata/Contextual information for assays - Finding exact testing results, such as the
numerical readout from particular assay, is easy. In contrast, finding the surrounding contextual
information related to assay conditions is difficult if not impossible. Ten different individuals
specifically commented on the difficulties associated with finding assay metadata such as:
project and target association for each assay, information for how the assay was ran, assay
relationships in the project (what was the primary, secondary/counter screen assay, etc.)
"Finding data is easy but finding the context of how it's generated is hard. An IC5o assay result
only has value to me ifl know how the assay was run, etc. I could go and read a 30 page
research (RDS) document but I still don't understand the context. Why was the assay changed?
This is not reported and it takes so much away from quality of information. "
"Avalon gets cloudy with legacy information. You don't know how assay was run, etc.
It would be nice to have easy access to these assay conditions. "
"Sometimes you can't even track down how the assay was run. It would take me four days to
find out how these five assays are different and how they cross compare ".
* Project Stage -Often, information detailing what project development phase a particular
compound is in is difficult to locate. In particular, two individuals mentioned difficulties with
tracking project stage information for compounds that were in more advanced development
stages.
" What stage is a particular compound in at any one point in time? In the later stages of
development this info is hard to find. I've developed my own personal list to keep track of
these. There should be a central place where this is made available to all. "
* Batch Data - Information related to a single compound can easily be extracted from Avalon.
However, extracting the same information for a series of compounds is often very difficult
using the available tools and data infrastructure. Five individuals voiced specific frustration
with their inability to extract batch data from Avalon.
"Avalon is very easy to access ifyou only need information on ten compounds. It's impossible
to access in batch way without the use of workaround tools. "
"My group is looking to identify macro level data trends. However, ifyou ask Avalon a
research question on a large scale (1, 000+ compounds) it falls apart. The system is too
clunky"
* Historical Data and Project Decision Rationale -Historical project data is difficult, if not
impossible to access. Fifteen different interviewees expressed frustration over not being able to
locate rationale surrounding compound synthesis, project team decisions, or compound failures.
"It's hard to find the rationale for the synthesis of a compound Is this a byproduct of some
synthesis route or the end goal of a problem that that the team was trying to resolve (i.e. is this
a heart safety issue?) Knowing this type of information would be unbelievable!!
"I have to go chasing chemists down and ask "why did you make this compound?"
"It's hard to understand what the history of a compound was. You can guess from assay data
or project team names. The research (RDS) reports get you a little bit farther but it's difficult
to piece together the entire story of the compound. You really need to find the project team
leader or someone that worked on this project. "
"Only the compounds going forward are captured - nothing documented for the ones that
don't get selected and rationale for why those didn't get selected is simply lost ".
Database Access and Password Protection
Interviewees were questioned about their ability to gain access to different databases within NIBR.
Over 50% of users reported that data base access was not an issue and that it typically took only 1-
2 days to gain access to the majority of NIBR databases. Clinical databases, outside of the NIBR
organization were more difficult for individuals to access. Several interviewees reported waiting
for 2+weeks to gain access to these databases. Others stated that they were simply unable to gain
access to clinical data.
While database requests for access were not a major issue, password control projection was often
cited as a frustration for users. Interviewees were not specifically questioned about the NIBR
password environment. None-the-less, seven users adamantly commented how often they were
required to enter various passwords, multiple times, in order to gain access to data. Two
interviewees went to extensive lengths to personally demonstrate the amount of password control.
In the first case the interviewer attempted to access an in silico profiling tool by navigating through
various bookmarked webpage links. Over fifteen minutes and five required password entries later,
the site was finally accessed.
"You have to use different passwords to get into all these systems. Then you spend half your life
typing in passwords and they all change at different times.
"Get rid of the password hell. Can we do away with this sometime? I want to be able to log in
once, and not have to repeatedly enter passwords through each new web browser. "
"Databases are nightmare - they ask me for password over and over. "
7.5 Theme #5: Web 2.0 Awareness
Wiki Awareness
Interviewee familiarity with internal and external wikis was assessed as well as awareness of
several social networking sites. Interviewees were asked if they had experience using wikis. 100%
of interviewees reported having at least looked at or used a wiki for information, 61% specifically
cited using Wikipedia.
Several internal Novartis wiki/web portals have been developed are currently in use within the
organization (Table 7). The high throughput screening (HTS) and safety profiling wiki were
developed within the Center for Proteomic Chemistry (CPC) group while the Target wiki was
developed within the Developmental Molecular and Pathways, a group primarily responsible for
identifying new disease targets. In addition to asking about outside internet based wikis,
interviewees were polled about their familiarity and usage of these various internal NIBR Web 2.0
tools (Figure 28).
Table 7: NIBR Currently Existing Wikis
Name Description / Functionality
High Throughput Primarily used as a web portal. Provides HTS project updates and links
Screening (HTS) to relevant project resources such as team members, relevant reports, etc.
Wiki
Primarily used as a web portal. Links to safety and target information
Safety Profiling Wiki associated with safety profiling screening assays. The majority of the
information is updated and provided by the CPC safety profiling group.
Target Wiki Wiki organized around disease target. Drug discovery targets are
organized by wiki page.
What Wlki's (if any) are you aware of at Novartis?
70%
60%
50%
50% --
40% - -
S30%
2.0% 20% --------------- t*-
High Target Wiki Profilirg Wiki None
Throughput
Screening
Figure 28: Interviewee Familiarity with Internal Novartis Wiki's/ Web Portals
Social Networking Tools
In addition to wiki usage, familiarity with several social networking tools was explored. Users
were asked if they used Facebook (www.facebook.com) and Linked-In (www.linkedin.com), two
popular networking tools. Only 15% of users reported that used Facebook while 67% of users had
used Linked-In (Figure 29).
The mention of Facebook often tended to be polarizing and somewhat generational. Although the
age of interviewees was not specifically asked for or recorded, younger Novartis employees
reported routinely using Facebook while many older or middle-aged employees stated that they had
"heard of Facebook" but choose not to use it. Two users had a very negative reaction to Facebook.
Comments included: "No, I don't need something to keep track of all of my friends!!" and "No, I'm
not into human networking."
Have you ever used Have you ever used
Facebook? Linkedin?
ia No n No
SYes 8 Yes
Figure 29: Facebook (n=26) and Linked-In Usage (n=24)
7.6 Theme #6: Wiki Usage and Motivations for Contributing
Motivations for Wiki Contribution
Motivation for user contributions to both general wikis as well as Novartis internal wikis was
explored. Interviewees were asked if they had ever edited or helped to create a wiki. A large
number of those surveyed, 44% of respondents had contributed to a wiki in some capacity. The
majority of those contributions were to a Novartis internal wiki, specifically the High Throughput
Screening wiki or the Safety Profiling wiki. Conversely, 56% of interviewees responded that they
had never contributed to or helped to create a wiki either inside of Novartis or elsewhere. When
asked why they had not contributed individuals cited a variety of reasons, the most common was
that they simply didn't have the time (Table 8).
Table 8: Reasons Cited for Not Contributing to a Wiki
Reason % of
respondents
I don't see the value 14%
It would be a conflict of interest to add knowledge to an 7%
external wiki that was associated with my work
Reason was not identified 36%
Would individuals be more motivated to contribute to an internal Novartis wiki verses an outside
internet wiki, like Wikipedia? Evidence of this is mixed. On the one hand, 81% of individuals
reported that they would add content to a Novartis compound wiki tool if it was available.
However, when asked how frequently they would contribute 60% of interviewees stated that they
would contribute either monthly or less than once a month (Figure 30).
How frequently would you contribute to a
compound wiki?
i Anytime I had data
* Weekly
a Monthly
a Infrequently (less than
once a month)
v Unsure
Figure 30: Anticipated contribution frequency for NIBR Compound Wiki
Critical Factors for Wiki Contribution
Several factors were identified from user comments as being critical toward obtaining adoption and
usage of a compound wiki.
Ease of Adding Information-Users consistently expressed their desire for a system that
required minimal work to add content. Novartis employees typically already have large
workloads and are consistently working under tight time deadlines. Anything that requires a
significant amount of effort would face adoption hurdles.
"To encourage adoption you should make this something that requires absolutely zero work "
"The wiki must require minimal mouse movement to encourage people to add content. IfI have
to go to the wiki, find the correct compound page, then click on edit, enter a password before I
can edit, forget it".
MediaWiki software, the platform used for Wikipedia, requires users to enter text in wiki syntax
language (Table 9). Although not complicated, the syntax can be intimidating for users who are
new to wiki editing. It also presents an additional learning curve. It is unclear that users would be
willing to overcome this learning curve to contribute to a Novartis wiki. Several wiki software
platforms are available that allow users to enter text in a MS Word like format for example, hitting
a "bold text" button, rather than requiring user to enter **bold text**. The use of such a software
editor will be critical in facilitating ease of use for data entry.
Table 9: Examples of Editing in Wiki Syntax Language -
**bold text** bold text
underline text underline text
normal superscript^^ normalsupe
rscript
Employees expressed their desire to add comments and content in multiple ways, rather than being
forced to open up a web browser and navigate to a compound homepage each time they want to
make a contribution to a compound page. Requests for posting functionality included having the
ability to directly post the contents of an email to a wiki page. One individual suggested having a
macro included in either MS Word or PowerPoint that would allow a user to highlight specific
content and post that content directly on the Compound Homepage.
"I'm already generating a lot of content about compounds in management reports etc. I'd like to
have a macro in MS Word that would allow me right click on text and specify "release content to
wiki." Otherwise entering in info becomes repetitive. I'm suddenly a high priced secretary putting
information in different places. "
* Easily link to multiple files/formats - Information content about compounds is currently
being generated in a variety of MS PowerPoint files, Excel documents, and Word reports.
Individuals will not re-create this information specifically for the wiki. Therefore, it will be
imperative to create an environment that supports linking to and uploading external file content.
* Web Portal Performance - Page upload time will be critical for performance. Components of
the Compound Homepage that extract and display information from other databases will need
to load swiftly. Users will not wait for the system to pull real time information from multiple
different databases. According to interviewee comments system speed and performance are
highly preferred over real time, 100% up-to-date information.
* Clear Definition of Data Sources -Compound information at Novartis exists in a variety of
databases and formats, often users rely on their knowledge of internal databases and sources to
determine what information is the most accurate and up-to-date. Web portal sections of the
Compound Homepage should identify the data source and if possible link back to the original
67 Wiki Syntax, Inline Formatting, Wikidot, n.d. Web. Accessed 19 March 2009 http://www.wikidot.com/doc:wiki-
syntax
data. An index page specifying the data source of each item would be helpful for this purpose.
One individual expressed the importance of being able to identify source data:
"It's not always hard to find data but the issue can be getting "good" data that you know is
accurate and reliable ".
Integration into project work streams - The most common theme that interviewees stressed
for user adoption was the incorporation of the Compound Homepage into existing project work
streams. As work within NIBR is primarily centers around project teams, a system that
integrates Compound Homepage usage into the project team work flows will be the most
effective for capturing compound information.
"I'd add information about once a month about the compounds I'm working on. However, ifI
was actively using this for my project, I'd do it more often ".
Additionally, integrating the compound homepage into existing work streams will ensure that
compound information anddecisions are captured as they occur.
"It would be difficult to make the compound and then later add comments. It would be easiest
to capture at the moment you made the compound - some filed lab notebook that would feed
into the Compound Homepage. People won't be willing to go back later when they've
generated hundreds of compounds."
"I've made thousands of molecules. I'm not going to go and comment on each one unless it's
part of registering the compound. Otherwise, this would take too much time. "
Based on the author's observations, the existing Novartis culture often focuses on short term
goals and deadlines. As such, the average scientist is not necessarily thinking about the value
of capturing information for long term organization learning. Integrating compound
information into the typical work flow would ensure that this information is both preserved and
shared throughout the entire organization. One individual commented:
"How should we motivate people to add content? This is the classic problem of having a rush
to get to the next deadline. Everyone in the project team knows what's going on so they know
why things are going on, what compounds have been made, etc. Putting info specifically into a
wiki would really be for the outside world. We don't recognize the value or importance of that
relative to our short term goals. "
Ability to comment on a group of compounds- Scientists at Novartis not only examine
individual compounds, but also routinely analyze sets of compounds (Figure 25). Interviewees
consistently commented that they wanted to be able to add commentary that applied to an entire
set of compounds.
"I'd like to have the ability to add the same comment to a specific set of compounds. I'm not
going to individually go to each Compound Homepage and add this comment for each
compound. "
"On my project we are working with approximately 1,900 compounds. Ifyou could divide list
up that big list into smaller series that would be more useful. You could then have a discussion
on a series, rather than an individual compound "
Potential Roadblocks for Wiki Contribution
* Time - Employees are consistently working under tight timelines and struggling to meet
immediate deadlines. Taking the time to add commentary to a compound homepage was
often perceived as a luxury. Several interviewees openly stated that adding comments to a
wiki would fall lower on the priority list.
"I love the idea of adding to a wiki but realistically I don't thinkpeople will actually have
time to put information in here. It's very hard to take the time to go through and make a lot
of commentary on things that have been done. We tried to do this - 2 years ago with Focus
but this never got off the ground. It turned into more of an email exchange. "
* Compound Space is Infinite - The Novartis compound library contains millions of
chemical compounds. It will be unrealistic to expect that employees will contribute
information on the majority of these compounds. The compound space is too vast in
comparison to the potential number of contributors.
"There is a good chance people won't add anything - especially for all library
compounds. "
* Organizational Culture - Organizational culture will be a significant driver for
Compound Homepage adoption. The user interviews provided an extensive glimpse into
the Novartis culture and attitudes about information sharing. A complete analysis of the
currently Novartis culture and its implications for wiki adoption are presented in the next
chapter.
Chapter 8: Novartis Culture and Three Lens Analysis
8.1 Three Lens Organizational Analysis Overview
Web 2.0 experts have previously noted that organizational culture is important for Web 2.0
adoption. 68MIT Sloan Management Professor John Carroll advocates a three lens approach to
analyzing company culture and how change will affect a given organization. He argues that it is
important to consider an organization based on three distinct viewpoints or "lenses": strategic,
cultural, and political. 69 This organizational analysis framework is taught within the MIT Sloan
MBA management curriculum and has been applied to NIBR organization in order to analyze
barriers of adoption for the Compound Homepage Web 2.0 tool. As part of the analysis specific
interviewee comments are highlighted and discussed as they provide additional insight into the
culture and challenges of managing organizational change.
8.2 Cultural Lens
The cultural lens component of the three lenses analysis explores organizational behavior based on
cultural values within the organization. An organization's traditions, customs, accepted norms, and
"the way we do things around here and why we do it" comprise organizational cultural.70 Cultural
norms and behaviors relating to data management and data sharing are explored below.
Continuation of Academic Culture
Novartis research has a culture driven by academic values and ideals. The majority of scientists
are at a PhD level, meaning that they have spent 4-6 years within an academic laboratory setting
getting aPhD, often followed by a 2-4 year academic post doctoral experience. As a result, the
university academic lab culture carries directly over into the Novartis research organization and
drives a number of cultural beliefs and behaviors.
Independence
Independence is highly valued within Novartis. Scientists are used to operating in the academic
environment with nearly complete autonomy. They expect a similar environment in the work
place. As a result, Novartis project teams operate as very independent units, and drive a project
through the drug discovery path at their own discretion.
68 McAfee, Andrew. Personal Interview by Juliet Duffy. Aug 08.
69 Carroll John, "Introduction to Organizational Analysis: The Three Lenses" MIT Sloan School of Management
Working Paper. 14, 1-13. Sloan Communications Office (2006).
70 Ibid. (69)
Evidence of Independence:
Novartis is starting to implement Microsoft SharePoint, a software package designed to
encourage team collaboration, forums, blogging etc. SharePoint is relatively new and
several groups within the Global Discovery Chemistry (GDC) organization as well as the
IT group (NITAS) are attempting to provide a standardized format for the team workspace
so that data search and file structures can be easily coordinated around the company. This
common workspace has received push-back from several team leaders. They have strongly
stated the desire to create their own unique team spaces, rather than comply with any type
of pre-defined template.
General Implications:
Independence is a double-edged sword. One on hand, it's a very necessary part of the
scientific process. Some of the greatest scientific break throughs would have been
impossible without independent thinking and experimentation. On the other hand, such
independence hinders a coordinated effort and systematic approach to drug discovery.
The Importance of the PhD and Subject Matter Experts
PhD's are designated at Novartis by the title "Lab Head", a title that confers an elevated status
within the research organization. PhD's make a majority of the decisions, tend to get preferential
access to data, and are in charge of running each research lab. PhD's further distinguish
themselves by becoming experts in certain scientific areas. Individuals have expressed hesitancy to
believe data or even scientific hypotheses unless they were made by so called experts.
Evidence:
* Up until only a short time ago Avalon, the data warehouse containing information about
research compounds, was only open by default to individuals with a PhD. In order for
someone with BS or MS qualifications to be able to gain access to data, a PhD had to
advocate on their behalf, often jumping through several organizational hoops to get their
associate approval. Although this has recently been changed and many non-pHD's have
access to Avalon, the mentality associated with restricted access still remains.
General Implications:
* It is the author's opinion that the organization has the potential to dismiss contributions
from non-PhD associates or those without deemed appropriate level of scientific expertise.
Compound Homepage specific implications:
How will the PhD hierarchy transfer to a Web 2.0 environment? Will individuals trust and
believe data if they don't know if the post was made by a PhD or a project "expert"?
Additionally, should non-experts be allowed to contribute to the user community? Will
others believe and value the information that these non-credentialed employees post?
Interviewees in the user research study were specifically asked "Should the wiki be open anyone
who wants to add content and links? Who should be allowed to add content and links?" Although
62% of NIBR employees believed that access should not be restricted, other individuals had
options about restricting user access. 38% of individuals believed that the Compound Homepage
should be restricted. Opinion was divided on if the system should just be restricted to contributions
from Lab Heads (PhDs) or Project Team Heads directly in charge of a specific project (Figure 31).
Who should be able to add content & links?
EOpen to vryone
Figure 31: User Opinions on Access Restrictions for Compound Wild
"The wiki should be open to everybody. People should not be afraid of adding something that
is not true. You should add what knowledge you have at that time, even if it contradicts
something already in the wiki. "
"This should be open to all lab heads and above. What about associates? Some of the
associates don't know enough. You could open it NIBR wide but the chance of someone putting
something stupid in here goes up astronomically. We need to have modest security. Restrict to
Lab Head and above- basically all PhD's that have a reason for using it."
Hesitancy to Share Data Prematurely/ Risk of Reputation
Academic culture fosters an aura of secrecy around data until it is ready for publication. In part,
this behavior originates from the need to pre-empt other labs from publishing first or stealing
information. In the academic world data is deemed ready to share when it is complete and has
passed rigorous analysis and peer review. Results are then announced to the world through
prestigious journal publications.
In the Academic world, sharing pre-mature data risks scientific reputation. As data is heavily
scrutinized by the community, scientists are hesitant to announce conclusions to the entire world
unless they feel that results are hole-proof, backed by solid research results.
Evidence:
* Several interviewees expressed their concerns about posting information that was visible to
the entire organization. Fears surrounding judgment by others and reputation were
specifically mentioned.
"People are reluctant to share data. They are simply afraid of sharing to a wider audience
because this essentially becomes the equivalent of a publication -you'd want to run the
experiment six to eight times to verify results before publishing. People want to be certain what
they say is true and verified. So people won't share at all. This will inhibit free form discussion
-you just can't share information very widely like that. "
"I'd like to add information but it's very tricky to make it so that you're not judged, and that this
is peer driven ".
"User contributedpart is going to be a huge hurdle. Some people are willing to contribute.
Others will be worried about wiki discussion part. They don't want to look stupid, uniformed,
inflammatory, etc. This is a cultural issue because contributions are not anonymous like
Wikipedia. In people's minds they could be judged".
General Implications:
* Individuals spend a lot of time and effort making data ready for publication. If time does
not allow for a complete analysis or report, results will often get buried on a personal hard
drive and never released beyond the project team.
Compound Homepage Implications:
* The culture of data sharing must change within the organization for a Web 2.0/wiki
environment to be successful. Specifically, management needs to address that it is expected for
individuals to share data even if the data is incomplete or turns out to be flawed. Rewards and
recognition for sharing ideas and information must be greater than negative ramifications of
risk to reputation and judgment of ideas by others.
* Web 2.0 relies on user generated content and an openness to sharing data and information.
Without a culture supporting this, a Web 2.0 initiative will fail. Specific measures that could
ease individuals into sharing data need to be considered. For example, setting the default
permissions on NIBR data folders access to open access, etc.
Data speaks volumes, but everyone is worried about interpretation
Scientists are uncomfortable releasing raw data without an extensive report or contextual
annotation to explain results. In a culture where data reigns supreme, the fear is that results will be
misinterpreted by those that may not have an understanding of the study or are missing the
complete background and context.
Evidence:
* Throughout user interviews two individuals brought up the fear of others, specifically
management, misinterpreting their data.
General Implications:
* A "data-open" environment suddenly becomes closed down for fear of misinterpretation
and interference by others.
Compound Homepage Implications:
* There could be widespread resistance to sharing data on the basis that it will be
misinterpreted, regardless of if this worry is legitimate or just a perceived risk.
* Web 2.0 might actually be a very useful vehicle for allowing scientists to explain their data.
Those who fear misinterpretation could elaborate extensively on results or provide linkages
and resources explaining how to appropriately analyze results.
Data Security and IP Protection
At first glance data security appears to be a strategic issue, a rational organizational behavior in
response to threats from competitive intelligence, data leakage, patent protection, etc. Probing
deeper reveals that extreme caution related to data security is sometimes part of the NIBR culture.
Evidence:
* Currently employees are required to complete training on NIBR data security. Although a
necessary step in protecting Novartis data, the training makes some employees overly
cautious about posting information. Many different interviewees during user research
mentioned that sharing or openly documenting information in a Web 2.0 environment could
be highly problematic due to security concerns.
* NIBR employees lock doors, hide documents, and restrict file access. Security concerns are
cited as the rationale behind this behavior.
* The default file settings on document storage sites are "restricted access"
* Password protection is abundant
General Implications:
* Access is restricted, making it hard for individuals to find data that they need in order to
perform their job function.
Compound Homepage Implications:
* Many employees will be hesitant to share data without very clear guidelines for
legal/security concerns. Specific individuals have stated that they will "err on the side of
caution" and simply refrain from posting information or contributing to the user community
due to security concerns.
8.3 Strategic Design Lens
The strategic lens component of the three lens analysis explores organizational strategy based on
rational analysis of opportunities and capabilities. The approach focuses on rational behavior and
logic driven decision making.7 Strategic opportunities associated with data management and the
Compound Homepage project are addressed from a rational perspective.
Localized Data Management
Novartis managers often aim to empower scientists and try to ensure that bureaucracy and
management does not get in the way of decision-making. This approach has given research
scientists additional freedom to focus on what they deem important but has created localized
cultures where standards for documentation and database management exist primarily at a
departmental (vs. global) level. In the absence of a coordinated global guidance individual
departments are developing their own ways of keeping track of data.
Evidence:
* Individuals and departments are determining rules and procedures for tracking data.
Departmental databases abound as well as microcosms throughout the NIBR organization
that operate very differently from one-another.
Table 10: Examples Departmental Specific Databases*
Department Database
Developmental & Molecular Pathways Affinity proteomics database.
Analytical Sciences Database for storing high resolution mass spectroscopy testing
results.
Clinical Development Group (TS) Database for capturing results of clinical trials.
Program Office Project management data.
Center for Proteomic Chemistry, PSU Protein Crystal Structure Database.
*Note: Table is non-inclusive and meant to only provide examples
Five individuals elaborated on NIBR's localized data management:
"Everyone does their own thing, independently setting up information."
"NIBR also has an oncology group in Emeryville, CA. They maintain their own databases, own
tools, etc. "
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"There is no global day-to-day recognized standard for documentation. There are some standards
within disease areas but these are not global."
"Novartis is comprised of many different sites and disease areas, each with its own different
cultures. Mandates about documentation are pretty much driven by local cultures."
Occasionally during interviews, the topic of management involvement arose. Three individuals
strongly expressed that management should play a minimal role in getting individuals to contribute
to the Compound Homepage. Comments reflected that wiki contributions were not up to
managers. Scientists need to determine what's useful to them and really define the wiki site and
management shouldn't force this upon people.
"Don't have management drive the Compound Homepage. In my opinion this really needs to be
a grassroots effort. Management would not be adding content so they wouldn't really have any
credibility to drive this. "
General Implications:
* Novartis culture is being driven bottom-up without consistency across the organization.
Multiple initiatives are being carried out by different departments without any type of
centralized coordination or leadership. This leads to duplication of efforts.
Compound Homepage Implications:
* In order to realize the global scale advantages of Web 2.0, leadership must buy into the
project on a global level. Economies of scale will not be achieved without organization
wide user adoption and a coordinated global Web 2.0 environment.
Wasted time and resources due to data silos and lack of central coordination
Strategically, the lack of central coordination makes it difficult if not impossible to find data. This
has very costly organizational consequences including a huge amount of time spent searching for
data, employees developing work-arounds, lost data, and repetition of experiments. Three
individuals elaborated on this point:
"Data from GNF, our sister group database is hard to access. I'd need to know to the database,
have the password, etc. to get access to this information. Sometimes I might just request to have
the data reproduced again at NIBR because sometimes it's easier. "
Lost Economies of Scale
The organization is missing out on tremendous economies of scale that could be realized from
sharing data across the entire organization. The inherent value within a large pharmaceutical
company is the ability to synthesize and aggregate information from a variety of sources and allow
all discovery areas to potentially benefit from that knowledge.
Costly to fix disparate systems and finally integrate data
The lack of coordination and central data storage policies has created a very tangled web of
systems and databases containing information in different file formats, naming terminology, etc. It
will be very costly to sort this out and integrate into one coherent system. An extensive data
management initiative is already underway to begin these activities. However, it has taken the
team an entire year just to start to untangle the web.
Legal ramifications regarding data sharing
There are a number of legal and regulatory issues to consider regarding documenting data and
sharing information. Legally, Novartis must take into consideration what type of documentation
exists around side effects or toxicity caused by different chemical structures. Documented
comments openly stating that a chemical early in the research stage is "toxic" or causes "cell
death" could later be misinterpreted and used against the company in a law suit if a marketing
pharmaceutical product was found to have serious side effects (e.g.Vioxx). One employee explains:
"It's extremely important to capture the annotation associated with a particular comment
regarding toxicity. A chemical is not just toxic in general - it's toxic in a specific cell line, under
certain testing conditions, at a particular dose. The same compound under different conditions
(i.e. lower dose, exposure time, etc) could be perfectly safe and very therapeutic. "
Although documentation regarding safety and toxicity is a strategic concern, it also overlaps in the
political fear/power arena. Individuals use the excuse of legal concerns to not document data or
refrain from sharing information on compound discontinuations. Sometimes it's because they want
to retain control over the data. Other times employees are not opposed to sharing information; it's
just safer for them to err on the conservative side. As such, Novartis needs to set very clear
guidelines regarding documentation of safety, toxicity, and side effects.
8.4 Political Lens
The political lens component of the three lens analysis explores who holds power within the
organization. The political view of the organization is "a contested struggle for power among
stakeholders with different goals and interests". 72 Political aspects associated with data
management and the Compound Homepage project is addressed below.
Data is power
Novartis, like many highly scientific organizations, is driven by data. As such, control and
distribution of data give an individual or a team power within the organization. In a completely
open data environment all employees within the organization would have equal access to data.
This would change the power balance.
Power Balance between IT and Science departments
The NIBR Information Technology CIO is relatively new within the organization. He has joined
within the last two years and is refining the IT group's role within the greater research
organization. As data associated with drug discovery is extremely scientifically complex, the IT
organization must partner closely with scientific experts in order to deliver beneficial data
solutions. A power struggle often arises between scientific organizations and the IT group due to
unambiguous roles and responsibilities. Scientists often want (and have) developed their own
programming, databases, and web solutions in the past. That said, they often lack the resources to
train others, roll out solutions to the entire research organization, ensure that their specific data
world integrates within the organization as a whole, etc. At the moment the power balance is
pretty equal between the two departments. As the IT organization grows in employees and scope,
the power balance may shift.
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Chapter 9: How Web 2.0 Can Help
Web 2.0 tools and technologies have the ability to significantly improve the current data
environment at Novartis. This chapter explores how the use of wikis, social networking software
and tagging could facilitate enabling internal Google like search, connecting people, and
establishing important relationships between biological and chemical space. Secondly, the chapter
enumerates how these various Web 2.0 technologies could provide Novartis with a significant
competitive advantage and boost the productivity of the company's research organization.
9.1 Search
Individuals generally report a very positive search and navigation experience on the World Wide
Web. Interestingly, this is usually not the case for an internal corporate intranet. Forrester
Research conducted a survey on usability of the corporate intranets. Only 44% of respondents
agreed that it was easy to find what they were looking for on their intranet.73 Comments from the
user study at NIBR, as well as the author's personal experience, also highlighted this view. The
Novartis intranet was no different and suffered from similar navigation difficulties.
"I use Google about fifty times a day. I can find a relevant publication much faster through Google
than through the Novartis internal tools. "
"I would love to have an internal Novartis Google search. We really need this. "
One interviewee was so adamant about better internal search that he viewed the installation of an
internal Google "pointed at all of Novartis's data" as the ultimate solution to solving Novartis's
data challenges.
" We have a Google algorithm problem- this is something that someone needs to solve. What is the
Google application pointed at currently (within Novartis)? Could this be expanded? Can you give
Google access to information that Avalon is pointed at? "
So why isn't the solution to NIBR's data management challenges to simply install an internal
version of Google and allow this search engine to have access to all NIBR data? Wouldn't this
instantly enable powerful search within the company firewall? Unfortunately, this is not the case.
The key to Google's superior searching ability lies in its patented search algorithm called
PageRank.
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Google's PageRank software algorithm gives every page on the internet a ranking of importance
from 0-10. This overall page ranking is determined by analyzing the number of external links that
lead to that particular website. Basically, each link is counted as a vote for that particular page.
For example, a very popular website may be referenced thousands or even millions of times by
other websites (via links), while an unpopular site will seldomly be referenced on other sites. The
PageRank methodology goes beyond just absolute number of links and also analyses the
importance of the website that casts a vote for a particular site. A vote (via a link) from a website
with a higher Google PageRank will count more than a vote from a website with a low PageRank. 74
In this manner the Google search engine capitalizes on the internet community's knowledge of
what is important. People will link to content that they find useful. This creates a very powerful
mechanism for filtering out good content from bad content. Harvard Business School Professor
Andrew McAfee comments on this issue "if you let people author web content and you let them
interlink, the cream is going to rise to the top in a sense; the most popular content will be evident
very quickly."75Tom Malone, a professor at MIT Sloan, refers to this concept as "collective
intelligence." Essentially millions of Web users have created an inherent structure in the Web by
creating linkages to their web pages. It is this collective intelligence built into the linkage network
that Google harnesses to create unparalleled search results.
In comparison to the World Wide Web, the Novartis corporate intranet doesn't have the same
degree of cross-linking. The corporate intranet is built by relatively few individuals and has a very
limited inherent linking structure. In order to change this structure many people have to be given
the ability to build links.76 One way to do this is to open the corporate intranet up to the entire
Novartis community. In particular, user editable wiki's will allow employees to create web pages
and link to content that they deem to be important. The creation of a large dynamic corporate
internet by many different users will allow a powerful searchable structure to emerge and enable a
powerful Novartis Google search engine.
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9.2 Social Networking
The user research at Novartis showed that scientists relied very heavily on their social networks to
find out information about a wide variety of topics. Roughly one third of all interviewees
discussed their use of social networks in finding information.
"To find data/information I'm looking for I have to be creative and use my network. You have to
call people, you have to know people. You've got to have a head start"
This suggests that the current data environment doesn't adequately support finding information. It
is easier for individuals to find out information by talking to someone they know. That said, these
observations also highlight the importance of face-to-face interactions or personal conversations
via phone calls in order to adequately discuss problems in depth and exchange complex scientific
information. MIT Professor Tom Allen, one of the first pioneering researchers of social network
mapping and an expert on communication patterns in the workplace describes the importance of
face-to-face interactions:
"In a workplace with a highly technical environment you need extreme bandwidth to convey highly
complex information. Face-to-face interactions are the best at getting this type of information
across. Other channels, such as email, simply don't have enough bandwidth. "- MIT Professor,
Tom Allen 77
Pharmaceutical research and drug discovery is extremely complex. Scientists are constantly
dealing with highly multifaceted, very involved research information. As a result, face-to-face
interactions, and where this is not possible video conferences/telephone calls help to convey
information most effectively.
How can a Web 2.0 site or Compound Homepage tool help scientists connect with one another? If
individuals are encouraged to share information via website postings on a wiki site, isn't this
counterproductive or a replacement for face-to-face interactions? Quite the contrary, simply
incorporating Web 2.0 social networking tools within the Compound Homepage can dramatically
improve the size and scope of an employee's network and therefore connections and access to
different types of information within the company. Often, just providing a medium, online or
otherwise, that connects informational experts with information seekers can facilitate further phone
conversations and higher bandwidth interactions.
77 Allen, Tom. Personal interview by Juliet Duffy. Sept 0 8.
For example, suppose a scientist was struggling to figure out how to solve formulation issues for a
particular compound. It would be extremely powerful if they could instantaneously identify, via
the Web 2.0 environment, other chemical compounds that had experienced similar formulation
issues. They would then want to know the teams associated with those compounds, and contact
names for scientists on those team. Given that information they would instantaneously be able to
jump from reading a few comments on an online wiki to picking up the phone and having a
meaningful conversation about formulation challenges and how best to tackle the specific issue.
Andree McAfee addresses the value of social networking within the business environment in his
online Blog:
"Consider the prototypical knowledge worker inside a large, geographically distributed
organization. She has a relatively small group of close collaborators; these are people with
whom she has strong professional ties. Beyond this group, there's also a set that includes
people she worked with on a project with in the past, coworkers who she interacts
with periodically, colleagues she knows via an introduction, and the many other varieties of
'professional acquaintance.'
Beyond this group there's a still-larger set offellow employees who could be valuable to
our prototypical knowledge worker if only she knew about them. These are people who
could keep her from re-inventing the wheel, answer one of her pressing questions, point her
to exactly the right resource, tell her about a really good vendor, consultant, or other
external partner, let her know that they were working on a similar problem and had made
some encouraging progress, or do any of the other scores of good things that come from a
well-functioning tie." - Andrew McAfee Blog78
Incorporating social networking aspects into the Compound Homepage tool would be extremely
powerful. Several overlaps exist between the "compound" world and the "people" network at
Novartis. These intersections should be fully exploited.
* Identify synthesis origin -Often, being able to track a particular compound back to the
person who first made (synthesized) the compound yields a tremendous amount of
information. It may provide not only the rationale for synthesis but also yield clues into
what other chemical molecules were made in a particular chemical synthesis, stability and
synthesis information, etc.
* Provide project associations for compounds and link project associations to project
team members. Chemical compounds are made in hopes of creating a specific drug that
78 McAfee, Andrew "How to Hit the Enterprise 2.0 Bulls eye" McAfee Blog, 3 Nov 07. Web. Access 5 March 09
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will modulate the activity of a particular target. Projects teams will make hundreds, if not
thousands, of compounds over the lifetime of the project. Associating particular
compounds back to individual projects can yield rich information about why a project team
was interested a certain compound, what scaffold groups were considered, what
modifications were made to the compound to improve certain drugable properties, etc.
Further linking this information back to the individuals on the particular project will
facilitate this type of discussion.
* Identify all individuals who post wiki comments on a compound page. Adding an
editable wiki page specifically for one compound allows individuals with knowledge about
that particular compound to self identify themselves as experts. An electronic
signature/name identification should be mandatory for all who leave comments. Linking
the name of the individual back to the company directory will facilitate further interactions.
9.3 Categorization by Tagging Compounds
Implementing tagging, another powerful Web 2.0 tool will help to organize the vast amount of
content and make the Novartis data world more searchable. To gain an understanding of tagging it
is useful to explore a case study on tagging digital photos and then transfer this analogy to the
compound world. The results demonstrate the powerful nature of tagging and how the ability to
digitize information is vastly changing how the world organizes information.
The amount of data in the world is vastly expanding. A popular video featured by syndicated radio
talk show host Kim Komando describes this trend of digital proliferation. "It is estimated that 4.0
exabytes (4.0*1019) of unique information will be generated this year, more than the previous 5,000
years. The amount of new technical information is doubling every two years." 79With so much new
information how are people keeping track? In his book "Everything is Miscellaneous" David
Weinberger explores this new digital age and examines how the messiness and miscellaneous
nature of the digital world is leading to new ideas, efficiency, and social knowledge. 80
David points to the organization of photographs as a prime example of information proliferation
and how the ability to categorize items in many different ways is having transformative effects.
Information from David's book is presented below and expanded upon in order to illustrate how
tagging has been applied to sorting and sharing photographs and what revolutionary implications
this could have for the organization of chemical compounds at Novartis.
Photo Sharing and Sorting
The advent of digital photography has made the incremental cost associated with snapping that
additional photo virtually zero. Ten years ago, in the era of Kodak film an individual might take
several rolls of film, roughly 48 photos during a typical vacation. Now, particularly for the photo
enthusiast, it is not uncommon to capture an entire digital photo card, 2 GB which for an average
picture resolution would be roughly 2,000 photos. Recently the author's fiance, a photo enthusiast,
succeeded in exceeding the counting feature on his digital camera. He has taken so many photos on
his digital camera that the digital number scheme has cycled through the allotment of file naming
numbers, (i.e. IMG_89732) and is now back to labeling photos IMG_00001, causing file conflicts
when photos are uploaded to the same hard drive that previous photos name IMG_00001 were
79 Fisch, Karl Living in Exponential Times. The Kim Komando Show, n.d. Web Video. Accessed 17 March 2009
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stored on. Even non photo enthusiasts that don't exceed the digital numbering allotments on their
cameras are inundated with literally thousands of photos on just a yearly basis. Organizing all of
these photos, with names like IMG_89732.jpg, has become a royal headache even for the most
compulsive organizers. As a result, the labeling of photographs has begun to evolve into a social
process with others pitching in to help us organize.8
Flickr.com, a photo sharing website, is a perfect example of how tagging is being used on a
community wide scale to assist with organization. Individuals post their photos on the site and
apply descriptive labels called "tags". Not only can a user apply tags to their own photos, but
community members can tag others' photos adding to the descriptive information. Essentially, the
categorization is both defined by and outsourced to the user community. The user categorization
scheme that emerges is referred to asfolksonomy, a categorization developed over time by "folks".
In contrast to taxonomy, the up-front organization scheme developed by experts, folksonomy is a
bottom-up, user driven classification system that reflects the relationships that people actually
use.82
Tagging benefits extent beyond simply outsourcing the work to the user community. Tagging
breaks down the constraints of the physical world and allows information to be classified and
stored in multiple places simultaneously. "Instead of items being placed in one particular area, or
occasionally in two, they can be classified in every different category in which users might
conceivable expect to find them." 83 This is very powerful because without an upfront, imposed first
order structure individuals with different needs can search through information in different ways to
most effectively meet their needs.
In order to demonstrate this concept, consider a hypothetical example of a collection of
photographs taken during a student's time at MIT Sloan. Over the course of two years of study
such a student might accumulate a multitude of photos relating to specific classes, student
orientation, extracurricular activities, hanging out with friends, etc. While the entire photo
collection is no doubt extensive, for the simplicity of this demonstration just six photographs have
been chosen below (Figure 32).
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Each photograph represents some aspect of student life at MIT and has been annotated with
metadata, essentially information about the particular photo. This metadata is organized into tags,
brief descriptions about each photo. For example, photo #1 is a picture of the "beer game" a game
played by all incoming business students at the MIT Sloan student orientation. The game is a
representation of a beer factory and demonstrates how small variations in demand are magnified
throughout the distribution supply chain producing an uncontrollable, highly variable system.
Photo #1 has been tagged "team work" because students play the game as a team. It is also tagged
"Juliet Duffy", the name of the individual we see playing the game. The "Sloan orientation" tag
refers to the fact that the beer game is played at during the Sloan student orientation. "Supply
chain" and "bullwhip effect" demonstrate the operations concepts learned in the game. The other
photographs within the collection have been tagged with similar descriptors providing additional
information about each photo.
Photo #1 Photo #2Photo #2
MIT MIT
SloanOrientation
Team Work Buildings
Beer Game Student Center
Juliet Duffy
Bullwhip effect Kendal Square
Supply chain
Photo #3
The lab - Nerd Golf Photo #4
MIT MIT
7, Sloan Turkey TrekStata Center
Sam Spring Break
Istanbul
Abe
Mini Golf
BredeCambridge
Stacy
Photo #5 Photo #6
MIT MIT
Sloan Turkey Trek Sloan Orientation
Spring Break Abe
Istanbul Juliet
Constantinople -Jason
Buildings Team Work
Rafting
Figure 32: MIT Sloan Photo Collection Water
Consider how one might organize these photographs in a photo album. In the physical world, you
are forced to choose an organizational scheme. All of the photos relating to spring break might go
into one physical album entitled "Spring Break 2009"while the other random MIT photos might be
organized in a general album simply called "MIT photos." Each photo would be classified in a
single album as it could only occupy one physical slot in a photo sleeve.
Now suppose that over the next semester the student decided to take a class on architectural themes
and motifs. Suddenly, the photographs relating to buildings might be very valuable. Among
thousands of photos it might be impossible to locate these without a significant amount of effort.
However, digitizing the photos and annotating them to with tags related to their content would
make such a search extremely fast and simple. One could type in "buildings" and instantly photo
#2 and photo #5 would be displayed from the collection.
In the digital world these photos could simultaneously exist in many different categories. Rather
than imposing an upfront organization scheme by placing the photos in a particular album, the
photos would exist as a miscellaneous giant pile and could be instantly organized to suit an
individual's particular needs of looking at the data. What albums would be useful from the above
collection? Perhaps, an administrator from the school wants to use the photographs. They might
be interested in assembling examples of team activities to showcase how MIT Sloan is highly
focused around teamwork. On the other hand, they may want photographs depicting the 1st year
orientation activities. A different stakeholder, a student named Abe, might just want to sort through
the collection and identify photographs of himself. The possibilities are endless.
Architecture Sloan Orientation Spring Break in Turkey
Photo # 2, Photo #5 Activities Photo # 4, #5
Photo# 1,# 6
Pictures of Abe Team Work Student Life
Photo #3, #6 Photo # 1, #6 Photo #1, #3, #4, #6
Figure 33: A Few Photo Album Possibilities
The ability to sort and instantly classify different photo albums is compounded in a community
environment where millions of users come together to each add their photos and tags describing
those collections. Flickr (http://www.flickr.com/) is a prime example of this phenomenon. The site
has over 225 millions photos already uploaded with roughly 5,000 new photos uploaded every
minute.8 4 Community users are entirely responsible for the categorization of content via tagging.
Remarkably, photos pertaining to any topic imaginable are easy to find.
"On Flickr it's remarkably easy to find photos on almost any topic and pull together collections of
photos on these that mix and match those topics. Want to find photos of dogs wearing red clown
noses? A search at Flickr finds twenty one of them. Researching car-crash art? Flickr finds two
hundred and thirty three photos that may help your studies. "85
Compound Sharing and Sorting
So how are the lessons related to tagging and photo sharing on Flickr applicable to the
pharmaceutical industry and Novartis's quest for discovering life saving medicines? The lessons in
data organization are remarkably powerful when applied to chemical compounds. At the heart of
the pharmaceutical industry are individual chemical compounds. Once a biological disease target
has been discovered the quest begins to develop and find one specific chemical compound that will
change the activity of this particular biological target while having minimal side effect profile.
How big is Novartis's photo, or chemical compound collection? Currently, the Novartis screening
library consists of over a million compounds. What if you could categorize and capture information
about every single chemical compound in a way that is similar to the photo sharing on Flickr?
Compounds could be tagged with not only scientific information, but also associations such as
people that have made the compounds, projects that compounds were used in, etc.
Six compounds are presented below with various tags (Figure 34). Similar to assembling different
digital photo albums, the compounds could be instantaneously grouped according to user needs. It
is useful to explore what specific "albums" could be assembled from the tagged information in the
theoretical compound collection.
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Figure 34: Theoretical Novartis Chemical Compound Collection 8
Note: the compound structures and resulting tag data are for illustrative purposes only. Data is completely arbitrary
and does not in any way represent real relationships or chemical compounds in development at Novartis.
86 Chemical structural pictures were taken from approved pharmaceutical compounds listed on Wikipedia. The
associated tagging relational data is entirely arbitrary and made-up for concept demonstration purposes.
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Project association -Project development teams routinely keep track of the chemical compounds
that they have synthesized. Several teams within the user interviews indicated that they had
assembled chemical lists of compounds relevant to the project team. These lists were further
segregated into different chemical "series" based on chemical scaffold similarity (refer to Figure 24
for an illustration of how compounds are organized by chemical series). Although project teams
have an intimate knowledge of the chemical compounds that they are working on, there is very
little visibility for this in the organization at large. Tagging compounds with both the project name
and the chemical series within the project would be useful to both project team members and
scientists in the organization at large.
Album #1
Album compiled: Project X2751, Series B
Compound #3, #6
Potential Album users:
- A scientist within project team X2751 wants to examine all of the chemical compounds that
the team has synthesized with core scaffold structure series B. He is compiling a
PowerPoint presentation relating to some structural activity relationship (SAR) studies for
an upcoming meeting and wants to make sure that he includes data for all relevant changes
to the core scaffold.
- A scientist outside of the project team is analyzing high throughput screening results from
her project. She notices that several of the compounds that had significant activity in her
screening assays were extensively investigated as part of another project (X2751). She
wants to identify all of the other compounds that were investigated as part of the X2751
project series and see how that data might relate to her specific project.
Development Stage -The amount of scientific information available for a specific compound is
directly related to the compound's development phase. A molecule that has only been used in D2
high throughput screening studies will have very little information compared to a molecule that
made it into the candidate selection point (CSP) development phase. In order to identify
compounds with a significant amount of information, it is useful for scientists to be able to view
chemical structures associated by development stage.
Album #2
Albums compiled: Stage: CSP
Compound #1, #4
Potential Album users:
- A Scientist trying to narrow down hits for their particular project.
"I'd like to be able to see ifa compound was selected for CSP. CSP is more of a highly refined
compound -people have taken a close look at this in the past. If this was a hit I'd go and look
at this again in our assays because there would be tons of quality information that I could use
for this compound "
Terminated Compounds -The vast majority of chemical compounds never become a
pharmaceutical drug. For every 5,000 - 10,000 compounds tested, 5 of those will reach clinical
trials and only one will become an FDA approved drug (Figure 7).Compounds could be tagged if
they were terminated in a project after reaching a particular development phase (D3 or
CSP).Information about compound termination is currently tracked within a project management
database but has poor visibility within the broader organization. Providing both global
identification and analyzing this select group of compounds would yield a tremendous amount of
information and benefit multiple individuals within the organization.
Albums compiled: Album #3
Terminated in CSP, phototoxicity
Compound #4
Potential Album users:
- A scientist analyzing screening results and deciding what compounds to select out of the
screen.
- A safety group, or quality team (i.e. quality plus) establishing additional tests and
mechanisms to identify phototoxicity or other issues earlier in the development process.
- Groups investigating compound repurposing (business licensing department, a number of
scientific organizations). Science develops and changes at an extremely rapid rate.
Compounds are often discontinued for reasons or problems that either might not be relevant
in other disease indications, or can be solved at a future data using technology that might
not be foreseeable at the current time. Both internal organizations as well as the business
licensing group often go through and "re-purpose" compounds, re-using these valuable
assets for other internal projects or licensing them outside of the company.
Validated Target or Pathway Hits- A specific biological target is screened in high throughput
assays against millions of chemical compounds in order to identify "hits," specific compounds that
bind to and modulate activity of the particular biological target. A chemical compound often binds
to many different targets. This has implications for side-effects and also potential use of the drug
in other disease indications.
Album #4 Album #5
Albums compiled: Validated Target hit XYZ Pathway hit: Pathway X
Compound #3,#5 Compound #5, #6
Potential Album users:
- A scientist in the safety profiling group has just discovered that a new enzyme, Target
XYZ, is responsible for producing a nausea related drug side-effect. They would like to
investigate all other Novartis compounds that are known to hit this enzyme.
- An early stage biologist is trying to understand a specific biological pathway. Knowing all
the compounds that change activity in this particular pathway would shed clues into
pathway mechanisms and lead to increased disease understanding.
Metabolites - When the body processes chemical compounds, the chemical structures are often
broken down into smaller components referred to as metabolites. Reactive metabolites can be
toxic and cause a number of different side effects.
Albums compiled: Album #6
Metabolite: ABC
Compound #3,#5
Potential Album users:
- A project team is struggling to modify a chemical compound so that it does not cause a
reactive metabolite. The team would like to ask "what other compounds have resulted in
this specific metabolite? How did the project teams of those compounds solve this issue?"
Associating Metadata via Tagging
As demonstrated, adopting a Flickr like tagging approach for chemical compounds could be
tremendously valuable. Tagging categories would expand beyond those listed in the hypothetical
example above. In fact, the more information that Novartis can associate with each chemical
compound, the more powerful the system will become.
David Weinberger elaborates on this point by bringing up the example of library catalog cards. 87
Before the digital age, library card catalogs held the metadata associated with individual library
books. Each library book had an associated catalog card would list a book's author, subject, title,
publisher, etc. Books could then be sorted by these various categories in different card catalogs.
The amount of metadata that could fit on each library card was limited by the physical card space.
Cards larger in size than a large index card would simply be unmanageable. In the digital world,
the amount of metadata that can be associated with a given object is quite considerable. As storage
has dramatically dropped in price, it is no longer expensive to capture large amounts of metadata.
In the digital world, the more information that can be associated with a particular chemical
compound, the easier it will be to find and make associations about that particular compound.
Indeed, "the solution to the overabundance of information is more information." 88 Our large
unwieldy digital photo collections become suddenly manageable when we extensively tag the
individual photos with many pieces of descriptive metadata.
Should all of the tagging information be added by the user community? On one hand, it makes
sense to leverage the Novartis research community at large to help organize and categorize
chemical compounds. Often a scientist will have very in depth insight into a handful of chemical
compounds that he/she has worked on extensively. Additionally, scientists are already compiling
lists of compounds that share certain properties. For example, a Developmental & Molecular
Pathways scientist was introducing compounds to cells then observing how gene transcription
changed as a result of the compound addition. He had compiled a rich network of clusters
compounds by associating them with this gene transcription data. Capturing such information in
tagging networks would be tremendously useful to the organization at large. User tagging is
perfect for a large portion of knowledge related work that is often unpredictable, arises on an ad
hoc basis, and demands flexibility.
In other instances data might be more static, already occur in a pre-existing database, or be more
easily generated by a computer algorithm. For example, tagging compounds as validated hits
against a specific target would make more sense to automate. It will be necessary to allow
87 Weinberger, David. Everything is Miscellaneous: The Power of the New Digital Disorder. New York, Henry Holt
and Company, (2007) Print.
88 Ibid. (87)
compounds to be tagged automatically by computer searches and algorithms as well as by
individual users within the Novartis community.
Why is Tagging so Powerful?
Tagging in part is so powerful because it allows users to slice the data in every conceivable way
possible. As demonstrated above, different users within the organization will want to answer very
different scientific questions. The MIT admissions officer does not necessarily care about the
photographs of various architectural buildings but is very interested in the pictures that depict the
Sloan orientation activities. Rather than trying to anticipate user needs and impose an upfront
organizational scheme, tagging makes all of the information accessible and lets users decide how to
explore relationships.
Such an organizational structure supports random browsing. Consider the difference between
exploring books on Amazon.com and within a conventionally organized book store. In a brick and
mortar bookstore the books are carefully categorized into specific sections: History,
Autobiographies, Cooking, Travel, Fiction, etc. A history buff interested in the US conflict in
Vietnam might thoroughly explore the history section but would miss an equal book of interest,
"Miss Saigon" a fictional musical about the cultural effects of Vietnam war, because it was
classified in music and film section. 89 However searching for Vietnam books on Amazon
Title on Amazon yields an amazing assortment of books. This is because books can be classified
in multiple places simultaneously. The user might not only discover "Miss Saigon" but could
come across a cooking book exploring Vietnamese cuisine or a travel book detailing a writers
recent journey to historical points of interest. Furthermore, Amazon takes tagging one step further
and automates tagging relationships through the use of extensions. The Amazon algorithm says to
users "attention: purchasers of this book "x" also typically like book "y."Suddenly, a reader is
enticed to browse and stumble upon new content. Similar "browsing" within the scientific
environment could easily lead to the discovery of new powerful relationships between compounds,
side-effects, and diseases that would not have originally been envisioned.
89Weinberger, David. Everything is Miscellaneous: The Power of the New Digital Disorder. New York, Henry Holt
and Company, (2007) Print.
How are Web 2.0 tagging approaches different from database searching?
Firstly, databases are highly structured and impose a pre-specified organizational structure. Wiki
inventor Ward Cunningham elaborates "For questions like 'What's going on in the project?' we
could design a database. But whatever fields we put in the database would turn out to be what's not
important about what's going on in the project. What's important is often the stuff you don't
anticipate." 90,91Scientists are constantly exploring new relationships or have a desire to ask
questions that might not be anticipated by the IT group. Furthermore, IT resources would be
instantly overwhelmed if every scientific group within the organization required the setting up of a
database to capture and use specific information. For example, during user interviews a scientist
within the protein structure unit group made the following request:
"Our group also generates a lot of information about compounds that fail in some way. These are
compounds that won't co-crystallize with the protein. I'd love to know if a crystallographer over
in Basel looked at it, even if it failed. I could learn a lot from his experience. "
Would a database get set-up to capture this information? This is highly unlikely. However, user
initiated tagging or comments on a wiki would make this instantly easy to capture. The scientists
could annotate the compound with "Attempted to crystallize protein X with this compound.
Attempt failed." The information could be captured and instantaneously make available to the
entire organization. No phone call to IT, or approval for a special database to capture this
information would be required.
Secondly, the current NIBR database environment is very disjointed. Individual databases are
often set up, run, and maintained by individual departments. It is currently impossible to link
between these various databases. A tagging structure would allow for the exploration of
relationships without necessarily having to link together these discrete databases.
For example, suppose a scientist was studying a disease that required the inhibition of a kinase. In
order to visualize how different compounds bound to kinase inhibitors it might be very powerful to
have a list of all compounds within the organization that were validated hits against kinase
inhibitors and had also been crystallized. Finding this list of compounds in the current data
structure would be impossible. Assay results would be stored in Pharon, a list of specific targets
that were kinase inhibitors would be in another database (if it existed at all) and all crystallized
90 Venners, Bill "Exploring with Wiki: A Conversation with Ward Cunningham, Part I" Artima Developers,(2003).
Web. Accessed 12 April 09 http://www.artima.com/intv/wiki.html
91 McAfee, Andrew "Enterprise 2.0: The Dawn of Emergent Collaboration" MIT Sloan Management Review, 47. 3
(2006). Print
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compounds would exist in yet a different database. However, consider the situation if the
compounds had been tagged. Finding this list of compounds would be as simple as searching for
the intersection of the tags "crystallized compound" and "validated hit against kinase inhibitor."
The list of results compounds could then be further explored. The actual crystallography data
would be available through the compound homepage linking page that would lead into the
crystallography database.
Another example of data connections made possible by tagging is demonstrated by a scientist
interested in improving the safety testing assays for cardiac irregularity (hERG activity). The
individual would be interested in asking 'What compounds have tested positive in hERGin vitro
assay A and have been evaluated in dog telemetry studies'? The current approach to answer such a
question would require tedious searching between two unconnected databases. Tagging compounds
"positive result in hERG assay A" and "dog telemetry study completed" would instantaneously
allow the intersection of each group to emerge and encourage further exploration of the identified
compounds.
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9.4 Competitive Advantage of Web 2.0
Web 2.0 technologies have the ability to provide Novartis with a significant competitive advantage
by vastly improving the data environment and boosting the productivity of the company's research
organization.
Decentralizing Information - One of the benefits of Web 2.0 technologies is that they provide a
common platform for knowledge work that is both visible and accessible to all areas of the
organization. This can help break down organizational silos and give individuals access to relevant
information regardless of where they are within the organizational structure.
"Hierarchies and organizational silos short-circuit tacit interactions: information moves up and
down a hierarchy at defined management levels. By contrast, to stimulate interactions
organizations want whatever information is relevant for solving a particular problem to be shared
among team laterally, in real time, irrespective of reporting channels and silos. " 92-McKinsey
Quarterly
Network Effects- Web 2.0 technologies have significant network effects. The more people that
add linkages, author, tag, etc. the more powerful the network becomes. Historically, increasing an
organization's size has made it more difficult to find information. Web 2.0 technologies act in the
opposite direction and make larger organizations more searchable and navigable than smaller
ones. 93 Suddenly, size is no longer a hindrance but a significant competitive advantage.
Collective Intelligence-Research talent is highly concentrated within NIBR. The majority of
employees have PhD's and years of experience in highly concentrated scientific specialties. The
collective intellectual capacity is on par with, if not exceeds, certain major academic research
institutions. As most employees could single handedly publish subject matter text books, imagine
how powerful and knowledge rich a Novartis compound Wikipedia could become if even a fraction
of those individuals dedicated their time toward authoring content. Furthermore, what better
expertise to establish a dense linking and tagging network based collective knowledge?
Scientific Relationships - A manager within the Global Discovery Chemistry organization
powerfully summarized how discovering relationships across biology, chemistry, disease areas can
create significant competitive advantage:
92 Beardsley, Scott, Bradford Johnson and James Manyika "Competitive advantage from better interactions" McKinsey
Quarterly 2 (2006). Print
93 McAfee, Andrew "Enterprise 2.0: The Dawn of Emergent Collaboration" MIT Sloan Management Review, 47. 3
(2006). Print
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"What is Novartis's competitive advantage? Pharmaceutical labs in India and China can
synthesize chemical compounds by the thousands for afraction of the cost. Our real advantage is
our wealth of historical data, being able to look at the data as an aggregate and create linkages
across different diseases, targets, etc. which is impossible to do without an organized, open data
environment. "
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Chapter 10: Project Homepage
10.1 High Level Overview: Projects, Compounds, Assays, Targets, People
Although this thesis focuses on defining how Web 2.0 could be used to specifically organize
chemical compounds, it is appropriate to step-back and present a quick high level overview of the
envisioned Novartis wide scientific web environment. Information at Novartis tends to fall within
several different broad categories or "bubbles". Each of these categories would serve as logical
entry points into the Novartis Web 2.0 system. 94
Target-As defined by Wikipedia, a target is a biopolymer such
as a protein or nucleic acid whose activity can be modified by a
pharmaceutical compound. Early in the development process
project teams focus on identifying targets and pathways that are
associated with diseases.
biological targets. Once a target has been identified efforts turn to
discovering (stage D2) and optimizing (stage D3) chemical
compounds.
Assays- Assays are the specific tests where compound activity
against a specific target or pathways is tested.
Projects- Projects refer to the inherent project teams working to
develop a drug for a particular target.
People- Refers to the individual employees at Novartis
Figure 35: High level Novartis Web 2.0 Organizational Structure
Although the Novartis wiki/Web 2.0 system would essentially be one giant organizational network,
it is useful to break down the system and examine how the environment should be structured based
on the different categories defined in (Figure 35). The table below lists a proposed description of
the organizational framework for each "bubble" and suggests individuals within the organization
that would be the primary users.
94 "Bubble" concept envisioned by Dejan Bojanic, The Novartis Institute for BioMedical Research, Center forProteomic Chemistry
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Table 11: Description of Proposed Novartis Web 2.0 Networks
Description Individuals that
might use this entry
point / framework
Wiki pages structured around targets - each biological target would have a specific Biologists, early
"homepage" containing & linking to information relevant for that particular target. stage researchers
Wiki pages structured around compounds - Every chemical compound within the Chemists, later stage
Novartis screening library would have a specific "homepage" containing &linking researchers
to information relevant for that particular compound.
Wiki pages structured around assays - Every assay within the Novartis would have All scientists
a specific "homepage" containing & linking to information relevant for that
particular assay.
Project team spaces - Every project team would have team space. In addition to Project teams,
capturing project updates, project status, listing team members, this wiki would be management
a virtual working environment for project team members.
The Novartis internal directory. In addition for providing contact information for Everyone in NIBR
individuals such as phone, email, mailstop, etc. the hub could serve a social
networking environment allowing scientists to connect with one another, tag
associations "I've working on project x", "I have expertise in Y" etc.
Although different Web based "bubble" environments will be important for the Novartis
organization to define and develop, only the Compound and Project Homepages were investigated
as part of this thesis. Project Homepages are touched upon in relation to Compounds as the both of
the "project" and "compound" web environments must be tightly integrated.
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10.2 Project Homepage Overview
Each project team at Novartis should have a designated "Project Homepage". This would serve as
a user editable knowledge management platform where the team could actively collaborate and
capture their work. The project team page would be structured as a series of associated team web
pages with navigation tabs at the top.
Navigation tabs at the top facilitate moving
between different pages associated with a
specific project homepage.
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10.3 Project Summary Page (Tab#1)
This would be the 1st page /tab displayed when visitors navigate to the Project Homepage site.
The Project summary page would give a brief overview of the project, target associated with that
project, project phase, etc. Project team members would be responsible for updating all
information. Webpage would serve as an interface for the new project management database.
arget - Clicking on the target link would lead the user to the
Target Homepage" where more specific information would
e available on the target. A-4b
Project Summary
Project Names Team M
Tgenein Project l
NCC Code: AOW365 Chemist
Biology Summary Other te
Target: 3982 Michael
Indication(s): chronic
mveloienous leukemia (CML)
Project Milestones
Phase: D2
Current Progress summary: Project recently
completed high throughput screening .....
Past Progress Summary Reports
embers*
ream Leader: Grey Nyberg
ry Lead: Christina Wells
am members: Carin Gray,
Stoner, Gabriel Schmidt
Figure 36: Project Summary (Tab #1)
Note: All project names, compound codes, targets, etc. are bitrary and do not represent actual ongoing work at Novartis.
*Names are fictitious and are not those of actual Novartis e loyees.
Project Milestones - Project updates and milestones would help communicate
projects latest status. Team project managers could use this web interface to enter
project tracking information in the project management database.
Project milestones could also assist organizational managers in keeping track of
projects throughout their department. The format would be standardized across all
disease areas.
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Team Members- Associating team members
with the specific project would facilitate social
networking and help scientists outside of the
project connect with relevant project experts.
Clicking on the specific name of the individual
would lead the user directly to the "People
Homepage", essentially the Novartis directory.
User could then call, email, text to follow-up
with project related questions, specific project
10.4 Project Compound/Assay Page(Tab#2)
Central to the concept of the project homepage would be a mechanism for keeping track of all
chemical compounds that are associated with the team project. 95Although not shown in the figure,
assays associated with the project could easily be tracked in a similar manner.
Tagging Compounds -The "Add Tag" button would allow the project
team scientists to easily tag compounds with additional information.
For example, the majority of team members in the user interviewers
organized compounds by chemical series. Users could add the
chemical series name (e.g. Ortho-biarylcarboxamides)and then simply
sort the compound list by chemical series. Tags could be added to
multiple compounds at one time simply by checking the box to the left
of each compound.
Project Compounds
& Assays
Project Compounds:
Add Tag Sort By Add/Remove
O Compound: XFR251, AryI-A i oquinoline
OECompound: RALI22, Phenyl-imida les
OCompound: 0FP444, Phenyl-imidazoles
O Compound: XPF128, Ortho-biarylcarboxam s
SCompound: OEN293, Ortho-biarylcarboxamide
El Compound: RFP271. Ortho-biarylcarbox ide
Figure 37: Project Compounds a d Assays (Tab 2)
Note: All project names, compound code targets, etc. are arbitrary and do
represent actual ongoing work at Novartis.
Permissions - Permissions for adding/removi compounds could be
restricted to team members only if teams had se rity concerns.
Adding/Removing Compounds - Team
members would add new compounds to the
project list by clicking the "add" button and
typing in the NVP # for the compound that they
wanted to add. Similarly, compounds could be
removed by checking the box next to the
compound and clicking "remove"
Adding a compound to the project list would
automatically tag the compound with associations
to a specific project, target, disease indication,
current project development phase, etc. This
would make tagging with project associations
part of the workflow and thus eliminate the need
for individuals to specifically navigate to the
Compound Homepage to tag compounds with
project associations. Similarly removing a
compound from the list, particularly if the
compound was in a more advanced development
stage, would automatically tag the compound
with a "termination" tag.
Sorting - The list of compounds could be
sorted by any number of different tags.
Additionally, the tags could be displayed next to
the compound list. In this specific example tags
associated with different chemical series (Aryl-
Aminoquinoline, Ortho-biarylcarboxamide, etc)
are displayed.
Compound Homepage Link - Each chemical compound on the project list
would link directly to its Compound Homepage enabling the scientist to
instantly find a wide variety of information associated with the compound.
95 Concept envisioned by Deborah Igo, The Novartis Institute for BioMedical Research, NITAS
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10.5 Project Work Space (Tab#3)
The project workspace would provide a platform based working environment for project team
members.
Wiki Space - A project wiki would give teams a common platform for posting output
related to tacit knowledge work. This environment should be unstructured allowing
teams to post, collaborate, and capture team project knowledge as they see most relevant.
Project Work Space
Project Team Wiki
Phototoxicity Results
Compound XPF128 seems like our
mostly likely candidate to getting
around the recent Phototox assay
results. The plan is to modify the N
group, and then re-submit for testing.
Phototox guidelines are outlined on
Oualitv+ website . Also check out
comments on the GDC discussion
board relating to this issue.
Team Files & Documents
Add Tag Sort by Add Document
Progress Summary, 04 April 09
Patent Lit Review, 22 Mar 09
Team Presentation, 14 Mar 09
PhotoTox results, 12 Mar 09
Management Update, 9 Mar 09
igure 38: Project Work Space (Tab 3)
Note: All project names, compound codes, targets, etc. are ary and do not represent actual ongoing work at Novartis.
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File & Document Storage - Teams currently
store project team information on a shared team
space in Lotus Notes. Migrating links or an
interface to these documents to either the new
SharePoint environment or a wiki would allow
these documents to be viewable to the
organizational at large.
Note: actual files should be stored independent of
the wiki system in a corporate document
management system. For example, Cisco uses
SharePoint's environment for an interface to view
documents but all documents are stored within
Documentum and simply linked into SharePoint.
Linking - A wiki would allow team members to help one another
Navigate throughout the organization, establishing links to
resources that that they find helpful for the team. Allowing the
user community to build this linking network will be essential
toward enabling "Google-like" intranet search capability.
Discussion Boards- The wiki space could either
directly incorporate team discussion boards or link
to specific discussion boards elsewhere in the
organization.
- -- II
Chapter 11: Compound Terminations
One of the benefits of organizing compounds in lists on the project workspace (Figure 37) would be
the ability to systematically capture information regarding the removal/discontinuation of
compounds from a specific project. Novartis currently captures information associated with
project terminations in a project tracking database. Although this information provides insight into
why the last remaining project compound was terminated it often does not provide visibility as to
why compounds earlier in the project were discontinued.
11.1 User Research
According to the user interview research, an overwhelming majority of scientists felt that capturing
information associated with a chemical compound termination was not only needed, but extremely
valuable for the organization.
"Information on compound failures would be invaluable or our group. In our team meetings we
talk about other compounds that we are interested in but often we have absolutely no context of if
they've been worked on before, etc. Just knowing the historical context of where this compound
was used in other projects, what were the issues associated with it would be powerful. "
"It's criminal we don't have post-mortems of why compounds fail. We wind up making the same
mistake 3, 4, or even 5 times. We're still reining in these in on hERG and phototox issues.
11.2 Process for Removing/Terminating Compounds
Part of the reason why compound terminations are not adequately captured by NIBR is that there is
not a specific process in place to do so. Adding a compound removal function to the project
compound list would establish such a process and tightly integrate it into the typical project
workflow.
In order to remove a compound from the project list users could check the box to the left of the
compound (Figure 37) and click the "add/remove" button. Depending on the specific development
phase the project was in, requirements for documenting rationale for compound removal could be
enforced before the compound could be removed from the project list. Table 12 below outlines a
few possibilities. Additionally, when compounds were removed from the project team lists,
associated termination rationale would be applied via tags to allow this metadata to be captured and
later indentified throughout the entire organization.
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Table 12: Requirements for Removing Compounds from Project Homepage List
Project Development Requirements for removing Information Captured
Phase compound from project list
N/A - Targets, not compounds are the focus of early
Early Stage Target development work. It is unlikely that specific
Discovery & Assay None compounds would be associated to particular projects
Development (DO, D) at this point in time.
N/A - High throughput screening assays often
Hit Finding/High generate hundreds of thousands of primary hits.
throughput Screening None Mostly, likely it would not be worth capturing the
(D2) compound history (in this particular format) at this
early stage in the development process.
* Indicate if decision pertains to one specific
* Team members would chemical compound, or all compounds in the
series. If the series is being discontinued all
form compounds within the series would be annotated
Lead Optimization (D3) compound(s) with with the same remarks/rationale.
* Tag compound(s) with
relevant discontinuation * Rationale associated with discontinuing
category compound/series
* Links to relevant testing results, documentation,
etc.
* Discontinuation
summary Report
* Associated
Candidate selection documentation &
process (CSP) relevant files * Primary reasons for compound discontinuation
& * Review by Program * Secondary reasons for compound discontinuation
Selected for proof of Office scientific * Supporting documentation (Review board
concept trial (sPOC) committee meeting minutes, PowerPoint presentations, etc.)
* Tag compound(s) with
relevant discontinuation
category
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11.3 Discontinuation Summary Reports
As part of this thesis project, capturing information for compound discontinuations was briefly
explored for compounds in the CSP and sPOC development stages. Thirty nine different
compounds that had been terminated in the either the CSP or sPOC stage were analyzed. A small
subset of these compounds were reviewed with a team of chemistry, toxicology, and safety
profiling experts in order to identify and classify root cause reasons for termination. Findings were
then compiled into discontinuation summary reports. A specific example of a compound
discontinuation summary report is provided below. A similar report format is suggested as a
requirement for removing compounds from the project homepage list that have been discontinued
at the CSP or sPOC project stage.
Note: Compound identifications, disease indications, etc. have been changed to keep information
confidential.
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Figure 39: Compound Discontinuation Summary Report Example
*Note: Compound identifications, disease indications, team names, etc. have been changed to keep information
confidential. Names are fictitious and are not those of actual Novartis employees.
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Primary and Secondary Discontinuation categories
Analysis of compound terminations revealed that the majority of compounds do not necessarily
have one specific reason or rationale associated with the compound termination. Often the story is
more complex, with a variety of potentially problematic issues. As it is important capture all
rationales for organizational learning, termination reasons were classified into either primary or
secondary categories. Primary reasons, designated in the report by "P", involved serious problems
that on their own would be justification for eliminating a compound from a project. In the example
above (Figure 39), primary discontinuations included hepatotoxicity and formulation solubility
issues. Secondary rationales, designated in the report by "S", are problems that could potentially
be solved but where the development path would be difficult requiring additional resources,
development time, etc. The secondary reason alone would not necessarily dictate termination.
However, a compound with multiple secondary issues might be too difficult to move forward.
11.4 Standardized Classification of Termination Categories
In order to effectively tag and analyze compound terminations standard nomenclature, as well as
user defined categories, should be associated with each compound. It will be important that the
defined terminology matches that in the project management databases so that the organization can
have common naming conventions for both project and compound terminations. Termination
categories have been defined for current and future project management databases, PICture and
Porto. A scientific review committee should be brought together to analyze these termination
categories and apply specific case studies to make sure that the classifications are complete and
accurate. Additionally, project team members need to be given the flexibility to apply user
generated tagging related to compound terminations. Even with a carefully defined upfront
categorization scheme it will be impossible to envision and capture every situation. With relatively
cheap digital storage the more tagging information that can be associated with a particular
compound, the better.
11.5 Termination Analysis Committee
The author's efforts tracking down information associated with compound failures revealed that
compound terminations tended to very political. While a large majority of Novartis employees
were very open to talking about their experiences with certain compounds, others were highly
guarded and hesitant to share information. Several internal sources additionally re-iterated that the
rationale for a compound termination was often very dependent on the information source and that
it was therefore necessary to speak with a large number of employees in order to capture the
complete story. For the reasons highlighted above, it would be prudent to establish a scientific
committee to review compound/project terminations for CSP, sPOC molecules and author the
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discontinuation summary report. Elements of committee structure and leadership are highlighted
below.
Committee Structure:
* Program Office Leadership- The NIBR Program Office functions as an overall umbrella
organization and provides a number of support services to both the NIBR disease areas and
platform groups including portfolio analysis. A committee structured to analyze compound
terminations and compile overall lessons learned would structurally fit well under this
umbrella.
* Scientific experts - It will be paramount to include scientific experts on the committee.
Not only will such individuals establish the credibility and legitimacy of a committee
within the larger scientific organization, scientific experts are also needed to evaluate the
complex issues associated with termination decisions. Program Office members cannot
effectively do this alone.
* Dedicated position -Committee membership could be a full time position that would rotate
every six months to a year giving various scientists throughout NIBR a valuable learning
opportunity for analyzing the portfolio at large.
Committee Benefits
* Unbiased Analysis- Decoupling compound termination analysis from the project team
would help to establish termination root causes without the team/ organizational biases.
* Organizational Learning - The committee could serve as a hub for organizational
learning allowing top management to capture lessons learned and ensure appropriate
business processes were in place to identify potential issues earlier in the development
process. For example, NIBR currently has a series of "Quality Plus" teams that are
instrumental in analyzing specific issues like cardiac arrhythmia (hERG). The committee
would simply be a higher level extension of the Quality Plus program.
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Additional Actions by Management
The concept of "fail fast" is often prevalent within the Pharmaceutical Industry. The idea is that a
company should quickly try to eliminate compounds that are not successful and fail them as early
in the development cycle as possible. This avoids spending time and resources on something that
will ultimately never become a viable drug. This approach often leads companies to focus on
quickly moving onto the next project and overlooks valuable knowledge that can be obtained by
learning lessons from project failures, compound histories, etc.
"Most people more interested in working on next project rather than documenting on why a
project failed or documenting terminated project. Very rarely are project post-mortems put
together"
Additionally, individuals fear failure and the implications for their personal career:
"Individuals have specifically told me that they don't want to be associated with a project failure."
NIBR leadership needs to institute a culture where it is not only acceptable to fail, but almost
expected. Drug discovery is immensely complicated with an inherent high failure rate: For every
5,000 - 10,000 compounds tested, 5 of those will reach clinical trials and only one will become an
FDA approved drug (Figure 7). Furthermore, the pace associated with drug discovery process
often forces scientists to make decisions based on the information that they have available at the
current time. Culturally, this should be recognized, understood and accepted.
"Reasons for termination are incredibly sensitive information because of both science and politics.
Many decisions have been made with incomplete data and nobody wants to be second guessed. You
might have made a Ist guess on minimal data. "
Instead of having employees run from failure because it is a "bad thing" the emphasis needs to be
placed on organizational learning from that failure - "What have we learned? How could we have
caught this earlier in the development process? What can we do next time to test for this earlier?"
Additionally, management could emphasize capturing "compound experiences" rather than
"failures." Compounds are often dropped by certain projects only to be picked up later for use in
other indications, delivery mechanisms, etc. Very often discontinuations are not true "failures."
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Chapter 12: Compound Homepage
Similar to the Project Homepage structure, each individual compound within the Novartis library
would have a designated "Compound Homepage". The homepage would serve as a user editable
knowledge management platform for individual compounds.
The Compound Homepage would be structured as a series of associated team web pages with
navigation tabs at the top of each to facilitate moving between pages.
Internal Data External Resources Tagging Comment Space
Navigation tabs at the top facilitate
moving between different pages
associated with a specific
compound homepage.
Compound Homepage
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12.1 Internal Data Page (Tab#1)
This would be the 1st page /tab displayed when visitors navigate to the Compound Homepage site.
The internal data tab would either directly display or link to organizational data associated with a
particular compound. The overall goal would be to unify diverse sources of information in once
easy to find place and allow user to find information with the "fewest number of clicks possible." 96
The internal data page is a non-user editable portal and simply displays or links to information
from other data sources.
Internal Data- Linking portal for all organizational data
associated with a particular compound.
Flexible Modules - Data is organized into specific pre-
defined modules. These modules can be added or removed
by the user.Internal Data 
Compound: AQW881
Physical Properties
Naming
Conventions
Birth Certificate
Project
Associations
Avalon Summary
Report
Compound Safety and
Availability & Toxicology
Identity
In Silico Modeling Metabolism &
Tools Pharmacokinetics
Analytical Data Affinity &
Proteomics Data
Biophysical
Characterization & Search
Crystallography
Figure 40: Novartis Internal Data (Tab #1)
Note: All project names, compound codes, targets, etc. are arbitrary and do not represent actual ongoing work at Novartis.
96 Dejan Bojanic, The Novartis Institute for BioMedical Research, Center for Proteomic Chemistry
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Modularity
Throughout the user research interviews scientists expressed a wide range of preferences for the
types of data displayed on the Compound Homepage. Preferences not only varied by organization
and workflow activity but also by personal preference. Based on this feedback, data was broken
down into specific modules. These modules could be either added or removed by the end users
similar to a Yahoo or iGoogle homepage (Figure 41).
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Figure 41: iGoogle Homepage, representation of different modules"
97 iGoogle site. Google, n.d. Web Accessed 20 April 09 http://www.google.com/ig
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Data Warehouse
Rather than connecting the various modules directly into existing databases it will be essential to
create a backend data warehouse (Figure 42). Creating a data warehouse would translate
information into a standardized format and have multiple advantages including: scalability, loading
speed, maintenance and backend access for various computational science groups. Data
warehousing would allow new modules to be added with various ease.
Module 1 Module 2 Module 3 Module 4 Module 5
SI I I
Data Warehouse
Database AE D- Database BI -
Database C Database D
Figure 42: Data Warehouse
12.1a Compound Picture Module
Scientists communicate chemical structures in pictures. The first module on the compound
homepage would not be user editable and would automatically display the chemical structure in the
upper left hand corner of the Compound Homepage.
STI571
N
HN N' N
I b
HN
0CC
Compound ID Number - The Novartis compound identification
number, referred to as the NVP number, would be displayed
immediately above the compound structure.
Note: All project names, compound codes, targets, etc. are arbitrary and do notrepresent actual ongoing work at Novartis.
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Compound Picture - Right clicking on the compound structure would allow
users to copy the compound onto the clipboard for export into other
programs. Options for immediately launching the compound into chemical
drawing tools (Isis, or Focus) could also be explored.
12.1b Naming Conventions Module
A wide variety of naming conventions exist for chemical structures. Examples include scientific
identifiers (IUPAC, InChI), digital representations (InChIKey, SMILES) chemical
society/Pharmacopoeia names (PhEur, USP), research codes, trade names, marketing brand names,
etc. Additionally, a number of commonly used scientific databases assign specific identifiers for
each chemical compound. For example, the Chemical Abstracts Service (CAS) is a comprehensive
database that searches scientific and patent literature. CAS assigns a unique chemical identifier
number, a CAS Number, for each chemical. Providing scientists with access to chemical
synonyms and chemical identifiers facilitates both internal and external search.
Synonyms (internal) - Many compounds have multiple internal codes/names. Older compounds
often have a Ciba-Geigy or Sandoz # associated with them. Chemicals further along in
development will have a development or clinical code #. User research indicated a high
preference for being able to view both internal and common external synonyms on the front
webpage (vs. buried deeper in links). As a result these are displayed up-front.
View all synonyms - All synonyms are notNaming Conventions Module
reflected on the front page of the module due toSynonyms (internal) space limitations. This link would open up another
pop-up window that displayed all the synonyms in
one place.
Common Synonyms (external) IUPAC, InChI, InChiKey, SMILES - Scientists
expressed interest in being able to view the IUPAC,
InChI, InchiKey and SMILES name but felt that listing
the complete name directly within the Naming
Conventions module will take up too much space.
Therefore, users are given the option to link to these
llll l ~names. Opening the "IUPAC, InChI, InChIKey,
SMILES" link would display the following table in a
pop-up window:
* Question Mark (mouse over) - A question mark mouse over
symbol that displays "click for info" upon mouse over could be
located next to various name items. Clicking would produce a pop-
up window explanation for the object. For example:
"The IUPAC International Chemical Identifier (InChI,
pronounced "INchee") is a textual identifier for chemical
substances, designed to provide a standard and human-
readable way to encode molecular information and to
facilitate the search for such information in databases and on
the web." - InChI Wikipedia Article
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UltraLink Preferred Name -The Novartis IT group has assembled a library of compound nomenclatures as part of the
UltraLink project. UltraLink not only captures chemical names but assigns a naming priority hierarchical structure. The
synonym browser is currently available and will be easy to link to the naming conventions module. A possible link to the
UltraLink preferred names, and its utility to scientists should be further explored:
UltraLink Priority StructureExample: Zoledronic Acid
12.1c Birth Certificate Module
A wide variety of information is related to the registration or "birth" of a compound. Scientists
expressed a strong desire to have access to names of individuals that synthesized the compound,
location of synthesis, synthesis rationale and other information relating to the compound
registration.
Select Compound Batch - Often different
batches of a particular compound are
synthesized. A drop down menu would
allow a user to select the compound batch that
they wish to see. By default the first synthesis
batch would be displayed.
Birth Certificate Module
Chemist, Lab Head - The Chemist and Lab Head names
are currently captured as part of compound registration
process. Providing these names hyperlinked to the Novartis
directory will allow scientists to directly follow-up and ask
questions with the appropriate colleague.
Select Compound Batch '
SRationale for Synthesis:
Compound was made in
project PRX487 as part of a
chemical series to eliminate
a hERG liability.
- Brede Wegener* 02/22/07
*Names are fictitious and are not those ofactu 1 Novartis employees.
Rationale for synthesis- Synthesis
rationale was one of the most
requested items during the user
research. A mandatory data entry
field could be added to capture this
information during compound
registration. That data field could
then be displayed in the birth
certificate module. Alternatively,
the section could be a user editable
wiki where scientists could annotate
compounds that they have made in
the past. A default message such as
"Rationale is missing. Please help
annotate me!" might encourage user
Company & Location- Chemical compounds are
synthesized at a variety of research locations within
Novartis. Additionally, many compounds are either i -
licensed from other companies or purchased as part of
collection from an external chemical supplier. Providin
clues about a compound's origins is often very helpful fo
tracking the compound history and understanding
previous scientific work.
Project Synthesized for: - Individuals that were interviewed for
user research routinely stated their desire to know what project the
compound was synthesized for. This information needs to be
captured as part of the compound registration process. Displaying
it in the birth certificate module will provide a linkage to the
Project Homepage where additional information about the project
is available.
Synthesis Pathway: - Chemists that routinely synthesize chemical compounds, as well as Analytical scientists who perform NMR,
specified that it would be helpful for them to be able to view the synthesis pathway. Such information also has the potential to save
a chemist a significant amount of time & effort. Before beginning a synthesis they could simply perform a structural similarity
search and view how a similar synthesis was performed. It's possible that if the compound was synthesized recently a fellow chemist
might have some chemical material left over from the prior synthesis providing a jump start. Additionally, synthesis information is
valuable when a compound near s development and will have to be produced on a large scale.
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12.1d Project Associations Module
A chemical compound can be associated with many different projects. It's useful for scientists to
be able to quickly investigate the compound's role in a particular project and potentially follow-up
with project team members. A simple table that associates compounds with projects would help
facilitate this task.
Project Code - Hyperlink allows for quick
navigation to the Project Homepage.
Project Asso ations Module
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Disease Indication & Target Class- Listing the disease indication
and target class provides a quick summary history of the compound.
Often, a compound can be associated with more than one disease.
Such information provides valuable insight into the biology and may
yield additional clues for investigating further indications.
I7
Target - Hyperlink allows for
quick navigation to the Target
Homepage.
Project Phase & Status- Gives a quick
synopsis of the current activity of the
compound. As hundreds of thousands of
compounds are often associated with a
particular project at the D2a stage, the
module may want to only display
compound/project associations starting
with the D2b or D3 stage.
12.1e Avalon Summary Report Module
Avalon is the Novartis data warehouse that provides assay results and additional information on
chemical compounds. It will be essential to provide both Avalon summary data as well as a link
into Avalon so that users can easily extract additional information from Avalon, access testing
results, etc. Link to Avalon - Hyperlink would allow for quick navigation into Avalon. The
hyperlink would pass the compound identification directly to Avalon so that a user would
not be reauired to re-sian in and re-enter the NVP# to execute the search.
4
Avalon Summary Report Module
Copm~tviy. .
Primary Assay Data HTS heat map*
* Heat map & IC50 Summary Results were developed by at Nov is by Berd hde.
H Question Mark (mouse over) - A question mark mouse ove symbol that
displays "click for info" would be displayed next to the heat map. Clicking the
symbol would produce a pop-up window explanation for the object. In this case the
following pop-up window would appear:
What is this heat map?
The primary heat map represents a collection of CPC primary screening data put together on
01/2008. It is a one-time snap shot of primary screening data and is NOT necessarily inclusive of all
primary assays that have been run by CPC.
How do I interpret this?
Each box on the grid represents a particular assay. The assays have been grouped first by technology
then by target in order to give a visual representation of primary screening results.
The coloring represents the amount of activity (% inhibition) measured in the assay.
Grey = Assay was not run
White = No activity (0% inhibition)
Red = The darker the red coloring the greater the % inhibition (+)
Blue = The darker the red coloring the greater the % inhibition (-)
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Assay grid (mouse over) -
The heat map allows users to
mouse over individual
squares. Upon mouse-over
assay statistics are displayed.
Compound Activity- Users expressed their
desire to be able to quickly see high level Avalon
statistics. The # of assays listed in Avalon would
indicate the amount of information listed in
Avalon for a particular compound. As one
interviewee animatedly expressed "I want to
know how much info is in Avalon and if it's
worth it to open Avalon to look at this info."
The # of IC50 curves listed gives an indication of
the compound's level of promiscuity. For
example, hundreds or thousands of IC50's curves
would indicate that the compound was highly
promiscuous or a frequent hitter.
Both # of total assays as well as # of IC50 results
would need to be referenced in the context of the
compound registration date. A compound that
was added to the library in the past few months
would have very few assays & IC50 curves. This
would not be an indication of an inactive
compound but rather a function of how long it
been in the library.
12.2 External Resources Page (Tab#2)
The 2nd tab displayed on the Compound Homepage would provide a linking portal to external data
associated with a particular compound. As discussion in the User Research chapter, propriety
concerns with passing compounds through the internal firewall would need to be addressed and
data resources would most likely need to be located within the Novartis firewall. Table 6,
within the User Research Chapter highlights the external databases that interviewees indicated they
used most often.
Database Name- Hyperlink directly
to the home page of the indicated
database.
In
External fo
Figure 43: Compound Homepage External Resources (Tab #2)
E Letter "D"(mouse over) - Mousing over the symbol displays
"click for database description". Clicking the symbol would
produce a pop-up window that gives a brief overview of the
database. For example, clicking the "D" symbol next to
ChemSpider would display the following:
Database Description*-ChemSpider is a chemistry
search engine open free to charge to the public.
Chemical structures are indexed into a single
searchable repository (*taken from ChemSpider)
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Database Search- Hyperlink automatically passes the
compound name to the indicated database allowing user to
instantly access results without re-typing in compound name.
dicates # of user reviews/ratings
r this particular data base.
UILetter "Ex"(mouse over) - Mousing over the symbol
displays "click for examples of information found in
this database". Clicking the symbol would produce a
pop-up window that provided specific example of
information that could be retrieved for that particular
database.
Database Ratings-Chemical
information is contained in
literally hundreds of external
databases. Some interviewees
indicated that were often
overwhelmed by sheer number
of database choices and tended
to use only a few bookmarked
favorites. Establishing a user
rating systems would allow the
best data sources to become
apparent and encourage
explorations of those sources by
users. The user rating system
would also be beneficial for
reviewing database licensing
agreements. Resources with
poor reviews would not have
licenses renewed.
Examples of Info find in ChemSpider:
Additional external data sources, commercial suppliers,
naming conventions, prediction of physicochemical
properties based on ACD/Lab algorithms.
12.3 Grouping/Tagging Page (Tab #3)
The 3 rd tab displayed on the Compound Homepage would allow individuals to tag individual or
groups of compounds, explore tagging relationships, and annotate tagging groupings via a wiki.
Compound Picture- As the "Tabbing/Grouping" tab encourages browsing to other compound homepages it will be important
to orient the user and remind him/her which Compound Homepage they are viewing. As individuals don't typically remember
NVP# structural associations, a picture of the structure will be imperative. Having the picture displayed on this page will also
help avoid tagging mistakes and insure that users are tagging the correct compound.
Tagging / Grou i g Tagging- Users could tag a single compound or apply a tag to
a group of compounds.
AQR851
I I inc ~inur 0 giop m inui i~ d1L U
Add a user tag to NVP-AQR851
Apply a user tag to multiple compounds
Pre-defined Tags
Suggest a pre-defined Tag
SProject AQW365 (545 members)
Project QWR883 (48 members)
Type 11 Diabetes (17 members)
Stearoyl-CoA -validated target hit (23 members)
Target Family GCPR., validated hit(1285 members)
Natural Product Library (10.233 members)
Synthesized by Brede Wegener (459 members)
Structural Similarity (100 members)
/ CSP (terminated) (42 members)
Terminated, Phototoxicity "p"(17memb s)
User Applied Tags I
L
Figure 44: Compound Homepagb agging/Grouping
User Defined Tags - U defined tags can be created at any
time by any member of the NIBR community (see discussion
below). User-defined tags are color codedmaroon in order to
allow the user to quickly distinguish them from pre-defined tags.
Tagging Group Wiki - Wiki space will be open to user
community to encourage discussion and further annotation of
the tagged group. Throughout the user research interviews /
scientists expressed a strong desire to comment on groups of
compounds. This wiki provides this.
Add a user tag to NVP-AQR851
Greg Stone Climax List (1,345 members)
Ciba-Geigy Terminated List (2000-1977) (781 members)
Failure to co-crystallize with protein (9 members)
Addition increases transcription of Gene ABC (13 members)
Unstable compound powder (11 members)
,Education office case studies of phototoxicity (7 members)
Tags that are underlined hyperlink to an associated "tag" wiki.
This wiki allows for the creation of additional tag related metadata
and provides a user forum for discussing the group of tagged
compounds. Potentially, users could also rate the usefulness of the
grouping/particular tag. An example Tag Wiki is below:
1-CC-"-"3 3311 I -- rr C"CL11 ~ ~
A scroll
bar allows
users to
scroll
though the
list of tags.
I ne numoer ol group tmemberltls s ltu to
right of each tag. Clicking on the members
brings up a NPV & structure picture list of
all compounds in thatgroup.
Pre-Defined Tags - These tags would be ags that have already
been defined by the organization, or m adata that is captured
systematically (see discussion belo . Pre-defined tags are color
coded green in order to allow the er to quickly distinguish them
from user created tags.
Tagging Group Created by: Carol Mahol
Date Created: 11/24/2008
Initial Group Members: WRT421, YIR554, ZR1271, AQR851.
PM0395, JK0539, RJS223
Rationale for Group Creation: I created this group as a result
of digging up some examples of compounds that had phototox
issues for an upcoming education office class on 12/08.
Additional info on these case studies is posted here
------------------------------------------------------------------------
Wiki Section Guidelines for posting to this wiki Example Postsf Successful/Not-successful case studies
Several of the compounds in this group were successfully
modified to eliminate the phototox issues (YIR554,RJS223) while
others resulted in termination (AOR851)- Carol Mahol 11/24/08
Structural Similarity- All of these compounds share a common
structural elements that allows for the breakdown into a reactive
metabolite XYR...... - Bill Egerton 11/28/08
m
f
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12.3a User Applied Tags
User defined tags could be created at any time by any member of the NIBR community. As
discussed in previous chapters, allowing the user community to add metadata and categorize
content via folksonomy has several advantages: the work of categorization is spread out among the
entire community, the categorization scheme is flexible, time delay is minimal (e.g. you don't have
to wait for information to be added to a database by IT data organizers), and tags reflect the
information structure and relationships that people actually use98. Additionally, user created
tagging will allow individuals to share relationships and knowledge about specific chemical
compounds throughout the entire research organization in real time, irrespective of organizational
boundaries. Several hypothetical examples of user created tags are highlighted below:
Education Office Case Studies of Phototoxicity Case Study
The Education Office at NIBR develops a number of scientific classes in order to train employees
on a wide variety of topics. In a hypothetical example a member of this organization named Carol
is creating an education course specifically to address phototoxicity. Carol has spent hours
compiling many detailed case studies of compounds that were phototoxic. Sometimes the
phototoxicity issue was resolved by the project teams, other times the compound was terminated.
Carol decides to tag her associated case study group of compounds. She navigates to the NIBR
Compound Homepage of AQR85 1, clicks "apply a user tag to multiple compounds", enters in a list
of compounds in addition at AQR85 1, and creates a tag category called "Education Office Case
Studies of Phototoxicity".
Not only does Carol choose to tag the group of compounds, but she also fills out a tagging wiki
(illustrated above). The tagging wiki captures additional metadata associated with the tag
including: the name of tagger, date tag group was created, rationale behind adding the tag, etc. It
also provides a forum for additional discussion of the tagged group. Carol uses the wiki to further
annotate her group of compounds: "Several of the compounds in this group were successfully
modified to eliminate the phototox issues (YIR554, RJS223) while others resulted in termination
(AQR851)".
Bill, a member of the Global Discovery Chemistry Group (GDC), stumbles upon Carol's grouping
while looking at the Compound Homepage of ZRI271 for an unrelated problem. Bill is one of
NIBR's experts on phototoxicity so Carol's tagged grouping immediately interests him. He clicks
on the "7 members" hyperlink to the right of Carol's tag on the ZRI271 Compound Homepage.
98 McAfee, Andrew "Enterprise 2.0: The Dawn of Emergent Collaboration" MIT Sloan Management Review, 47. 3(2006). Print
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From there is he able to view all of the compounds that Carol has tagged. Bill compares structural
similarities of the compounds in Carol's group and comments on the tag wiki regarding his
observations.
Furthermore, Bill doesn't know Carol but now has instant access to her contact information via the
"People Homepage" by clicking on the hyperlink "Carol"_Bill picks up his phone and calls Carol to
discuss a few of the phototoxicity case studies in more detail. During the course of their
conversation Bill also suggests two other compounds that would be very valuable for Carol to add
in her class next month. Carol then manages to persuade Bill to stop by her scheduled class in
December as a guest speaker. Two individuals who previously didn't know one another are now
connected and actively dialoging to help address a drug discovery challenge. Both Bill and Carol
are tremendously benefiting from the interaction. The entire time required for Carol to create the
initial group of tags? Just 7 minutes.
Unstable Compound Powder Case Study
Jason Brucker, a very meticulousness organic chemist in the NIBR GDC organization keeps a very
detailed record of his chemical inventory. Jason has worked in drug discovery synthesizing
chemicals for a number of years. His experience has taught him the value of keeping certain
chemicals in his personal inventory as they are often useful starting points for a synthesis,
eliminating the need to perform a number of prior reaction steps. Jason stores these extra
chemicals in his laboratory typically in powder form. As some chemicals are prone to degradation
over time, Jason will often run a quick identity check on the mass spec if he is using a stock
powder that he knows is older.
Over the years Jason has compiled a list of compounds that have proven from his personal
experience to be unstable over time. One day Christina, one of Jason's colleagues asks Jason for
this list. Christina is synthesizing something very similar to what Jason has produced in the past
and wants to make sure that it's not on Jason's "unstable" list. Christina suggests that Jason should
post this list to the Compound Homepage, as it might potentially benefit other chemists within the
organization. Following Christina's advice, Jason navigates to the Compound Homepage and tags
eleven different compounds with the user tag "unstable compound powder". He annotates the tag
wiki as to why he created the grouping.
As Jason is very detailed oriented, he has saved old mass spec results, as well as a PowerPoint slide
detailing a proposed mechanism of action of breakdown from some of his compounds that have
degraded. Annotating the tag wiki inspires Jason to dig up these documents from his personal hard
drive. As NIBR's policy is to not store files physically in the SharePoint wiki site, Jason places
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these files in one of his public directories on Documentum, the company's new document storage
system. From Documentum Jason obtains a hyperlink to the location of his documents. He embeds
this hyperlink in the tagging wiki simply stating "spec results and PowerPoint detailing proposed
mechanism of degradation located here"
Six months later, Steve, a project team leader is reviewing high throughput screening results for his
project. Compound AQR851 appears as a very strong candidate with a large percentage of
inhibition of the project's target. Before running further testing Steve decides it might be prudent to
poke around on the Compound Homepage to see if he can learn anything about the history of
AQR851. As Steve scrolls through the list of user generated tags he notices that compound
AQR851 is tagged with "unstable compound powder. "As this particular tag is a maroon colored
user generated tag Steve initially treats this with a bit of skepticism and realizes that the
information may be a bit open to interpretation. Still, this information is concerning. Steve clicks
on the tag to open the tagging wiki. He reads Jason Brucker's comments and follows the link to
Jason's PowerPoint slide which proposes a mechanism of degradation for AQR851. Jason has
clearly documented that AQR851 degrades into compounds X & Y. Steve now wonders if his
assay results were caused by AQR851, compound X or compound Y. He contacts the compound
library management group to share his concerns and request mass spec identity testing of the
AQR851 powder held in the compound archive. One week later testing results come back. Sure
enough, compound AQR851 has degraded. In fact, the powder is mostly now compound X, not
compound AQR85 1!
The organic chemists on Steve's project team quickly synthesize a fresh batch of compound X.
When the team repeats the target specific assay testing with a purified solution of compound X
they are able to verify that it was compound X, and not compound AQR851 that causes the large
percentage inhibition of the target. Compound X is not even currently in the Novartis library!
Compound X is submitted for library registration. Steve navigates to Compound X's homepage to
add the "rationale for synthesis" and to annotate his team's experience with compound X. He links
this to the comments on Jason's tagging wiki and the compound AQR851 homepage.
User Applied Tags and Tagging Wikis Summary
From just the two examples above the reader can see how user generated compound tags, coupled
with the power of user annotated wikis could be immensely powerful for NIBR. User generated
tags and wikis are particularly important as they provide a very flexible way for individuals to
capture relationships and knowledge work as it is happening. As seen from above, often the tags
are unpredictable and could not have been foreseen in an upfront based, top-down organizational
scheme.
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12.3b Pre-determined Tags
Individual vs. Group Questions
How do "pre-determined" tags differ from user generated tags, and how are these also useful for
the organization? Pre-determined tags are nothing more than the metadata that already exists for a
particular compound. In other words, reviewing "pre-determined" tags is just another way of
simply viewing data that exists for a particular compound.
Within the Internal data section tab of Compound Homepage, different linking modules were
explored. The modules provide links to or display information relating to one particular
compound. For example, suppose that a scientist wanted to locate the chemist responsible for
synthesizing compound AQR851. He/she would navigate to the AQR851 Compound Homepage,
click on the Internal Data tab, scroll down to the "birth certificate" module and then look at data
field titled "synthesized by chemist." The name "Brede Wegener" appears so the scientist knows
that Brede Wegener synthesized compound AQR851.
This is great if the user just wants to know about compound AQR85 1. However, what if the user
wanted to explore that same question in a different way? What if the scientist kept randomly
encountering compounds synthesized by Brede Wegener that just happened to be of particular
interest. The scientist might want to view all of the chemical compounds that had ever been
synthesized by Brede Wegener. Navigating to randomly selected chemical compound homepages
and searching for "Brede Wegener" as the synthesizer would not only be tedious, in a collection of
millions of compounds it would be impossible. So how would an individual accomplish this task?
By simply organizing the information in a different way, via "pre-determined" tagging, the task is
remarkably easy. A simple algorithm search of an already existing Novartis database would
identify all of the chemical compounds that had been synthesized by Brede Wegener. These could
be tagged with "synthesized by Brede Wegener ". Once tagged it would be easy to view these as a
group of compounds. The scientist would simply navigate to the "tagging /grouping tab," scroll
through the list of pre-determined tags to locate the "synthesized by Brede Wegener tag."
Immediately they would see that this group has 459 members meaning that Brede has synthesized
459 other chemicals (Figure 44). Clicking on the "459 members" hyperlink would display a list of
NVP#'s and associated pictures of the structures of all 459 group members. Navigation and further
exploration of these compounds would be easy as each NVP# would be hyperlinked back to that
particular compound's homepage.
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Questions related to an individual compound are compared with situations / questions that might be
asked of a group of compounds (Table 13). The Internal Data tab or linking functionality of the
Compound Homepage would usually be best suited to answer individual compound questions
while the Tagging/Grouping tab would allow users to explore questions relating to an entire group
of compounds.
Table 13: Examples of Individual vs. Group Compound Questions
Subject Individual Questions Group Questions
There are a lot of really interesting
I'm interested compound AQR851. I'd love to talk to compounds that I've discovered came from
Compound
the scientist that made this compound. Who contract lab RTY. What are all the
Origin
synthesized AQR851? compounds we have in the library that were
made by this same contract lab?
I know that RQB571 hits enzyme target XYZ
I suspect that compound RQB751 is a promiscuous
Target but what are all of the other chemicalhitter. What are all of the specific validated targets
Class compounds that are validated hits against this
that RQB751 has hit?
enzyme XYZ?
I'm thinking of including compound RYU123 into I'm studying hERG activity. What are all the
my project. Oh wait, comments and links to assay chemical compounds that have been
hERG results on the Compound Homepage shows that it implicated in hERG? What can I learn about
has unsolvable hERG issues. Let's not use this the commonalities of this group?
compound.
Note: All project names, compound codes, targets, etc. are arbitrary and do not represent actual ongoing work at Novartis.
Search vs. Pre-determined Tags
In the previous example of searching for all compounds synthesized by Brede Wegener, why not
just execute a search for "compound synthesis Brede Wegener" instead of accessing the
information through pre-determined tagging structure? Although searching is very powerful and
will also be included in the Novartis web structure, specifically listing pre-determined compound
tags within the Compound Homepage structure has several advantages over a simple search.
First of all, search architecture would need to be in place to allow searching to return the
appropriate information. Perhaps the data relating to the compounds that Brede Wegener has
synthesized is located in the compound registration database. Does the current Novartis wide
search engine query this database? If not, maybe the database does have a search interface but it
would require a user to first find this interface. This means that a scientist who is new to the
organization would have know that a) a database exists for compound registration b) it contains the
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name of individuals who synthesized the various chemicals c) the database is called ABC d) the
web interface to search this database is located at hyperlink xyz123. Secondly, even if the
Novartis wide search engine queried this database in addition to other organization information it
might return links that are unrelated to this specific question. For example, the organic chemistry
group's internal webpage might be a hit "the GDC group supports all of
NIBR's synthesis needs....... Group members include: Jack Johnson, , Jennifer
Duffy, etc."
Lastly and most importantly, the pre-determined tagging structure encourages random browsing
and the exploration of relationships in a way that searching does not. Synonymous with browsing
through the Amazon.com bookstore, a user might not know exactly what he/she is searching for
but none-the-less stumble across powerful, interesting information. The tagging structure of the
Compound Homepage website establishes the framework for this random browsing and actively
encourages the exploration of relationships between compounds, assays, side effects, disease
indications, people, etc.
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12.4 Compound Wiki Page (Tab #4)
The 4 th tab displayed on the Compound Homepage would allow the Novartis user community to
collectively compile knowledge related to a specific compound and display this information to the
entire organization. Unlike the "tagging wiki" information that is posted on the compound wiki
would pertain only to one specific compound (vs. a group of compounds).
Wikipedia Editing Organization- The Compound wiki History- The names of article authors, dates of editing
should adopt the structure of Wikipedia and allow users to view contributions, as well as previous edit versions of the wiki can
an article, contribute to an editing discussion specifically about be viewed via the "history" hyperlink."
the contents of the article, edit the page, add new sections to the
article and view the page editing history. / Wiki Guidelines- Guidelines are posted for users who are
S relatively unfamiliar with wikis, how to edit, etc. The
guidelines section links to several examples of compound
Compound Wiki wiki pages that are "ideal wiki pages". These example pages
can serve as a template for the creation of new content.
Article Editing Discussion Edit thB ae
iki/Discussion Board GuidelinesNew section History Add a file
What is a wiki for?How do I edit this?
TRQ772 History GuidelinesWiki Example Pages
- l TRQ772 has been used in an mber of different Novartis What goes on the discussion board vs. Wiki?
projects internal data proect ble. Most recently it is a
NH sPOC candidate for the treatm nt of bipolar disorder. TRQ772 Discussion Board
S NH2  Post NewPost Reply
Synthesis & Preparation Author:JullianBayfiled
Carbamazepine can be synthesized using a nu ber of different routes. Date Posted: 10/14/07
Route A and route B are preferable as they elim nate the need for Subject: Additional Indications
highly toxic and reactive intermediate J. Addit onally, care should be
taken not to heat this compound over 40 0C as it egrades significantly Does anyone know if the project team has looked
at higher temperatures f11. at using this compound to also treat ADD? This
Interactions compound indications is not currently listed
Valproic acid and valnoctamide both interact with carbamazepine, as under the indications module but I came across
they inhibit microsomalepoxidehvdrolase (mEH), e enzyme another similar literature compound, 5H-
responsible for the breakdown of carbamazepine-, ,11 epoxide into dibenzorb,flazepine-5-carboxamide that had the
inactive metabolites. l By inhibiting mEH, valproi acid and same mechanism of action. As such, the ADD
valnoctamide cause a buildup of the active metaboli 
, 
prolonging the indication might be worth exploring!
effects of carbamazepine and delaying its excretion*
Figure 45: Compound Homepage Wiki (Tab #4)
Add a File - Interviewees throughout the user research stressed the importance of
being able to attach files to the wiki. Observations further confirmed that compound
information is kept in a variety of PowerPoint presentations, picture bitmatfiles,
excel documents, MS Word files, etc. Users need to be given a place to actively
store this valuable information so that it is accessible to the entire community. The
"add a file" hyperlink would allow a user to add a file into a publically viewable
folder of the Novartis document organization system that is associated with the
particular compound, in this case compound TRQ772. The user could then obtain a
hyperlink for this document to place in the wiki or discussion board.
Discussion Board- The compound
discussion group encourages scientific
discussion about a particular compound in
the form of forum posts and replies to the
topic. This discussion board is included to
ensure that the wiki article is compilation of
knowledge (think compound encyclopedia
page) and does not turn into a discussion
forum for questions, ideas, etc.
Wiki vs. Discussion Board Content
It is important to distinguish between a compound wiki and discussion board related to a specific
compound. The compound wiki is a collaborative type document that captures information about
the compound. The document is created and updated by the user community as the compound
moves through the drug discovery process. The further along in the drug discovery process, the
more will be known about a particular compound, and the more can be added to the wiki article.
The compound wiki can be thought of as a flexible, ever changing encyclopedia article about a
particular compound. Although discussion about the wiki may take place on the "editing
discussion tab" this discussion is restricted to conversation and dialogue about what to add to the
encyclopedia article, how the article should be formatted, edited, presented, etc.
Conversely, the compound discussion board provides a forum for any type of discussion about the
compound. It does not necessarily have to be related to any of the content present in the wiki. The
example on the TRQ772 discussion board above illustrates this point. The user Jullian Bayfield
has posted a comment about a potential additional disease indication for the compound. As the
Attention Deficit Disorder (ADD) disease indication has not necessarily been investigated it is not
currently part of the collective knowledge compound encyclopedia. That said, the comment is very
powerful and needs to be captured. The compound discussion board is the appropriate forum to do
SO.
The compound discussion board is currently presented on tab #4 to the right of the Compound
Wiki article. This amplifies the distinction between what is on the wiki vs. what goes in the
discussion board. That said, this may not be the appropriate location. Further investigation should
take place to see if the discussion board should be incorporated on the compound wiki page
(tab#4), or if another tab should be added to the Compound Homepage specifically for a compound
centric discussion group.
Compound Wiki (tab #4) vs. Internal Data linking portal (tab #1)
If the internal data linking portal (Compound Homepage tab #1) captures all of the organizational
information associated with a particular compound why is it necessary to also have a wiki? Yes,
the wiki provides a text-based format for explaining information and results. In a sense it's a
summary overview of the body of knowledge associated with a particular compound. The internal
data tab directs individuals to very specific data while the wiki provides the high level compound
experience or summary overview of that accumulated knowledge.
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Upfront Organizational Structure
Rather than impose an upfront organizational outline, it is recommended that users be allowed to
define the organizational structure of the wiki. Certain sections may be very relevant for certain
compounds while other sections may not pertain at all. To assist users in determining what type of
information can and should be written about in the wiki, specific examples of model compound
wiki pages are provided in the user guide at the top of the wiki. Scientists can review these pages
to get an idea of what structure is appropriate. In addition, editors are encouraged to debate
structure and organizational content of the wiki in the "editing discussion section."
Maintaining Quality / Dealing with Controversy
In a wiki type environment, anyone can create or delete the content of another user. This inherent
structure leads to an internal quality control mechanism. The founder of Wikipedia, Jim Wales
explains "The wiki model is different because it gives you an incentive when you're writing. If
you write something that annoys other people, it's just going to be deleted. So if you want your
writing to survive, you really have to strive to be cooperative and helpful." 99
99 Rand, Matt "Best of the Web: Extreme Blogging," Forbes, 13 Dec. 04. Web. Accessed 21 Feb 09
http:www.forbes.com/best/2004/1213/bow001 .html.
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Chapter 13: Conclusion and Future Steps
Novartis needs to take several future steps to facilitate the creation of Compound Homepage and
other elements of the new global scientific web environment. Currently, Novartis is actively
undertaking several Web 2.0 and data improvement initiatives. Upgrades to many existing data
systems are taking place, allowing metadata to be standardized and have common nomenclature.
The company is also working on restructuring the internal web, implementing user driven
SharePoint team sites, discussion boards, idea boards. Furthermore, several departments have
made significant progress with the implementation of both target and safety profiling wiki
environments.
Top Leadership and Organizational Commitment- In order to establish a global Web 2.0
environment, NIBR needs to officially commit to creating and implementing a new web-based
navigation environment for scientific data. Currently a couple of departments are spearheading the
effort but it is unrealistic to expect such an extensive initiative to be carried only at a departmental
level. There needs to be a substantial commitment from top leadership to provide official resources
and leadership support. The project needs to be staffed with multiple full time job positions.
Individuals could be pulled from the NITAS organization, Center for Proteomic Chemistry, Global
Discovery Chemistry or hired from an outside web consulting firm such as Avenue A. Razorfish
(AARF).
Scientific Web Team-A "scientific web" leadership guidance team should be established. The
team will guide and specify the overall organizational structure for the scientific web environment
(i.e. Compound Homepage, Assay Homepage, Target Homepage, People, Project and Search). As
many of the different spheres overlap and link together it is imperative that the system is first
scoped out at a high system wide level with all of the working pieces in mind.
Build the System - Envision and build each of the different scientific spheres (target, compound,
project, assay, people, and search).Make sure that user experience is similar between all systems so
that users don't have to learn a different format or deal with a different interface when they jump
from one world to the next. Additionally, each scientific sphere will need to be tightly integrated
into the existing workflow to encourage adoption and provide "immediate benefit" for users.
Web 2.0 Training - Several literature review articles stressed the importance of training
employees on how to use new Web 2.0 tools. John Castledine, the Director of Learning and
Development for Pfizer's Global Research and Development (PGRD) Division, reflects on Pfizer's
implementation of Pfizerpedia:
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"There can be little doubt that for an organization to encourage the adoption of Enterprise 2.0
there must be a perceived overall benefit in doing so. To achieve sustainable change, it is vital
that these benefits are presented from the frame-of-reference of the key stakeholders. For
example. information overload is a major concern for most colleagues. Hence without
understanding RSS feeds, blogs become yet more websites to add to your favorites list.
Similarly, wikis and social bookmarking tags offer welcomed options to reduce email traffic
within teams. "100
Employees should participate in training to learning about wikis, blogs, RSS feeds, tagging, social
networking, etc. Case studies of Flickr, Delicious, Yelp, Facebook and Wikipedia could be
presented. Homework would include creating a blog, authoring content on Wikipedia, etc. This
exposure will help employees understand and feel comfortable contributing to the Web 2.0
environment. This is especially important for older generations who have not necessarily grown-up
actively participating in a user generated content environment.
Homepage Training/Organizational Communication- It will be very important for management
at all levels to clearly and consistently communicate expectations associated with the new scientific
web via training, talking about web environment in staff meetings, etc. Guidance needs to actively
be established and communicated surrounding items such as: how to add document attachments to
the wiki, the procedure for associating tags, etc. User community rules should also be clarified.
For example, it's very important that users have the chance to disagree over posted content;
however they should hash out editorial disagreements in the editing discussion section of the
compound wiki, or perhaps an allocated discussion thread post rather than on the compound wiki
article itself.
Management Involvement - Management's direct involvement in encouraging user contribution
will be absolutely crucial for the adoption, usage and overall usefulness of the Web 2.0
environment. Many Web 2.0 tools require participation on a mass scale in order to achieve
significant network effects. For example, if only a few users on Flickr tag photos, the majority of
content never gets classified and searching via tags becomes worthless.
Lack of user participation becomes magnified in smaller communities. In large internet based user
communities just a small number of users typically contribute content. McKinsey surveyed many
users of online video sites to learn what motivates users and analyze user posting patterns. They
discovered that just a few users posted the majority of the video content. Depending on the site 3-
10 "Pfizerpedia: knowledge repository at Pfizer" Chartered Institute of Personnel and Development, n.d. Web.
Accessed 21 Feb 09 http://www.cipd.co.uk/helpingpeoplelearn/pfzrpd.htm
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6% of the membership added 75% of the videos available for download and just 2% of the member
base accounted for more than half of all videos viewed. 10 1 If the user community itself is very large,
with millions of users such as Wikipedia, 3% still constitutes a substantial number of contributors.
However, in a smaller based community with only 10,000 employees, contribution rates of only
3% could be problematic.
As the value of Web 2.0 systems are driven by the number of active contributors, it is imperative
that management must actively promote the initiative rather than taking a hands-off approach and
just relying on it to "take off' on its own. Harvard Business School Professor Andrew McAfee
elaborates: "One huge fallacy of using Web 2.0 technologies within a corporation could be
described as "if we build it, they will come." 10 2
Different Approaches to Drive Contribution
Andrew suggests that corporations may actually have some distinct advantages over internet web
communities in that they can actively influence user contribution 0 3. One approach would be to
specify that users must contribute, but not necessarily dictate or micromanage what exactly how
and where they choose to contribute. For example, an employee's goal plan might specify that
they need to contribute 200 times to the user community over the course of the next year. This
contribution could be anything from tagging an object, editing a wiki, writing a section of a wiki,
posting on a discussion board, rating content, etc.
Darren Lennard managing director a European investment bank Dresdner Kleinwort Wasserstein
(DrKW) describes his personal experience in driving wiki adoption:
"To encourage use, Lennard put up an initial wiki page with a vague mission statement on
it, e-mailed everyone to tell them about the new tool and what it could do, and encouraged
them to start using it. Nothing happened. People weren't clear on what it was, what it
should be used for or what its advantages were, so they stayed away. 'I realized that I had
to be a lot more directive ifI wanted behaviors to change' says Lennard, 'and I also had to
put up wiki content that required users to get involved.' Lennard posted that agenda and
action items of an upcoming meeting and suggested that people use the wiki for their
'01 Bughin, Jacques "How companies can make the most of user-generated content" The McKinsey Quarterly (2007).
Print.
102 Brynjolfsson, Erik and Andrew McAfee "Beyond Enterprise 2.0: The Future of the Web", MIT Sloan Management
Review 48. 3 (2007). Print.
103 McAfee, Andrew. Personal Interview by Juliet Duffy. Aug 08.
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responses to them. "I told my desk that I would no longer read e-mails on some topics" he
104
says
Other companies have experimented with additional enticements. In the McKinsey user
generated content study, companies that were able to identify thought leaders and nurture users
who posted quality content "boosted the overall number of contributors and improved quality
of the postings." Other companies strove to make contributing and participation fun for
employees. At Google employees placed online bets on the likelihood that particular ideas
would be adopted. Still others, such as Intuit, used job rotation programs. Certain employees
were periodically invited to contribute to the company's internal dialogue on a full-time basis.
105
Regardless of the decided upon approach, Novartis leaders need to be actively involved in order to
avoid the "if we build it, they will come" fallacy. User contributions will be essential to achieving
the value and network effects of Web 2.0
Culture Change
Lastly, but most importantly, Novartis will need to establish an organizational culture that
promotes information sharing, earning from and acceptability of failure, public dialogue, and trust.
A number of the cultural barriers that Novartis will need to overcome are discussed in detail in the
User Research and Novartis Culture and Three Lenses Analysis chapters. Actively working to
change the culture must be a constant conscious initiative by leadership at all levels.
104 McAfee, Andrew "Enterprise 2.0: The Dawn of Emergent Collaboration" MIT Sloan Management Review, 47. 3
(2006). Print
105 Bughin, Jacques "How companies can make the most of user-generated content" The McKinsey Quarterly (2007).
Print.
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Conclusions
Web 2.0, the ultimate platform for tacit based knowledge work has finally arrived. User driven,
collaborative platform based tools including wikis, web mash-ups, discussion boards, linkage based
search engines, and tagging have the potential to vastly change how information is managed and
how knowledge work is captured.
Web 2.0 has particular relevance for the pharmaceutical industry as drug discovery is an extremely
knowledge intensive activity. Applying Web 2.0 tools to NIBR's targets, assays, people, projects,
and compounds in a well thought out framework has the potential to yield tremendous productivity
improvements in the drug discovery process.
In this new "scientific web" environment information will be set free. Knowledge will no longer
be contained within organizational silos or behind data gatekeepers. It will flow freely to who-ever
needs it regardless of where they sit in the organization. Pre-existing forced classification schemes
will be eliminated so that they cannot bury important relationships into a forced one-dimensional
format. Compounds, targets, and assays will use tagging to simultaneous classify information
under multiple categories. This will enable users to instantaneously and effectively slice and
combine the data any way that they can possibly imagine.
Lastly, effectively harnessing the collective intelligence of thousands of scientists within Novartis's
worldwide research network will enable a paradigm shift. Where previously organizational size
was an impediment, size will now be beneficial. A large, extremely knowledgeable user
community can more effectively annotate metadata, hyperlink to important content, establish tags,
and collectively author content. Such activities will not only improve the search ability of
information but also allow important scientific connections to emerge linking biology to chemistry
and furthering Novartis's understanding of disease.
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Appendix A: User Research Interview Questions (full interview version)
Q 1: Name
Q2: What organization are you in?
Q3: How long have you been at Novartis?
Q4: What is your educational background? (biologist, chemist, biochemist, etc.)
Q5: How long have you been in the Pharma Industry? Was this in a drug discovery role?
Q6: If you've had a job elsewhere in Pharma/biotech how did the data environment compare to
what we have at NIBR?
Q7: What is your job function? What does your group do?
Q8: Do you deal with compounds on a 1:1 basis or more as a set?
Q9: What information about particular compound(s) do you generate on a regular basis? Where is
this information that you generate currently stored? (ex: reports, databases, etc)
Ql0: What is the Novartis culture like surrounding documentation of work? Do people check that
things get documented appropriately? Do they care? Does this come up in yearend reviews?
Q 11: What internal information about particular compound(s) do you use/consume on a regular
basis? Where is that information stored? How often do you access each of these databases/info
sources? Which ones are most important? (please rank priority)
Q12: What are the key pieces of info you need to make a decision(s) in your role/job?
Q13: How easy it is to find access to the internal information you are looking for? (scale 1-10 with
1=extremely hard)
Q14: What information is easy to find?
Q15: What information is hard to find? What makes it hard to find/access?
Q16: How much of your time do you spend looking for information? (avg. time per week) Any
specific examples?
Q17: If you don't have access to a certain internal database how long does it take for you to get
access? Any examples?
Q18: If you cannot get access to a database, or simply don't know where to find something what do
you do?
Q19: What external data sources do you use? (ex: PubMed) and what information do you typically
extract from these sources? How often do you access each of these databases/info sources (daily,
weekly, etc)? Which ones are most important? (rank priority)
Q20: How often do you go outside of Novartis to access information in an external database?
(daily, weekly, once a month)
Q21: Do you think you would reference external databases more frequently if these databases were
available in one easy to find/click portal?
Q22: What wiki's (if any) are you aware of at Novartis?
Q23: Which wiki's do you currently use?
Q24: If all Novartis wiki environments were integrated into one, what would be the entry point that
you would use most often? (Target, Profiling, Compound, HTS Pipeline)
Q25: Do you have any experience with using Wiki's (such as Wikipedia)? How much?
Q26: Have you ever edited or helped to create a Wiki?
Q27: Should Wiki be open to adding users content and links? To what extent? Who should input
info? Open to anyone in Novartis? Project team members only?
Q28: How should the user added dialogue be structured? Pre-populated outlines to discourage
random contributions?
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Q29: How could we encourage people to add content to the wiki and avoid the blank page
syndrome?
Q30: If the interface allowed for user input would you be interested in adding notes/text to keep the
Wiki up to date?
Q31: How often do you see yourself contributing to the Wiki? (weekly, daily, monthly distribution
Q32: Have you ever used Facebook? (yes/no)
Q33: Have you ever used Linked-in? (yes/no)
Q34: Do you think the "friends" applications / ID of networks within Facebook could have
relevance for compound Wiki? If so, how?
Q35: How could the friend/association groups be useful (other than just interesting info to have)?
Q36: Would a compound Wiki in general be useful to you? Would you use this tool
(yes/no/maybe)?
Would you use the compound wiki in team meetings? How frequently?
Q37: Is there any specific information or functionality that you'd like to see included in Wiki?
Q38: Is there any kind of data analysis that could be done with Wiki that you couldn't do by just
accessing databases individually?
Q39: What would these tools be? Could they change how you make decisions?
Q40: Would you be open toward participating in a test run of a pilot compound Wiki?
Q41: Compound Failures. Why do compounds fail? What would be useful for you to track?
Q42: What should the goal of the compound wiki be?
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Appendix B: User Research Interview Questions (abbreviated interview version)
Q : Name
Q2: What organization are you in?
Q3: How long have you been at Novartis?
Q4: What is your educational background? (biologist, chemist, biochemist, etc.)
Q5: How long have you been in the Pharma Industry? Was this in a drug discovery role?
Q6: If you've had a job elsewhere in Pharma/biotech how did the data environment compare to
what we have at NIBR?
Q7: What is your job function? What does your group do?
Q8: What is the Novartis culture like surrounding documentation of work? Do people check that
things get documented appropriately? Do they care? Does this come up in yearend reviews?
Q9: Do you deal with compounds on a 1:1 basis or more as a set?
Q10: What information about particular compound(s) do you generate on a regular basis? Where is
this info that you generate stored? (ex: reports, databases, etc)
Q 11: What internal information about particular compound(s) do you use on a regular basis?
Where is that information stored? How often do you access each of these databases/info sources?
Which ones are most important? (rank priority)
How easy it is to find access to the internal information you are looking for? (scale 1-10 with
1=extremely hard)
Q12: What information is easy to find?
Q13: Do you think you would reference external databases more frequently if these databases were
avail. in one easy to find/click portal?
Q14: Links to external databases? If so, what?
Q 15: What Wiki's (if any) are you aware of at Novartis?
Q16: Which Wiki's do you currently use?
Q17: Have you ever edited or helped to create a Wiki?
Q18: Panel #1 functionality (linking)
Q19: Panel 2 functionality (general user input). What should be included? Who should be able to
add contents? Should these contents be structured? If so how?
Q20: How could we encourage people to add content? Avoid the blank page syndrome?
Q21: Would you add content? How often (weekly, daily, monthly) Why or why not?
Q22:Have you ever used Facebook? (yes/no)
Q23: Have you ever used Linked-in? (yes/no)
Q24: Panel 3 application: Do you think the "friends" applications / ID of networks within Facebook
could have relevance for compound Wiki? If so, suggest some useful "friends/network" groups
Q25: Would the friend/association groups be useful or just interesting info to have?
Q26: Of the three panels (panel 1,2,3) what would be the most useful to you? Should we
emphasize one of these functionalities over the other?
Q27: Is there any specific information or functionality that you'd like to see included in Wiki?
Q28: Who would be the users at each stage of the development process (or stages that you are
familiar with) how could this wiki improve quality or fail faster?
Q29: Would you be open toward participating in a test run of a pilot compound Wiki?
Q30: Compound Failures. Why do compounds fail - what would be useful for you to track?
Q31: Individuals that would be good to contact
Q32: Other comments
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Appendix C: Example of Novartis Safety Profiling Report
(Note: Compound information is for a non-proprietary, publically released compound)
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Appendix D: User Research Compiled list of Grouping Suggestions
# Users
Suggesting Tagging/Group Suggestion
addition
11 Project/Program association
9 target hit (in general) - general consensus that these should be validated hits
Similar Chemo type (backbones and scaffold similarity) - desire to search against both internal and
external compounds
8 Synthesized by this Chemist (First Name, Last Name)
Target families (I belong to family of GCRP, Kinase inhibitor, nuclear receptor, etc) Families I would
5 include: Kinase, GPCRs, Channels and Nuclear Hormone receptors these are the four main groups.
Others ex: "potent renin inhibitor", protease
5 Disease association, indication
3 Target hit - safety profiling target hit / off-target hit
3 Act on a specific pathway, I exhibit activity in this pathway
Chemotype or chemical series designation (what compounds a scientist /project team made within a
given series)
2 By project phase (I'm in phase D2a)
2 Individuals that have worked on this compound
2 Similar/same pharmacophore groups
2 Assays compound has been run in
2 Other compounds that have IC50 curves in a particular assay.
Target (validated hit is ambiguous, I'd like to see top 10% of compounds that are active against this
target."
1 Potent hERG inhibitors
Promiscuous hitters in pharmacology safety profiling assay (different than just hitting one safety
profiling...combo of a & b & c & d)
1 Promiscuity against regular target (like kinases) I'm validated against 10 kinase (hitting 3 or more bad)
1 Compounds that hit a certain safety assay (ex: compounds that have hit a hERG assay)
1 Going beyond Disease areas - Specific indications (ex: tumor suppressor)
1 I've been used in indication xxx for POC
1 I've been used in indication xxx for a full-phase development trial
Structure - *pair wise comparison - the number of compounds that are identical but one change away
(one atom deleted, or added)
Structure - by changing functional groups. this compound with a phenyl but there is also the pryidol.
Instead of phyenol but hetrocycle.
1 Structure - by substructure
Scaffold - purines, etc. esteroids, benzodyasipines - how many of the compounds in the archive that
belong to the purine family ?
1 We all produce/or have been linked to xx side effect
1 Frequent hitter in xx assay technology
1 list of individuals within Novartis that have commented on a compound in the Wiki
1 Formulations (I'm used as a topical, pill, etc)
1 Compounds that have made it to CSP
1 Individuals that part of the project
1 Toxicity
1 Categories of activities based on assay results ex: this group of compounds has Kinase activity
1 Predicted activities based on structure (predict this will have kinase activity)
1 Discontinued compounds (and it what stage)
Compounds that have had a false (+) in HTS - if certain compounds kept coming up you could link this to
1
maybe interference in a certain assay, etc.
Binding to targets with assay information. Example: "we are active against the same target but in a
different assay - equivalent of we went to the same school but in different years"
1 Explore liabilities associated with compounds (safety, etc)
1 Other NCBI databases
1 In-licensed from another company or synthesized internally
1 "Ugly compounds" - these may interact with a target but chemist won't touch it.
1 Hit against families (kinase, GPCR) and even sub-families of those
1 General Social Network relationships
1 Compound is in an external patent
1 Homologues were else is this binding - to the rat target? Human target? Etc
1 Receptor family
1 "Bad apples" We have a couple of thousand compounds that we know we hate"
1 Where did compound come from? (i.e. contract lab in Singapore?)
1 Hit in a particular assay
1 Individuals that have ever requested this compound (in TRT) and for what purpose
1 Compound structure analogs (viewing clusters of compounds) - with a slide able scale
1 Reactive structure
1 Frequent hitter (promiscuous compounds) - maybe broken down by assay?
1 # of steps in synthesis
1 Common known targets "HDAC inhibitors"
Generic mechanism of action Ex: I belong to the family of cytostatics,l don't allow cells to replicate/anti1
poliforative.
1 Series for how solubility got better optimizing compounds
Products of parallel synthesis - prepared in a similar way (see diagram in Juliet notebook). This would be
1 like all 24 compounds you prepared together in a parallel. Intermediate 1, intermediate 2, group these
as parallel library, this would have to be defined by the individual chemist.
1 compound group with good bioavilaiblity
1 lousy stability in microsome - high in vitro clearance.
1 very low inhibition IC50 (P2 on safety profiling) - I'm an inhibitor of 2C9 I'm an inhibior for 2D6
1 Collaborators (other companies) that have worked on this compound - requested by strategic alliances
1 Origin - where did this compound come from? Another company? A partner Collaboration?
148
